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SCOPE OF THE THESIS 
This thesis describes the characterization of a lysosomal protein, the 'protective 
protein', that has at least two functions. On the one hand it protects lysosomal ~­
galactosidase and neuraminidase from degradation within the lysosome, hence its 
name. On the other hand it has peptidase and deamidase activities, that could be 
involved in protein turnover in lysosomes and hormone (in)activation. Degradation 
is distinguished here from proteolytic processing, although both involve peptide 
hydrolysis. The first is, however, an aspecific random process, carried out at multi-
ple sites, whereas the second is a highly specific (single) event. Given the putative 
function of the protective protein it seemed appropriate to start with an overview of 
intracellular sites of protein degradation, followed by a section on the biogenesis of 
lysosomes. The introduction ends with a summary on what is known about lysoso-
mal storage disorders, a group of genetic diseases that are due to defects in lyso-
somal proteins. The protective protein itself is impaired in the rare disorder galac-
tosialidosis and studies on this disease have been the basis for the discovery of the 




1.1 intracellular degradation 
Intracellular catabolism of macromolecules ensures a counterbalance to the pro· 
cesses of biosynthesis and endocytosis and prevents the improper accumulation of 
products that would in turn impair the normal physiology of the cell. By means of 
degradation a cell can remove toxic or damaged components, generate energy, 
regulate cellular processes and, in times of starvation, provide the building blocks 
lor the synthesis of new macromolecules. Degradation is carried out by a multitude 
of enzymes that are themselves subject to digestion for the same aforementioned 
reasons. It is widely agreed upon that intracellular breakdown can be divided into 
non-lysosomal and lysosomal degradation. The first is a collection of those 
degradative systems, cytosolic and compartmentalized, that are located outside 
lysosomes. The second includes breakdown carried out by the lysosomal hydro-
lases. Because in eukaryotic cells many macromolecules are degraded in a com-
partmentalized manner, unwanted hydrolysis elsewhere is prevented. At the same 
time the organized breakdown requires that either substrate or enzyme, or both, 
are tagged with signals that enable them to meet each other at the appropriate time 
and in the correct subcellular compartment. 
Since all enzymes are endowed with a certain specificity the breakdown of 
macromolecules often occurs in a stepwise fashion. Complexes of enzymes ca-
talyzing sequential steps speed up the degradation because the substrate travels a 
minimal distance, is passed on in a favourable conformation for the next hydrolytic 
step and the complexed enzymes may enhance each others activity when assem· 
bled. Examples of and variations on these general themes within a cell will be dis· 
cussed in the next sections. 
1. 1. 1 Non-lysosomal pathways of protein degradation 
In mammalian cells all proteins are in a state of continuous turnover, with individual 
polypeptides being broken down at widely differing rates (for a recent review see 
Rivett, 1990). Degradation responds to changes in nutritional and hormonal condi-
tions and to changes in the metabolic state of the cell (Ballard, 1987; Mortimore, 
1987). Depending on their half lives proteins have been divided into short· and 
long-lived. The level of intracellular ATP influences the degradation rates of both 
classes (Gronostajski eta!, 1985), although ATP-independent cytosolic proteolysis 
has also been reported (Woods and Lazarides, 1985; Fagan eta/, 1986). 
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Short-lived cytosolic proteins are the prime targets for non-lysosomal path-
ways of protein degradation, as has been shown by the use of inhibitors of lysoso-
mal function. One major system for selective cytosolic protein degradation is the 
ubiquitin pathway (reviewed by Ciechanover and Schwartz, 1989; Jentsch et at, 
1990; 1991 ). Its selectivity depends largely on the ability of certain specialized en-
zymes, namely the ubiquitin-activating and -conjugating proteins E1, E2 and auxi-
liary factor E3, to recognize and tag proteins destined for degradation. This is 
achieved by the formation of a link between the C-terminal glycine of ubiquitin with 
the z-amino group of an internal lysine residue of the substrate protein. Polyubi-
quitination can take place at defined lysine residue(s) within the 76 amino acid 
long ubiquitin polypeptide, resulting in branched chains (Chau et at, 1989). These 
structures are thought to be the real signal for degradation. Selective turnover of 
ubiquitinated substrate proteins is then carried out by an ATP- and ubiquitin-de-
pendent protease complex oi high molecular weight (Fagan et at, 1987; Hough et 
at, 1987). However, ubiquitin has also been found coupled to stable proteins and 
ubiquitin-conjugating enzymes have been implicated in other basic cellular func-
tions such as DNA repair and cell cycle control (for review see Jentsch et at, 1991 ). 
Therefore, it is now understood that the marking of proteins for selective degrada-
tion is not the only role of the ubiquitin system. 
The structural characteristics of a protein that determine its turnover rate are 
not well understood, but some rules have been proposed that relate protein pri-
mary structure to stability. One of these, the "N-end" rule, applies for ubiquitin-de-
pendent degradation and relates the N-terminal amino acid of a protein to its intra-
cellular stability (Bachmair et at, 1986). This signal, however, may be restricted to 
unfolded, nascent or highly flexible polypeptides (Rechsteiner, 1987) and/or it may 
operate on cleaved products of intracellular proteins (Dice, 1987). In addition, it 
depends on the correct location of a lysine residue, that could be the acceptor of a 
)Oiyubiquitin chain (Bachmair and Varshavsky, 1989). Regions, rich in proline, 
glutamic acid, serine or threonine called PEST domains, have also been implicated 
in selective turnover, since they are common in primary structures of several short-
lived proteins (Rogers et at, 1986). It has been demonstrated that deletion of such a 
PEST-domain from the cytosolic enzyme ornithine decarboxylase yields a 
truncated product that is considerably more stable (Ghoda et at, 1989). However, a 
second PEST region in this enzyme, still present in the truncated product, is appa-
rently less influential, indicating that folding of a protein may mask determinants 
that otherwise would act as targets for degradation. In accordance with this is the 
finding that the rate of degradation of 35 proteins of known crystallographic struc-
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lure, microinjected into Hela cells, did not significantly conform to the aforemen-
tioned rules (Rogers and Rechsteiner, 1988a; 1988b; 1988c). Other events that 
may modify a polypeptide and render it abnormal and hence unstable are: da-
mage (e.g. oxidation), phosphorylation or natural mutation(s). 
The delineation of non-lysosomal pathways of protein degradation has 
shifted scientific interest towards the isolation of the cytosolic and nuclear pro-
teases responsible for intracellular protein turnover. Two high molecular weight 
complexes have been identified, which could fulfill this function (for review see 
Rivett, 1989a). One is a 1500 kDa (26S) particle, capable of degrading ubiquiti-
nated proteins in vitro in an ATP-dependent fashion (Fagan eta!, 1987; Hough et 
a!, 1987). The other is smaller (-600 kDa) and has been given many names, the 
most common being multicatalytic proteinase complex, MCPC (reviewed by Rivett, 
1989b). The latter can be part of a 26S proteolytic complex (Driscoll and Goldberg, 
1990) and it is present also in yeast, where it is called proteinase yscE (Achstetter 
eta!, 1984). Recently, it has been shown that certain subunits of the yscE complex 
are also important in the degradation of ubiquitinated proteins (Heinemeyer eta!, 
1991) and are essential for life (Fujiwara eta!, 1990; Heinemeyer eta!, 1991 ). 
Several hypotheses could explain why these proteases are of such a high molecu-
lar weight: the dissociation and association of key components, such as inhibitors 
or activators, allows a careful regulation of the proteolytic activity; the multifunc-
tional and multicatalytic nature of the complexes involves many subunits; the for-
mation of a channeling mechanism which binds and then cleaves ubiquitinated 
proteins sequentially, thereby avoiding diffusion of possible poisonous peptide in-
termediates, requires a multicomponent complex (Heinemeyer eta!, 1991; Rivett, 
1989a;1989b). 
Besides the aforementioned example of cytosolic protein degradation, 
membrane enclosed non-lysosomal turnover has also been documented. In mam-
malian cells another selective degradation system has only recently been recog-
nized in the endoplasmic reticulum. ER (for review see Klausner and Sitia, 1990). 
Its place so early in the secretory route is on one hand logical since here it can re-
move redundant or abnormal proteins before they become harmful to a cell, or ac-
cumulate to toxic levels within the ER. On the other hand it seems odd that another 
set of non-lysosomal proteases exist, thus far undiscovered, that exercise a func-
tion similar to the lysosome yet in an earlier biosynthetic compartment. Neverthe-
less. ER degradation is insensitive to lysosomotropic agents such as NH4CI and 
chloroquine, and it is not prevented by cycloheximide or other inhibitors of au-
tophagosome formation such as methyladenine or colchicine (lippincott-Schwartz 
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et a/, 1988). Furthermore, it is accelerated by depletion of cellular calcium 
(Wileman eta/, 1991 ), a cation thought to be important for the maintenance of ER 
structure (for review see Koch, 1990). The finding of a lag-time between completion 
of protein synthesis and start of ER degradation as well as a partial block in degra-
dation at 16 oc suggest that it takes place at a site physically separated from the 
earliest biosynthetic compartment (lippincott-Schwartz eta/, 1988). The energy re-
quirement of this process is contradictory in two reports of the same group 
(Lippincott-Schwartz eta/, 1988; Klausner and Sitia, 1990). 
Thus far a specific signal for ER-retention and -degradation has only been 
defined in the a-subunit of the T-cell receptor, TCR (Bonifacino eta/, 1990a; 
1990b). The domain is located in the transmembrane region of the a-chain and it is 
characterized by positively charged amino acid residues. Association with the CD3 
8 subunit of the TCR complex is also mediated by this region. This assembly masks 
the retention/degradation signal and allows further complex formation and exit out 
of the ER. Other examples of proteins that might have putative signals for ER 
degradation are HMG-CoA reductase and apolipoprotein B-1 00 (Klausner and 
Sitia, 1990). An alternatively spliced subunit (H2A) of the asialoglycoprotein recep-
tor is also degraded in the ER, the determinant lor turnover being 5 amino acids 
immediately next to the transmembrane domain (Amara eta/, 1989; Lederkremer 
and Lodish, 1991 ). Notably, like the TCR a-chain, these are all examples of nor-
mally occurring membrane associated proteins. In contrast, no specific determinant 
has yet been identified lor the degradation of normal soluble ER proteins. Instead, 
only aberrant (mutated, chimaeric) or incompletely assembled soluble proteins 
have been shown to follow this degradative route with widely differing half Iiies 
(e.g. Lau and Neufeld, 1989; Sitia eta/, 1990; Stoller and Shields, 1989; our own 
results in Chapter 2). This could be related to the tendency of some proteins to form 
aggregates, thereby altering their proteolytic susceptibility. Alternatively, multiple 
pathways of ER-degradation may exist resulting in different rates of turnover. It re-
mains to be determined whether proteins like the TCR a-chain are selectively de-
graded by proteases recognizing a specific tag, or selectively targeted to a novel 
proteolytic compartment (Klausner and Sitia, 1990). 
The two non-lysosomal pathways of protein turnover depicted above func-
tion in protein depletion but their contribution to the production of essential amino 
acids for biosynthetic purposes is limited. The latter function is assigned to the 
lysosomal-vacuolar system, which will be described below. 
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1.1.2 Routes to lysosomal degradation 
lysosomes can be defined as a group of heterogeneous acidic vacuoles, sur-
rounded by a single membrane with as a main function the digestion of macro-
molecules. They can be viewed as the terminal degradative compartment 
(reviewed by Kornfeld and Mellman, 1989). In yeast and plants vacuoles fulfill a 
similar function but they are involved also in metabolic storage and cytosolic ion 
and pH homeostasis (Kiionsky eta/, 1990). The pH of the lysosome is estimated to 
be -4.7, it is maintained by an H+-ATPase pump and it is essential lor organelle 
function (for review see Ohkuma, 1987). In fact, weak bases (e.g. ammonia, chloro-
quine) can diffuse into lysosomes and become protonated and trapped, with con-
sequent increase of intralysosomal pH and dysfunction. As far as their contribution 
to protein turnover is concerned, some authors state that lysosomes mainly de-
grade long-lived proteins (see reviews by Mortimore and Khurana, 1990; Rivett, 
1990). 
The routes by which macromolecules that need to be degraded reach the 
lysosomes are summarized in Figure 1. Extracellular material is taken up either 
selectively by receptor-mediated endocytosis (see section 1.2.3) or non-selectively 
by pinocytosis and phagocytosis. lntracellularly, micro- and macroautophagy ac-
count for most of the non-selective breakdown of cytosolic proteins. Microau-
tophagy is the term coined to describe the invagination of the lysosomal mem-
brane, followed by formation of intralysosomal vesicles containing cytoplasmic 
material. Macroautophagy is the process by which preexisting ER membranes en-
gull portions of the cytosol and form autophagosomes (for review see Marzella and 
Glaumann, 1987). As studied in the perfused rat liver, these vesicles are initially 
surrounded by two membranes, derived from preexisting smooth ER, with the in· 
termembrane space equivalent to the lumen of the ER (Dunn, 1990a). They then 
fuse with primary lysosomes, i.e. lysosomes that do not contain degraded material, 
to form a secondary lysosome or auto lysosome (Dunn, 1990b). Macroautophagy is 
in part a regulated, reversible process, which can be enhanced among others by 
stress. Starvation of liver cells by depletion of certain amino·acids induces it after a 
lag-time of -8 min. The effect is an increased non-selective protein turnover, which 
provides the cell with new amino acids. Recently it has been shown in cultured 
mouse mammary carcinoma cells that the ubiquitin-activating· enzyme E1 is neces-
sary lor the heat-induced increase of lysosomal protein breakdown (Gropper eta!, 
1991 ). E1 may act either on the formation of the autophagic vacuoles or on the tar-
geting of cytosolic proteins (Gropper eta/, 1991 ). This finding links the cytosolic 












~.~ 4fj) ~ 
dosomes 
L~ Micro-
.: ·.··<iiJI autophagy 
/V 
"Prp73" 
- ~ ~ 
- l, •, 
Cytoplasmic protein pool .. 
Pinocytosis . 




Shown is a eukaryotic cell in which the various pathways to lysosomal (protein) break-
down (their names are italicized), that are discussed in the text, are active. The direc-
tions of these routes to lysosomes are indicated with open arrows. Newly synthesized 
lysosomal enzymes are delivered to endosomes along the pathway marked with filled 
arrows and are subseqL{ently transported to tysosomes. The different intracellular 
compartments and vesicles are not drawn proportional to each other. AV: autophagic 
vacuole, L: lysosome, AL: autophagolysosome, R: ribosome, ER: endoplasmic reticu-
lum. 
Dice and coworkers have demonstrated that cytosolic proteins can also be 
selectively broken down in lysosomes under stress conditions, like serum depletion 
(reviewed by Dice, 1990). This induces certain proteins to expose an amino acid 
stretch either identical or similar to Lys-Phe-Giu-Arg-Gin (KFERQ), which allows 
16 
their recognition by a member of the heat-shock protein (hsp) 70 family, termed 
prp73, that in turn targets them to the lysosome. The actual mechanism by which 
these substrate proteins are subsequently translocated through the lysosomal 
membrane is unknown. The rationale behind this selective targeting is that upon 
starvation the liver responds first by non-selectively turning over proteins through 
enhanced macroautophagy and then shifts to the selective degradation of dis-
pensable proteins containing KFERQ-Iike sequences (Dice, 1990). 
Another example of targeted vacuolar turnover of a cy1osolic protein was re-
cently found in yeast. Fructose 1,6 biphosphatase (FBPase), a key enzyme in glu-
coneogenesis, is highly expressed when cells are grown in poor glucose medium. 
When cells are then switched to rich medium the enzyme is targeted to the vacuole 
and selectively degraded. It is noteworthy that FBPase has a remote KFERQ-se-
quence (Chiang and Schekman, 1991 ). 
1. 1.3 Protein constituents of the lysosome 
The degradative power of the lysosome is mastered by a set of acidic hydrolases 
and other supporting constituents, some 70 of which have now been described. 
Each enzyme recognizes a specific bond and sometimes additional features on a 
substrate and is classified accordingly. Lysosomal hydrolases have a low pH opti-
mum and, except for the proteinases, many form higher order structures. 
Because of the focus of this thesis some consideration will be given first to 
the lysosomal peptide hydrolases, collectively called cathepsins (a corruption of a 
Greek term meaning '1o digest"), although they are not the biggest group (reviewed 
by Kirschke and Barrett, 1987). Like all other proteases cathepsins are subcatego-
rized depending on whether they cleave within or at the extremes of a polypeptide 
chain, i.e. whether they are endoproteases (protel.o.ases) or exoproteases 
(carboxy- or amino peptidases). Based on the four known cataly1ic mechanisms 
utilized by proteases to hydrolyze a peptide bond, these enzymes are further clas-
sified as serine-, cysteine-, aspartic acid- and metallo-proteases. 
The serine proteases are specified by the socalled cataly1ic triad of Asp, His, 
and Ser amino acid side chains, that form a "charge relay" system in which electron 
density is "pushed" towards the serine-oxygen. In the three-dimensional conforma-
tion of active serine proteases these amino acids are neatly arranged next to each 
other in the order Asp-His-Ser, with the latter residue in the active center. In their 
primary structures instead these residues can be located far apart. The develop-
ment of class specific inhibitors such as the compound diisopropylfluorophosphate 
17 
(DFP), that only reacts with the active site serine, has made assignment to a certain 
group of proteases more easy. 
So far the best characterized lysosomal endoproteases are cathepsins B, H, 
L (cysteine type) and D (aspartic acid type) for which the corresponding cDNAs 
have been cloned. Remarkably, these proteinases are isolated as monomeric en-
zymes and it has been calculated for cathepsins B and D that their intralysosomal 
concentration could be as high as 25-45 mg/ml (-1 mM) (Kirschke and Barrett, 
1987). This finding should be kept in mind when interpreting data obtained in vitro 
since such experiments are mostly performed using lysosomal enzyme concentra-
tions that are a few orders of magnitude lower. Contrary to the proteinases the exo-
proteases are mostly isolated in higher order structures. Both amino- and car-
boxypeptidases have been characterized but, except for the protective pro-
tein/cathepsin A, no other primary structure through eDNA cloning is known. Given 
their high intralysosomal concentration and aspecificity it is assumed that lysoso-
mal proteases have overlapping proteolytic activities and they do not need to act 
sequentially on a substrate. 
The most diverse group of lysosomal hydrolases are the glycosidases. 
These are mostly exo-enzymes, specific for a glycosyl unit and its anomeric lin-
kage. Hence they have to work in concert to sequentially remove monosaccharides 
from a variety of natural substrates. In this case enzyme complex formation would 
definitely add to the rate of substrate hydrolysis. Figure 2 shows two examples of 
macromolecules that are broken down in lysosomes in an ordered fashion and the 
enzymes involved in this event (for review see Aronson and Kuranda, 1989). Steps 
in the sequential degradation of macromolecules could be identified because of 
the presence of accumulated substrate(s) in tissues and urine of patients with a 
lysosomal enzyme deficiency. The latter can also be induced using inhibitors of 
lysosomal enzymes. Such studies have indicated that in glycoprotein breakdown 
peptide hydrolysis enhances the speed of oligosaccharide hydrolysis, probably 
because of the relieve of steric hindrance (Kuranda and Aronson, 1987). 
Some hydrolases need an additional non-enzymic factor (activator) for full 
deployment of activity. Two of such activators have been characterized biochemi-
cally and purified some time ago. One cofactor was termed sulfatide activator pro-
tein, or SAP, because of its in vivo action on the substrates of arylsulfatase A, i.e. 
the sulfatides (Fischer and Jatzkewitz, 1975). 
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Figure 2 Macromolecular substrates for lysosomal enzymes. 
Upper half: the stepwise degradation of Go 1 a-ganglioside to ceramide, 
reaction 1} requiring neuraminidase, 2) 8-gafactosidase, and 3} B-
hexosaminidase A. respectively. If one of these enzymes or those acting 
later (arrowheads) is deficient storage products arise. Lower half: 
breakdown of Asn-finked glycoproteins in lysosomes. Reactions catalyzed 
by the glycosidases are indicated with the open arrows, again these have 
two work in concert. The protein backbone can presumably be broken 
down at random. 
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In vitro this cofactor also stimulates the degradation of GM1-ganglioside and 
globotriaosylceramide by 13-galactosidase and a-galactosidase, respectively (Li 
and Li, 1976). Its function is to extract the lipid substrates from membranes to make 
them available for hydrolysis. The second cofactor is essential lor the activation of 
membrane associated lysosomal glucocerebrosidase (Ho and O'Brien, 1971 ), but 
it acts on the enzyme rather than on the substrate. It has recently been 
demonstrated that both the aforementioned colactors as well as two other heat 
stable activator proteins, now collectively called saposins, are derived from a single 
high molecular weight precursor by proteolytic processing (Furst eta!, 1988; 
O'Brien eta/, 1988). Interestingly, this uncleaved proform was shown to be similar 
to a sulfated glycoprotein secreted by rat sertoli cells, which may have a function in 
spermatogenesis (Collard eta/, 1988). Thus, multiple functions seem to be 
gathered within one amino acid sequence. A 22 kDa cofactor of J3-hexosaminidase 
A, needed for the hydrolysis of GM2-ganglioside but not related to the saposins, 
has also been isolated and sequenced (Meier eta/, 1991; Xie eta/, 1991 ). The 
lysosomal protective protein, although needed for the stabilization and activation of 
J3-galactosidase and neuraminidase respectively, differs from the other cofactors in 
that it has a distinct enzymatic activity (see chapter 2). 
After complete hydrolysis of a macromolecule, low molecular weight building 
blocks need to be transported accross the lysosomal membrane for reutilisation 
and to clear the lysosomes. This might occur in some cases by simple diffusion. 
However, an increasing number of carrier-mediated transport systems have been 
demonstrated to exist. Thus, metabolites like cystine (Gahl eta/, 1982), acidic 
monosaccharides such as sialic acid and glucuronic acid (Mancini eta/, 1989), 
neutral hexoses (Mancini eta/, 1990), phosphate (Pisani, 1991 ), calcium (Lemons 
and Thoene, 1991) and Vitamin 812 (ldriss and Jonas, 1991) are specifically 
transported. 
In addition to the enzymes, activators and transport proteins lysosomes 
contain structural components which are the lysosomal integral membrane proteins 
(LIMP), also called lysosome-associated membrane proteins (LAMP) or lysosomal 
membrane glycoproteins (lgp). As deduced from the available primary structures 
this is a family of glycoproteins with a short cytosolic tail (1 0-11 amino acids), a 
single transmembrane segment and a heavily glycosylated (sialylated) luminal 
portion (Granger eta/, 1990). At present the function of these different membrane 
components is not known. It is assumed that their abundant glycosylation may 
serve to protect these proteins (Barriocanal eta/, 1986) as well as the lipid bilayer 
(Schauer, 1985) from degradation by lysosomal hydrolases. Normally the LAMPs 
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are detected almost exclusively on the lysosomal membrane, but certain cellular 
processes, like differentiation, may modulate their glycosylation state and cell sur-
face expresssion, suggesting a role for these proteins in cell adhesion (Amos and 
Lotan, 1990). Upon stimulation with thrombin, activated platelets expose LAMP-1 at 
their surface and in this case it was reasoned that the protein could aid in platelet 
aggregation (Febbraio and Silverstein, 1990). This provides another example of an 
extralysosomal role for a lysosomal protein. 
Protein sequencing and deduction of primary structures from cloned cDNAs 
encoding various lysosomal proteins have failed to show any linear stretch of 
amino acids common to this class of proteins. This was somewhat surprising since 
many of these enzymes are targeted in a similar manner to lysosomes. However, 
these studies did make clear that many lysosomal proteins are homologous to 
other proteins present either within or outside the lysosome and that there may 
even exist cognate proteins in lower eukaryotic and/or prokaryotic organisms. 
Table 1 lists the different protein families, with the various lysosomal and non-lyso-
somal members. It is apparent that a similar enzymatic activity is often the basis for 
a partial sequence identity among different proteins. For example the lysosomal 
enzymes a- and 13-hexosaminidase are homologous, as are a-galactosidase and 
a-N-acetylgalactosaminidase and the family of sulfatases. The lysosomal enzyme 
involved in the degradation of glycogen, a-glucosidase, is homologous to the non-
lysosomal intestinal brush border sucrase/isomaltase. The protective protein 
shares sequence identity with the yeast vacuolar carboxypeptidase Y as well as 
with the Golgi complex located KEX1 gene product and several plant serine car-
boxypeptidases. Here, the finding of sequence homology has revealed that the 
protective protein bears protease activity. 
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Table 1. Related lysosomal and other proteins (the tabfe is adapted from Neufeld 1991) 
related lysosomal proteins protein hornologues refs•> 
J3-hexosaminidase o:- and j3-subunits j3~N-acetylglucosaminidase 1-7 
(Dictyostelium discoideum) 
_ j3-glucuronidase ~-glucuronidase (E- coli) 8-12 
a-galactosidase a-galactosidase (yeast. E. coli) 13-17 
a-N-acetylgalactosamlntdase 
a-glucosidase intestinal brush border 18 
sucrase/isomaltase 
acid phosphatase prostatic acid phosphatase 19-21 
arylsulfatases A and B microsomal steroid sulfatase 22-29 
N-acetylglucosamine 6-sulfatase arylsulfatase (sea urchin) 
iduronate sulfatase 
lysosomal integral membrane proteins 30 
cathepsins 8, H, L, S papain family of thiol proteases 31, 32 
cathepsin D renin/pepsinogen family of aspartyl 33 
proteases 
protective protein/cathepsin A serine carboxypeptidase family {yeast, 34 
plants) 
a) 1 : 
5: 
Myerowitz eta!, 1985; 2: Korneluk eta!, 1986; 3: Proia et at, 1987; 4: Bapat et at, 1988; 
Graham et al, 1988; 6: Neote eta/, 1988; 7: Proia ,1988; 
8: Nishimura et at, 1986; 9: Oshima eta!, 1987; 10: d'Amore eta!, 1988; 11: Powell eta!, 
1988; 12: Miller eta/, 1990; 
13: Bishop eta!, 1986; 14: Kornreich eta!, 1989; 15: Tsuji et a!, 1989; 16: Wang eta!, 
1990; 17: Wang eta/, 1991; 
18: Hoefsloot eta!, 1988; 
19: Yen eta/, 1987; 20: Pohlmann eta/, 1988; 21: Robertson eta!, 1988; 
22: Geier et a/,1989; 23: Peters et al, 1989: 24: Stein eta/, 1989a; 25: Stein eta/, 1989b; 
26: Kreysing eta!, 1990; 27: Peters eta!, 1990; 28: Schuchman eta/, 1990; 29: Wilson et 
a/, 1990; 
30: see references in Zot eta/, 1990; 
31: see references in Kirschke and Barrett, 1987; 32: Ritonja eta!, 1991; 
33: Faust eta!, 1985; 
34: see chapter 2. 
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1.2 Biogenesis of lysosomes 
1.2. 1 Transcription, translation and translocation 
More than ten genes encoding different lysosomal proteins have been isolated and 
characterized. These studies have shown that with the prominent exception of the 
gene encoding 13-glucocerebrosidase (Reiner eta!, 1988) the respective promo-
ters are very GC-rich and bear characteristics of promoters present in house-
keeping genes, which are ubiquitously expressed. However, tissue specific ex· 
pression of mRNAs encoding lysosomal proteins has also been observed (e.g. 
cathepsin 6: San Segundo eta/, 1986; see also chapter 2). This might indicate a 
differential need for these proteins in various tissues. Remarkably, the cathepsins 
B, H, L, and D are overexpressed and secreted in increased amounts in certain tu-
mours (Rochefort eta!, 1987; Sloane eta/, 1987). This process may contribute to 
the metastatic potential of the transformed cells, because of the degradation of ex-
tracellular matrix by the proteases. 
Some of the genes encoding lysosomal proteins give rise to transcripts, that 
undergo alternative splicing. These include the genes for 13-glucuronidase 
(Oshima et al, 1987), j3-galactosidase (Morreau et al, 1989; Yamamoto eta!, 
1990), sphingomyelinase (Quintern eta/, 1989; Schuchman eta!, 1991 ), a-N-
acetylgalactosaminidase (Wang et al, 1990; Yamauchi eta!, 1990), the sulfatide 
activator protein, or saposin 1 (Holtschmidt eta!, 1991; Nakano eta!, 1989; Zhang 
eta!, 1990; Zhang eta/, 1991) and aspartylglucosaminidase (Fisher and Aronson, 
1991 ). Only in the case of 13-galactosidase, j)-glucuronidase and sphingomyeli-
nase the cDNAs, derived from the alternatively spliced transcript, were expressed. 
In all instances, however, the protein products were enzymatically inactive. Thus far 
none of the alternatively spliced transcripts has been shown to encode a physiolo-
gically functional protein. 
The segregation of secretory proteins, including lysosomal, from other 
polypeptides begins at the level of translation and is mediated by a discrete to-
pogenic signal, called the signal sequence (Biobel, 1980). Statistical analysis of 
several known signal sequences revealed that they do not share any amino acid 
homology and vary considerably in length. Still they maintain characteristic fea-
tures that include an N-terminal region with a positive net charge, a hydrophobic 
central core of 7-16 amino acids and a C-terminal domain consisting of 4-6 rela-
tively polar residues (von Heijne, 1986). When the signal sequence ·,s exposed on 
a nascent chain it is recognized and bound by the signal recognition particle, SRP 
(Walter and Biebel, 1980; 1982), which causes a transient arrest of translation. It is 
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the SRP that directs the nascent polypeptide-ribosome complex to a "docking" 
protein (SRP receptor) on the ER-membrane (Gilmore eta/, 1982a; 1982b; Meyer 
et at, 1982). This event permits association of the ribosome to its receptor (Savitz 
and Meyer, 1990), GTP-dependent release of the SRP from the signal sequence, 
cessation of translation arrest (Connolly and Gilmore, 1989; Gilmore and Biebel, 
1983; 1985) and translocation of the signal sequence through the ER-membrane. 
Finally, GTP-hydrolysis is probably needed for the subsequent release of the SRP 
from the "docking" protein, which enables the various components to mediate an-
other round of signal sequence binding and translocation. The latter two processes 
can be biochemically uncoupled, indicating that they are sequential reactions 
(Nicchitta eta/, 1991) . Recently, Simon and Biebel (1991) have demonstrated the 
existence of a proteinaceous protein-conducting channel within the ER membrane 
that mediates translocation of nascent polypeptides and is kept open by attached 
ribosomes. These studies show that only protein-protein interactions determine the 
fate of a translocating polypeptide chain and that the lipid bilayer of the ER mem-
brane is not involved in this process. At the luminal side of the ER a signal pepti-
dase cleaves off the signal sequence to release the preform of a secretory 
(lysosomal) protein. 
Inside the ER a prominent modification of precursor proteins that takes place 
co- or posttranslationally is glycosylation on specific Asn residues in the primary 
sequence context Asn-X-Ser/Asn-X-Thr (X being any amino acid except Pro). The 
reaction is accomplished by transferring a triantennary structure of 14 sugar 
molecules (9 mannose, 3 glucose, 2 N-acetylglucosamine) en bloc from a lipid 
carrier, dolichol-pyrophosphate, to the protein (reviewed by Kornfeld and Kornfeld, 
1985). In cultured cells glycosylation can be prevented by addition of drugs like tu-
nicamycin (for review on inhibition of the biosynthesis and processing of N-linked 
oligosaccharide chains see Elbein, 1987). ER localized glucosidases and man-
nosidases remove posttranslationally the terminal glucose residues and one man-
nose from the oligosaccharide side chains. 
Translocation and glycosylation are accompanied and/or followed by the 
folding of the precursor polypeptide, an event that includes formation of correct 
disulfide bridges. Previously, the concept of self-catalyzed or spontaneous protein 
folding and assembly was generally accepted, the information for proper folding 
being completely enclosed within the primary structure of a given protein. More re-
cently, however, this notion has been abandoned in favor of the theory of "protein-
catalyzed" protein folding (for review see Rothman, 1989). The process is now 
thought to occur in a number of discrete steps under the guidance of a specialized 
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class of molecules, called "molecular chaperones" (for reviews see (Ellis et at, 
1989; Ellis and van der Vies, 1991 ). These are members of a family of "heat shock" 
proteins (hsp), termed as such because they were first detected in increased 
amounts after heat treatment. It is now established that they are also constitutively 
expressed proteins. Chaperonins bind to partially unfolded proteins, thereby pro-
moting a proper conformation and preventing the aggregation of polypeptides. Cy-
cles of binding and release are possible at the expense of ATP. Exposed hy-
drophobic domains in a partially unfolded precursor could be viewed, analogously 
to the signal sequence, as the targeting domains to which the chaperonins could 
bind (Landry and Gierasch, 1991 ). Protein folding within the ER was shown to be 
mediated by a a member of the hsp70 family (Munro and Pelham, 1986), a protein 
that turned out to be identical to the immunoglobulin heavy chain binding protein, 
SiP (Haas and Wabl, 1983). Not only does SiP aid in the folding of newly synthe-
sized luminal proteins, it also mediates the assembly of multicomponent protein 
structures (reviewed by Hurtley and Helenius, 1989; Pelham, 1989). In yeast, the 
homologue of SiP is also required for the translocation of secretory proteins into the 
ER (Nguyen et at, 1991). Another ER enzyme, protein disulfide isomerase or POl 
(Edman et at, 1985), catalyzes thiol-disulphide interchange in vitro and aids in the 
formation of correct disulfide bridges in newly synthesized precursors in vivo 
(Freedman, 1989). 
Attaining a proper conformation is a prerequisite for exit out of the ER and 
this has been termed the quality-control system of this compartment (Hurtley and 
Helenius, 1989). It prevents unassembled, denatured, mutated or otherwise aber-
rant proteins to cause damage further down the secretory pathway. Perhaps as a 
consequence of their prolonged lifespan in the ER these faultily folded precursors 
are cleared by the aforementioned ER-degradation system. 
Soluble proteins such as SiP and POl carry out essential functions and must 
be constitutively present within the ER. This compartment is filled with these and 
other resident proteins, collectively termed reticuloplasmins (Koch, 1987). How is 
the segregation between resident and traversing proteins accomplished ? It has 
been proposed that the lumen of the ER has a highly ordered supramolecular pro-
tein stnucture, maintained among others by calcium (for review see Koch, 1990). 
This scaffold could be the major determinant in the retention of soluble reticulo-
plasmins. Perturbation of cellular calcium levels indeed causes the secretion of 
several resident ER proteins (Booth and Koch, 1989). However, a small proportion 
of proteins escaping from this stnucture would have to be selectively retrieved. SiP 
and POl are retained because they contain a specific signal consisting of a C-ter-
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minal extension of the 4 amino acid residues Lys-Asp-Giu-leu, or KDEL (Munro 
and Pelham, 1987). In higher eukaryotes the KDEL-sequence requirement is not 
strict , as a limited number of other residues have similar effects (Andres eta/, 
1990). A variation of this retention motif is present in yeast, where the signal is 
HDEL (Pelham et at, 1988). It has been demonstrated that the KDEL-sequence is 
responsible for retrieval of resident proteins, presumably from a compartment be-
tween the ER and Golgi which has been called "salvage compartment". Soluble 
proteins that lack this signal leave the ER. These observations have been substan-
tiated by the identification in yeast of a receptor that recognizes the "HDEL" signal 
(Lewis et at, 1990b; Semenza et at, 1990). Also in man two putative receptors have 
been identified, one of which is homologous to the yeast receptor (Lewis and Pel-
ham, 1990a; Vaux et at, 1990). 
Some transmembrane ER proteins, like the adenoviral E3/19K glycoprotein, 
contain retention motifs different from the KDEL sequence on their cytoplasmically 
exposed tails, indicating they are retrieved by different factors (Jackson eta/, 1990; 
Nilsson et at, 1989; Paabo eta/, 1987). 
1.2.2 Targeting to /ysosomes 
The major pathway for segregation of soluble lysosomal enzymes starts in the pre-
Golgi/Golgi compartment (Lazzari no and Gabel, 1988; for review see Kornfeld and 
Mellman, 1989). At this site lysosomal proteins are specifically recognized by the 
enzyme UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-
phosphotransferase (phosphotransferase), that transfers N-acetylglucosamine-1-
phosphate to specific mannose residues on selected Asn-linked oligosaccharide 
moieties. This process is followed by the removal of terminal N-acetylglucosamine, 
catalyzed by a second enzyme, N-acetylglucosamine-1-phosphodiester a-N-
acetylglucosaminidase, that leaves free mannose-6-phosphate (M6P) residues, 
one or two per oligosaccharide chain. In spite of the specifictty of the reaction the 
protein determinant on lysosomal precursors that is recognized by the phospho-
transferase is not a linear amino acid sequence, but rather a combination of non-
contiguous stretches brought together in three dimensional space (Baranski et at, 
1990). The structure must also be oriented properly with respect to the substrate 
oligosaccharide chain. In the case of lysosomal cathepsin D a lysine residue is a 
critical component of the protein determinant (Baranski et at, 1990). 
Transit through the three defined regions of the Golgi stack, i.e. cis-, medial-
and trans-Golgi, brings about a further modification of the oligosaccharide chains 
on the heterogeneously phosphorylated lysosomal proteins. This is achieved by 
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Golgi resident glycosidases and glycosyltransferases, of which some 100 different 
types are presumed to exist (Paulson and Colley, 1989). Modification by a glycosyl-
transferase is taken as evidence that a protein has traveled through the compart-
ment where the transferase is located. The stepwise addition of sugars like N-
acetylglucosamine, galactose and sialic acid builds "hybrid" or "complex" types of 
oligosaccharide chains on lysosomal proteins (see Figure 2). Instead, unmodified 
side chains are said to be of "high mannose" type. Only the latter and the "hybrid" 
chains contain M6P residues. At the trans-side of the Golgi complex, in a reticular 
structure called the trans-Golgi network, TGN (Griffiths and Simons, 1986), lysoso-
mal protein precursors with a fully modified M6P recognition marker are recognized 
by and bind to a specific receptor. The ligand-receptor complexes are at this point 
ccmpetent for targeting to lysosomes. 
The discovery of the M6P recognition marker (Kaplan et at, 1977) led to the 
identification of two distinct M6P receptors, MPR (Hollack and Kornfeld, 1985; Sa-
hagian eta/, 1981), for which the corresponding cDNAs have been cloned from 
various species and the primary structures determined (for review see Kornfeld and 
Mellman, 1989, and references therein; Ma eta!, 1991 ). One is about 300 kDa and 
binds ligand in the absence of divalent cations (cation independent- or CI-MPR). Its 
preproform is composed of a signal sequence, followed by a large extracellular 
domain, containing 15 contiguous repeating elements 16-38 % identical to each 
other, a transmembrane domain and a cytoplasmic tail. The smaller receptor is 46 
kDa and exhibits enhanced ligand binding affinity in the presence of divalent 
cations (cation dependent- or CD-MPR). It is also an integral membrane glycopro-
tein, oriented in the same way as the CI-MPR. Moreover, its extracellular domain is 
homologous to each of the repeating units of the CI-MPR, indicating that the two re-
ceptors are derived from a common ancestor. Both receptors exhibit different affini-
ties for ligands and have different pH optima. The CI-MPR assumes a monomeric 
conformation, whereas the small receptor is presumably dimeric, although mono-
and tetrameric forms have also been reported (Waheed eta/, 1990a; Waheed and 
von Figura, 1990b). As monomer and dimer, respectively, the Cl- and CD-MPR can 
bind one mole of diphosphorylated ligand per mole of "native·· receptor. From the 
ligand side efficient binding to the receptor depends on the degree of phosphoryla-
tion, the type of oligosaccharide chain (Faust and Kornfeld, 1989) and in some 
cases protein determinants. The latter parameter was found to play a role in the 
segregation of cathepsin Lin transformed mouse fibroblasts, where it is the major 
excreted protein (MEP). In these cells MEP displays a reduced binding to the CI-
MPR in comparison with other lysosomal enzymes, which results in the enhanced 
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secretion of this protease {Dong et af, 1989). This is in spite of the presence of an 
oligosaccharide chain with high binding capacity for the same receptor {Lazzari no 
and Gabel, 1990) . 
As mentioned above newly synthesized lysosomal enzymes are segregated 
at the level of the TGN. Ligand-receptor complexes following the biosynthetic route 
are clustered in clathrin-coated pits, that bud off and are transported to a prelyso-
somal compartment {see also section 1.2.3). The low pH of the latter causes disso-
ciation of lysosomal proteins from their receptors, which can then recycle to the 
TGN. Agents that raise intra{pre)lysosomal pH impair the dissociation of the 
ligands from their receptors, which are in turn both recycled. In the absence of 
unoccupied receptors newly synthesized lysosomal precursors cannot cluster into 
coated pits and take a non-selective or default pathway, resulting in their enhanced 
secretion. In the biosynthetic route the CI-MPR is more effective in targeting 
lysosomal precursors. Evidence lor this is the observation that overexpression of 
murine CD-MPR in a murine cell line, deficient in the CI-MPR, never completely 
restores the efficient sorting of lysosomal enzymes {Ma et a/, 1991 ). 
Overexpression of the CD-MPR in cells that normally express both types of 
receptor actually enhances secretion of lysosomal proteins {Chao et af, 1990). An 
explanation for this phenomenon is that the CD-MPR releases its ligands too early, 
i.e. in a compartment where secretion can still occur. These recent studies raise the 
question whether the CD-MPR is also involved in receptor-mediated secretion of 
lysosomal precursor proteins. 
A receptor-mediated targeting to lysosomes takes place also at the plasma 
membrane, where it is called endocytosis. Secreted lysosomal precursor proteins, 
carrying the M6P recognition marker, can be taken up and delivered to the lyso-
some. About 10 o/o of the lysosomal enzymes are delivered via this endocytic route. 
Surprisingly the CD-MPR is not involved in endocytosis even though it does reach 
the plasma membrane {Stein eta/, 1987). Probably at this site it can not efficiently 
bind the ligand {Watanabe eta/, 1990). 
Deletion mutagenesis of the CI-MPR has shown that the cytoplasmic tail 
contains the relevant and distinct signals for targeting in the biosynthetic as well as 
endocytic routes {Canfield eta/, 1991; Lobel eta/, 1989). The signal for endocyto-
sis is a general motif rather than a specific sequence. It consists of an aromatic side 
chain {e.g. Tyr, but in the CI-MPR this residue can be replaced by Phe), separated 
from a bulky hydrophobic amino acid side chain by two amino acids, one of which 
positively charged. This signal is present in primary structures of other transmem-
brane proteins {Canfield eta/, 1991 ). Examples are the CD-MPR {Johnson et af, 
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1990), the low density lipoprotein receptor, LDLR (Chen eta!, 1990), h-LAMP-1 
(Williams and Fukuda, 1990) and lysosomal acid phosphatase, LAP (Peters eta!, 
1990). 
Remarkably, the CI-MPR was found to be identical to the insulin-like growth 
factor II receptor, IGFIIR (Morgan eta!, 1987). Although the binding sites for lyso-
somal proteins and IGFII are located at different positions, these ligands compete 
for a single receptor molecule. The biological significance of the dual function of 
the receptor is not yet clear. Interestingly, chicken CI-MPR lacks affinity for IGFII 
(Canfield and Kornfeld, 1989). It has been proposed that the CI-MPR evolved its 
IGF-binding function to target the hormone for degradation before it can transmit a 
growth signal (e.g. Haig and Graham, 1991). However, there is also evidence that 
the receptor is involved in signal transduction through IGFII binding. In addition to 
the M6P-dependent route other pathways for lysosomal enzyme targeting exist. A 
well documented example of a protein that makes use of such an alternative 
mechanism is LAP. This protein is synthesized as a membrane bound precursor 
with a short cytoplasmic tail (Pohlmann eta!, 1988; Waheed eta!, 1988) and it is 
transported to the lysosome via the plasma membrane (Braun eta!, 1989). Recy-
cling between plasma membrane and endosomes can occur before LAP ends up 
in lysosomes. Also in this case the endocytic signal invokes an essential Tyr 
residue in the cytoplasmic tail, but contrary to the CI-MPR in LAP this residue can-
not be replaced by Phe (Peters eta!, 1990). In lysosomes LAP is converted to a 
soluble form by the sequential action of a cytoplasmic thiol protease and a lysoso-
mal aspartyl protease (Gottschalk eta!, 1989). Aside from LAP other enzymes uti-
lize a M6P-independent mechanism for lysosomal enzyme targeting. These in-
clude j3-glucocerebrosidase (Aerts eta!, 1986; 1988) and the LAMPs (Kornfeld 
and Mellman, 1989; Williams and Fukuda, 1990). Moreover, some tissues like liver, 
or cultured cells like HepG2, have alternative systems for targeting lysosomal en-
zymes, even those that contain the M6P recognition marker (Rijnboutt eta!, 1991 ). 
In conclusion, while it is clear that the M6P sorting system is the most prevalent and 
best characterized for lysosomal proteins, other routes also exist, which will pre-
sumably be better defined in the near future. 
1.2.3. Selective vesicular transport 
Protein transport between compartments of the secretory route is carried out by 
vesicles. Receptor-mediated endocytosis has contributed largely to the current un-
derstanding of the mechanisms of vesicular transport. The process is initiated by 
the formation of clathrin networks underlying the plasma membrane. Clathrin, the 
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name means "lattice-like" (Pearse, 1987), is a protein complex with a three-legged 
structure (triskelion) that consists of three heavy and three light chains (for reviews 
see Brodsky, 1988; Keen, 1990; Pearse, 1987). Of the latter two groups exist, LCa 
and LCb, that can bind in any combination to the heavy chains (see review by 
(Brodsky eta!, 1991 ). Alternative splicing of mRNAs encoding the light chains gives 
rise to tissue specific forms of LCa and LCb. Clathrin spontaneously forms cage-
like structures in vitro. Clathrin networks induce the local invagination of the plasma 
membrane, thereby sequestering clustered receptor-ligand complexes. The so-
formed "clathrin-coated" pit buds off and becomes a coated vesicle. Uncoating of 
the vesicle commences soon after. The process requires ATP and is catalyzed by a 
member of the hsp70 family, which is identical to the prp73 protein. Selective, 
clathrin-controlled transport operates not only in the endocy1ic route, but also in the 
segregation of newly synthesized lysosomal proteins at the level of the TGN. Regu-
lated secretion through the formation of secretory vesicles requires clathrin as well, 
whereas constitutive secretion does not (Orci et af, 1987). 
A group of characteristic proteins, called "adaptins", have been isolated that 
link clathrin to receptor-ligand complexes, via the cy1oplasmic tails of the receptors. 
Adaptins are assembled into complexes called AP-1 and -2, or HAl and -II 
(reviewed by Keen, 1990), which promote coated pit and -vesicle formation. Within 
the vesicles adaptins are located between the membrane and the clathrin-cage 
(Vigers eta!, 1986a; 1986b). AP-1 resides exclusively at the TGN, whereas AP-2 is 
localized to the plasma membrane. The latter recognizes the aforementioned 
'1yrosine signal" (Canfield eta/, 1991) in the cy1oplasmic tail of the CI-MPR 
(Glickman et af, 1989), whereas another determinant is important for coated pit 
formation at the TGN (Lobel et af, 1989). Both complexes contain proteins of 100-
115 kDa, a- and j3-adaptin in AP-2, B'- and y-adaptin in AP-1, and smaller proteins 
of about 50 and 17 kDa. (see Keen, 1990). 
1.2.4 Endosomes/lysosomes 
After uncoating, an endocy1ic vesicle packed with receptor-ligand complexes or 
empty receptors (e.g. CD-MPR) can fuse with a compartment at the periphery of the 
cell, called the early endosome (reviewed by Gruenberg and Howell, 1989b). The 
latter is a collection of vesicles with tubulovesicular extensions, that can fuse with 
each other. Fusion requires cy1osolic factors, among which are a ras-like GTP-
binding protein, rab5 (Gorvel et af, 1991 ), and the N-ethylmaleimide (NEM)-sensi-
tive fusion protein, NSF (Diaz et af, 1989). The slightly acidic pH of the endosome 
may cause release of certain ligands from their receptors. Recycling receptors es-
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cape the degradative pathway, perhaps via the tubular extensions, whereas the 
majority of the ligands remains confined to the multivesicular main body of the en-
dosome and is subsequently transported to late endosomes or prelysosomes. 
Early and late endosomes are different entities. They can be distinguished by vari-
ous biochemical and morphological criteria (Schmid et at, 1988), and appear to 
have differential need for microtubules (for review see Kelly, 1990). It is, however 
not clear how transport between these compartments is organized. One model 
states that late endosomes derive from earty ones simply by maturation (Stoorvogel 
et at, 1991 ). Another view assumes that they are preexisting compartments that 
communicate via vesicular traffic (Gruenberg et at, 1989a). A third model 
envisages an interconnected network of early and late endosomes (Hopkins et at, 
1990). Late endosomes are presumably the site where newly synthesized lysoso-
mal enzymes arrive (reviewed by Kornfeld and Mellman, 1989). The pH is low 
enough for dissociation of ligands from the CD/CI-MPR. The next step is the forma-
tion of a fully equipped lysosome. No recycling of ligands is possible from the lyso-
some and its membrane is devoid of MPR (Griffiths et at, 1988). 
Many lysosomal proteins have been shown to undergo discrete proteolytic 
processing, called "maturation", prior to or upon arrival in lysosomes. Various func-
tions could rationalize this process. First of all, a precursor and not a mature protein 
may contain targeting information necessary to shuttle it to lysosomes (see chapter 
2). For some proteins maturation could simply be a consequence of the proteolytic 
environment of the lysosome, something that could apply for the enzyme 13-hexo-
saminidase that is as active in its precursor form as in its mature state (Hasilik and 
Neufeld, 1980a; 1980b). However, in the case of the protective protein/cathepsin A 
proteolytic processing converts an inactive form (zymogen) to an active one (see 
chapter 2). In this case maturation becomes a functional event and ensures the re-
lease of the peptidase activity only within the endosomal/lysosomal compartment. 
Various functions may underly the maturation of cathepsins B, H, Land D, which 
occurs in several steps (for review see Erickson 1989). A first endoproteolytic event 
causes the loss of a propeptide segment and is followed by further proteolytic pro-
cessing as well as N- and/or C-terminal amino acid trimming. Previously, it was 
thought that the propeptide also served to prevent early proteolytic activity. While 
this may hold true intracellularly, it was recently found that secreted precursor forms 
of these cathepsins are catalytically active under certain conditions (Erickson 
1989). The function(s) of the further intralysosomal processing and trimming of 
these cathepsins is not exactly known, but in the case of cathepsin D it might ren-
der the enzyme less stable (Horst and Hasilik, 1991 ). Therefore, another function of 
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processing could indeed be to alter stability and/or conformation of lysosomal en-
zymes. 
1.2.5 Non-selective vesicular transport 
Non-clathrin-coated vesicular transport, is a non-selective process dealing with 
"bulk" flow of proteins from ER to Golgi and between the different Golgi stacks 
(reviewed by Hicke and Schekman, 1990; Rothman, 1991 ). Several steps in the 
formation and fusion of non-clathrin-coated vesicles have been defined. Vesicle 
budding is catalyzed by cytosolic factors, among which is a complex, called the 
"coatomer'', that consists of at least seven components (Waters et af, 1991 ). One of 
these is a 110 kDa protein, ~-COP, that is homologous to ~-adaptin of the AP-2 
complex, indicating that the molecular mechanisms involved in selective and non-
selective vesicle formation have some similar features (Duden et af, 1991; Serafini 
eta/, 1991 ). After budding the "coatomer'' is removed in a reaction that requires a 
ras-like GTP-binding protein. The vesicle then fuses with an acceptor membrane, 
by means of the same factor, NSF, that is involved in fusion of early endosomes. 
Fusion is inhibited by NEM and causes the accumulation of uncoated vesicles 
(Malhotra et af, 1988). NSF has been purified from Chinese hamster ovary cells 
(Block eta!, 1988) and its corresponding eDNA cloned (Wilson et af, 1989). Sur-
prisingly this factor is the mammalian homologue of the yeast SEC18 gene product, 
that is essential in one of the early steps in the transport of secretory proteins 
(Eakle eta!, 1988). In fact the yeast sec18 protein can functionally substitute for the 
mammalian NSF (Wilson et af, 1989). These data indicate that vesicle fusion is an 
evolutionary conserved process that is controlled by distinct GTP-binding proteins 
working in concert with NSF and other cytosolic components (Bourne, 1988). 
The bulk flow of proteins from ER to Golgi in non-clathrin-coated vesicles is 
also called "anterograde" transport. This process concomitantly depletes the ER 
from a considerable amount of lipid. A counteracting mechanism was shown to 
exist that could regulate lipid flow and take care of the retrieval of ER resident pro-
teins from a post-ER compartment. This "retrograde" transport system utilizes 
microtubules and it can be visualized under conditions that slow down anterograde 
transport (Lippincott-Schwartz eta/, 1989; 1990). Recent experiments indicate that 
antero- and retro-grade transport systems might use a common set of components, 
that catalyze (a) crucial step(s) in the advancement of both processes (Orci eta/, 
1991 ). If true the balance between the two transport systems would simply be regu-
lated by their competition for limiting factors. 
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1.3 lysosomal storage disorders 
Previous sections described the role of lysosomes in degradative processes and 
pathways along which lysosomal proteins are sorted. Faulty targeting or reduced 
stability and/or activity of a lysosomal enzyme, due to a mutation in its gene, are 
conceivable. This leads to a deficiency of such an enzyme, causing accumulation 
in lysosomes of non-degradable substrates and eventually cellular dysfunction. 
The latter forms the basis of a lysosomal storage disorder. The concept was de-
veloped by Hers (1965), who was the first to discover a lysosomal enzyme defi-
ciency (acid a-glucosidase) in a disorder called glycogenesis type II, or Pompe 
disease. Since this description over thirty lysosomal storage disorders have been 
documented,which are commonly grouped according to the accumulated sub-
strate(s) (see Neufeld, 1991 for a recent review). The mode of inheritance of these 
disorders is autosomal recessive, except for Fabry disease (a-galactosidase defi-
ciency) and Hunter syndrome (iduronate sulfatase deficiency), which are both X-
linked. Individual lysosomal storage disorders are generally very rare but within 
defined isolated populations the incidence oi a disease may be much higher. This 
was for example the case in the Ashkenazi-Jewish and French-Canadian popula-
tions, where GM2·gangliosidosis (hexosaminidase A deficiency) frequently oc-
curred but voluntary carrier detection has almost eliminated the disorder in these 
groups. The carrier frequency for a mutated hexosaminidase A allele is estimated 
to be 1:30 within the first group (Petersen eta/, 1983). 
A characteristic feature of lysosomal storage diseases is that even within 
one disorder patients may show widely variable clinical symptoms. Several at-
tempts have been made over the years to correlate clinical heterogeneity to bio-
chemical parameters. One model proposes a "critical threshold" of residual lyso-
somal enzyme activity, above which the mutated enzyme can cope with incoming 
substrate and postpone the most severe symptoms of a disease (Conzelmann and 
Sandhofl, 1983). The model demonstrates the importance of substrate influx in 
addition to residual enzyme activity in the development of a disorder. More recently 
the biochemical characterisation of lysosomal proteins has been facilitated and 
extended by the isolation of their corresponding cDNAs, which has concomitantly 
enabled the identification of different gene mutations involved in different variants 
of a lysosomal storage disorder. The major conclusions that can be drawn from all 
these studies carried out in many laboratories will be briefly summarized here. 
It has been shown that many different mutations may underly a given lyso-
somal storage disorder, even within isolated populations such as the Ashkenazi-
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Jewish. In the latter group, however, enrichment of lew mutated alleles was also 
found. Therefore, the clinical and biochemical heterogeneity detected in earlier 
studies could in part be caused by genetic variability. From the data gathered on 
the two most extensively studied lysosomal enzyme deficiencies, namely those of 
j3-hexosaminidase and J3-glucocerebrosidase, one can deduce that the majority of 
the patients with a given lysosomal storage disorder will be compound heterozy-
gotes, i.e. they carry two different mutated alleles. The combination of both alleles 
has to be considered in predictions of clinical outcome from genotype assesment. 
Only in a few cases such a genotype-phenotype correlation could be made. For 
example, in Gaucher disease, which is caused by a deficiency of the lysosomal en-
zyme ~-glucocerebrosidase, the "Asn370 to Se( mutation has thus far only been 
found in patients with the milder non-neurologic form of the disease (Tsuji et at, 
1988). However, other data indicate that genotype-phenotype correlations are not 
always perfect. Homozygosity for the "Leu444 to Pro" ~-glucocerebrosidase allele 
in patients with Gaucher disease is normally associated with a severe neurono-
pathic form (Firon et at, 1990; Tsuji et at, 1987; Wigderson eta/, 1989), but in pa-
tients of Japanese origin the same mutation is associated with the non-neurono-
pathic type (Masuno et at, 1990). 
Mutational analysis has further demonstrated that apparently similar protein 
deficiencies can be caused by different gene mutations. For example lack of a 
lysosomal protein in patients' tissues can be the result of gene deletions, gene re-
arrangements, splicing errors, or otherwise unstable mRNA. Other mutations might 
result in amino acid substitutions that cause improper folding of a lysosomal en-
zyme precursor, followed by its degradation in the ER. Only few mutations will 
allow residual functioning of a lysosomal protein, whereas the majority of 
alterations will completely inhibit enzymatic activity. Alleles giving rise to less 
severe disease will, therefore, probably be limited. It remains to be determined 
whether their presence in a population confers some kind of selective advantage to 
heterozygotes. 
The advent of techniques enabling genotype assigment in a lysosomal sto-
rage disorder have added DNA based methods, in addition to enzymatic detection, 
to the field of prenatal diagnosis. Hopes for improved therapeutic methods for 
treatment of this group of diseases in the near future have been raised now that 
many cDNAs encoding lysosomal enzymes are available. Since this allows most 
lysosomal proteins to be overproduced and purified using recombinant DNA tech-
nology the original idea of enzyme replacement therapy (Hers, 1965) has received 
renewed interest. It is based on the fact that lysosomal enzymes can be taken up by 
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receptor-mediated endocytosis. In patients with a lysosomal storage disorder one 
could envisage the administration of sufficient amounts of purified normal enzyme 
that would be targeted to lysosomes and overcome the deficiency. A weekly infu-
sion with purified human placental 13-glucocerebrosidase, modified for endocytosis 
by macrophages, in a child with type I Gaucher disease demonstrated clinical im-
provement (Barton eta/, 1990). However, nothing is known yet about the long term 
effects of these infusions. Therefore, the next stage of this therapeutic approach 
should be the very careful examination whether the structure of recombinant en-
zymes permits a regular intake by patients. 
Bone marrow transplantation and gene replacement are being mentioned 
as other feasible therapeutic approaches. In both cases the target tissue is the 
bone marrow that contains the he,matopoietic stem cells. The idea is that once dif-
ferentiated and circulating these cells would provide normal enzyme to deficient 
cells through secretion or direct cell-to-cell contact. Bone marrow transplantation 
has been carried out and biochemical and clinical benefit was shown in some pa-
tients (Krivit eta/, 1990). For gene replacement the attention is focused on achie-
ving retrovirus-mediated integration of recombinant eDNA into hematopoietic pro-
genitor cells of the patient. Whatever the therapy, it is still the consensus that the 
blood brain barrier can not be crossed by exogenous enzyme, therefore those pa-
tients with neurological symptoms may not be cured of their severe complaints. 
Studies on any lysosomal storage disorder and on the effect of a certain 
therapeutic strategy for this disease would greatly benefit from the existence of 
animals, carrying a disease-producing mutation in the gene encoding the lysoso-
mal protein of interest. However, such model systems of human disease have thus 
far been limited to the rarely detected animals with a naturally occurring lysosomal 
storage disorder. As it is possible now to "knock out" a gene by homologous re-
combination in (murine) embryonic stem cells (Thomas and Capecchi, 1987), or 
even to insert a selected point mutation in the chosen gene of interest via the "hit 
and run" procedure (Hasty et at, 1991 ), more of these model systems will become 
available in the near future. It is obvious that this will be of great benefit to the un-
derstanding of the factors that underly this heterogeneous class of diseases. 
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2. EXPERIMENTAL WORK 
2.1.1 Introduction 
lysosomal protective protein was discovered through its deficiency in the distinct 
metabolic storage disorder galactosialidosis, a disease characterized by the 
severely reduced activities of the enzymes 13-galactosidase and neuraminidase. In 
order to understand the relationship among the three proteins some of the relevant 
properties of the latter two glycosidases are reviewed first. 
Lysosomal !3-D-galactosidase is involved in the turnover of a variety of natu· 
ral substrates such as glycoproteins, gangliosides and glycosaminoglycans, from 
which it hydrolyzes the non-reducing terminal galactose residues (for review see 
O'Brien, 1989). As mentioned previously, the in vitro degradation of GMt-ganglio-
side by j3-galactosidase is accelerated in the presence of a particular activator 
protein, SAP-t. The enzyme will also hydrolyze several artificial substrates, among 
which is the fluorescent compound 4-methylumbelliferyi-13-D-galactoside, utilized in 
most studies. The gene encoding human lysosomal j3-galactosidase has been lo-
calized on chromosome 3 (Shows et at, t978) and mutations in this locus result in 
the lysosomal storage disorders designated GMt-gangliosidosis and Morquio B 
syndrome. In the former the major accumulated substrate is the ganglioside GMt 
(see Figure 2), whereas in Morquio B syndrome 13-galactosidase affinity for the gly-
cosaminoglycan keratan sulfate is abnormally low (Paschke and Kresse, t982; van 
der Horst et al, 1983). 
13-Galactosidase activity has been detected in a number of tissues and 
species and depending upon the extraction procedure and source of material en-
zymatic activity is recovered in mono-, di-, tetra- and multimeric forms (e.g. Hoek-
sema et at, 1979; Hoogeveen et at, 1983; Norden et at, t974; Potier et at, t990; 
Scheibe et at, 1990; Verheijen et al, 1982; 1985; Yamamoto et at, 1982; Yamamoto 
and Nishimura, 1987). The mature enzyme can be conveniently isolated using the 
affinity matrix p-aminophenylthiogalactoside-CH-Sepharose (van Diggelen et at, 
198t). Using this purification method high and low molecular weight aggregates 
were also found to persist. 
In human cultured fibroblasts j3-galactosidase is synthesized as a high 
molecular weight precursor of 85 kDa, which is processed into a mature lysosomal 
protein of 64 kDa (d"Azzo et at, 1982), with a half life of about 10 days (van Digge-
len et at, 1981 ). In mutant human fibroblasts with an isolated 13-galactosidase defi-
ciency heterogeneity in biosynthesis and processing is observed (Hoogeveen et at, 
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1984). It has been calculated that in the normal enzyme purified from human liver 
three carbohydrate chains per J3-galactosidase molecule are present (Overdijk et 
a/, 1986). A similar biosynthetic processing pattern compared to human fibroblasts 
is detectable in mouse macrophages (Skudlarek and Swank, 1979). The hall life of 
J3-galactosidase in the latter cell type was calculated to be 2.9-3.5 days. In this cal-
culation turnover is defined as the sum of enzyme degradation as well as secretion, 
each of which contributes in roughly equal amount to the disappearance of newly 
synthesized molecules (Skudlarek and Swank, 1981; Tropea eta/, 1988). Mature 
13-galactosidase, derived from mouse macrophages also carries three oligosac-
charide chains (Tropea eta/, 1988). 
The cDNAs and genes encoding human and mouse 13-galactosidase have 
recently been isolated (see publication 2; Morreau eta/, 1991; Nanba and Suzuki, 
1990; 1991; Oshima eta/, 1988; Yamamoto eta/, 1990). The structure of the hu-
man enzyme will be dealt with in publication 2. Murine 13-galactosidase, for which 
the corresponding eDNA was cloned after its human counterpart, is about 80 % 
identical to the human enzyme. Similarity is only significantly lower towards the C-
terminus of the two proteins (Nanba and Suzuki, 1990). As mentioned previously, 
the human gene gives rise to alternatively spliced transcripts, that encode the 
classic, catalytically active J3-galactosidase protein, but also a non-lysosomal form, 
which is inactive towards the artificial substrate used (publication 2). A similar 13-
galactosidase-related protein can not be encoded by the mouse gene, since the 
reading frame of the putative alternatively spliced message would contain several 
stop cedens and give rise to a truncated polypeptide (Morreau eta/, 1991 ). This 
indicates that the 13-galactosidase-related protein, if physiologically functional, 
performs this role only in man. 
Lysosomal N-acetyl-a-neuraminidase hydrolyzes terminal sialic acid 
residues linked to oligosaccharides, glycoproteins, glycolipids and the artificial 
substrate 4-methylumbelliferyi-N-acetylneuraminic acid. A single neuraminidase 
deficiency gives rise to the lysosomal storage disorder sialidosis (for review see 
Beaudet and Thomas, 1989). Urine and fibroblasts of patients with this disorder 
were found to contain mainly sialyloligosaccharides as secreted or stored products, 
respectively (reviewed by Cantz and Ulrich-Bott, 1990). The enzyme is encoded by 
a gene on human chromosome 10 (Mueller eta/, 1986). 
Mammalian lysosomal neuraminidase has been difficult to purify because of 
its lability upon extraction from most tissues and its apparent membrane-bound 
character. There appear to be several mammalian neuraminidases, that so far 
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could only be distinguished by specific biochemical parameters and because of the 
lysosomal enzyme deficiency in the disorder sialidosis (see review by Corfield et 
a/, 1981; and Lieser eta/, 1989; Mendla and Cantz, 1984; Samollow eta/, 1990; 
Schneider-Jakob and Cantz, 1991: Usuki eta/, 1988; Verheijen eta/, 1983). How-
ever, it is possible to purify a soluble form of acid neuraminidase together with ~­
galactosidase, the protective protein and other polypeptides in a stable high 
molecular weight complex from bovine testis and other tissues and species 
(Hiraiwa eta/, 1991: Potier eta/, 1990; Scheibe eta/, 1990; Verheijen eta/, 1982; 
1985; Yamamoto eta/, 1982; Yamamoto and Nishimura, 1987). Photoaffinity la-
beling studies have demonstrated that within the bovine testis complex the 
neuraminidase polypeptide carrying the active site is a 55 kDa protein (van der 
Horst eta/, 1990). In contrast, the complexed human placental enzyme was shown 
to be a heavily glycosylated polypeptide of 66 kDa (van der Horst eta/, 1989), or 61 
kDa (Warner eta/, 1990). Nothing is known yet about the synthesis, routing and 
maturation of this highly intriguing enzyme. 
There is a distinct lysosomal storage disorder that differs from the isolated ~­
galactosidase and neuraminidase deficiencies mentioned above in that both gly-
cosidase activities are severely affected. After the first report of a patient with this 
combined lysosomal enzyme deficiency (Wenger eta/, 1978) more of these cases 
were shown to exist among patients with different clinical phenotypes. The "new" 
disorder, termed galactosialidosis (Andria eta/, 1981 ), is rare and is transmitted in 
an autosomal recessive mode (see reviews by Andria eta/, 1981; Galjaard eta/, 
1984; O'Brien, 1989; Suzuki eta/, 1984). Based on age of onset of the disease 
three phenotypes are distinguished: 1) a severe early infantile form, which leads to 
death at or soon after birth and is characterized by CNS involvement, macular 
cherry-red spots, visceromegaly, renal insufficiency, coarse facies and skeletal ab-
normalities; 2) a milder late infantile type, that usually manifests itself at 6-12 
months of age but remarkably does not result in mental retardation, at least in those 
patients thus far examined and followed up (Chitayat eta/, 1988; Strisciuglio eta/, 
1990); 3) a juvenile/adult form, which is mainly found in Japan and is characterized 
by slowly progressive CNS symptoms, including motor disturbance and mental re-
tardation, skeletal abnormalities, dysmorphism, macular cherry-red spots and an-
giokeratoma. Investigations aimed at deciphering the nature of accumulated pro-
ducts in placenta and urine from galactosialidosis patients revealed them to be 
mainly sialylated oligosaccharides, as in the disorder sialidosis (Okada eta/, 1978; 
van Pelt eta/, 1988a;1988b; 1989). 
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The defective gene in galactosialidosis was demonstrated by complementa-
tion analysis to differ from those encoding I)-galactosidase or neuraminidase 
(Galjaard eta/, 1975; Hoogeveen eta/, 1980) and to be localized either on chro-
mosome 20 (Mueller eta/, 1986) or 22 (Sips eta/, 1985). Further evidence for the 
participation of another factor in the regulation of J3-galactosidase and neura-
minidase came from "uptake" studies. The activity of both glycosidases in galac-
tosialidosis fibroblasts is restored to near normal levels when these cells are cul-
tured in medium, suplemented with secreted proteins derived from medium of con-
trol, GM1-gangliosidosis or sialidosis fibroblasts, but not of galactosialidosis cells. 
Uptake of a "corrective factor" is impaired if concomitantly with the secreted mate-
rial 1 mM M6P is added to the medium of the recipient cells (Hoogeveen eta/, 
1981 ). As is now known, the latter compound competitively inhibits MPR-mediated 
endocy1osis of lysosomal protein precursors. Indeed the "corrective factor" later 
turned out to be a phosphorylated protein (Hoogeveen et af, 1986). 
In galactosialidosis cells J3-galactosidase has normal hydroly1ic properties 
but its half life is less than one day, compared to ten days in normal cells (van 
Diggelen eta/, 1981; 1982). Biosynthetic labeling and immunoprecipitation analy-
sis revealed that fibroblasts derived from an early infantile galactosialidosis patient 
synthesize a normal quantity of the 85 kDa J3-galactosidase precursor. The latter 
undergoes delayed endoproteoly1ic processing and the mature form is rapidly 
turned over (d'Azzo eta/, 1982). Only after addition ofleupeptin to the medium of 
these cells could a 66 kDa intermediate be visualized, that was also detected in 
leupeptin-treated normal cells. These data indicated that in galactosialidosis cells 
J3-galactosidase is normally synthesized but it is rapidly degraded upon maturation. 
Surprisingly, proteins of 54 and 32 kDa that were immunoprecipitated together with 
J3-galactosidase from control fibroblast extracts, were completely absent in the early 
infantile galactosialidosis cell lysates. The 54 kDa form turned out to be the precur-
sor of the 32 kDa polypeptide. Since its deficiency in galactosialidosis leads to the 
increased turnover of J3-galactosidase and to a complete absence of neura-
minidase activity (d'Azzo eta/, 1982), the "corrective factor" was later named 
"protective protein" (Hoogeveen eta/, 1983). 
The multimeric form of J3-galactosidase that is detected in extracts of normal 
tissues is absent in galactosialidosis fibroblast lysates (Hoeksema eta/, 1979; 
Hoogeveen eta/, 1983). However, if the latter contain normal protective protein, 
taken up by receptor-mediated endocy1osis, J3-galactosidase is again found in a 
multimeric aggregate. It was postulated that the 32 kDa protective protein forms 
high molecular weight complexes with J3-galactosidase in lysosomes and that this 
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event prevents the rapid proteolytic degradation of 13-galactosidase molecules 
(Hoogeveen et af, 1983). Immune electron microscopy has provided indirect evi-
dence for this hypothesis (Willemsen et at, 1986). The model was extended to in-
clude neuraminidase. This enzyme copurifies in complex with 13-galactosidase, the 
protective protein and other polypeptides after p-aminophenylthiogalactoside affini-
ty chromatography of bovine and porcine testis glycoprotein preparations 
(Verheijen et af, 1982; Yamamoto and Nishimura, 1987). Using human placenta 
similar results are obtained with the notable difference that neuraminidase activity 
has to be generated by concentration and 37 oc incubation of the glycoprotein 
preparation (Verheijen et at, 1985). In the stabilized sample monospecific antibo-
dies against the 32 kDa form of the protective protein coprecipitate both J3-galacto-
sidase and neuraminidase activities. Thus, in vitro a complex exists of the three 
aforementioned glycoproteins. Given the combined hydrolase deficiency in ga-
lactosialidosis it was proposed that this complex is a normal constituent of lyse-
somes and the function of the protective protein is to stabilize and activate the other 
two enzymes by virtue of the association. 
In normal fibroblasts proteolytic conversion of precursor to mature protective 
protein starts 30 min after synthesis (Palmeri et af, 1986). Aside from the early in-
fantile fibroblasts mentioned above, several galactosialidosis cell strains synthe-
size a mutated 54 kDa precursor in varying quantities, but no mature form is im-
munoprecipitated after a chase of 2 hr (Palmeri et at, 1986). In a late infantile cell 
strain minute amounts of immunoprecipitable 32 kDa polypeptide were detected 
after treatment of the fibroblasts with the protease inhibitor leupeptin (Palmeri et al, 
1986). Similar results were obtained using other strains derived from patients with 
the same phenotype. This has led to the suggestion that the presence of residual 
32 kDa polypeptide is a distinct feature in late infantile galactosialidosis 
(Strisciuglio et at, 1988). 
We have cloned the cDNAs encoding human, mouse and chicken protective 
proteins and human 13-galactosidase in order to investigate their respective primary 
structures, the function(s) of the protective protein, its interaction with 13-galactosi-
dase, and to identify mutation(s) underlying the different lysosomal storage disor-
ders. Our findings and main conclusions are reported in publications 1-6. In publi-
cation 7 the gene encoding human protective protein is unequivocally localized on 
chromosome 20, by using in situ hybridization. 
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Summary 
The ~protective protein" is a glycoprotein that associ-
ates with lysosomal B-galactosidase and neuramini-
dase and is deficient in the autosomal recessive dis--
order galactosialidosis. We have isolated the eDNA 
encoding human "protective protein." The clone rec-
ognizes a 2 kb mRNA in normal cells that is not evident 
in fibroblasts of an early infantlle galactosialidosis pa-
tient. The eDNA directs the synthesis of a 452 amino 
acid precursor molecule that is processed in vivo to 
yield mature ~protective protein,~ a heterodimer of 32 
kd and 20 kd polypeptides held together by disulfide 
bridges. This mature form is also biologically func-
tional since it restores ~-galactosidase and neuramini-
dase activities in galactosialidosis cells. The predicted 
amino acid sequence of the ~protective protein~ bears 
homology to yeast carboxypeptidase Y and the KEX1 
gene product. This suggests a protease activity for the 
~protective protein.~ 
Introduction 
The lysosomaJ enzymes ~-o-gaJactos"1dase (E.C. 3.2.1.23) 
and N-acetyl-o.-neuraminidase (sialidase, E.G. 3.2.1.18) 
are hydrolytic glycoproteins responsible for the catabol-
ism of a variety of natural and synthetic substrates (for 
reviews see Corfield eta!., 1981; O'Brien, 1983). Mutations 
at their structural genes cause deficient or severely al-
tered enzyme activities with consequent accumulation of 
undegraded substrate(s) ·m the lysosomes. The resulfmg 
metabolic storage disorders associated with a single ~-ga­
lactosidase deficiency are GM1-gangliosidosis and Morquio 
B disease (Groebe et al., 1980; O'Brien, 1983), whereas 
sialidosis is due to an isolated neuraminidase deficiency 
(Gantz et al., 1984). 
There is, however, another autosomal recessive dis-
ease, genetically d'1stinct from GM1-gangliosidos"1s and 
sialidosis, that is currently designated galactosialidosis 
(Andria et al., 1981) because of the coexistent deficiency 
of 6-galactosidase and neuraminidase in patients with this 
disorder (Wenger et al., 1978). Different clinical pheno-
types have been observed, ranging from very severe early 
infantile (E. I.) forms, fatal within childhood, to milder late 
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infantile (L.I.) and juvenile/adult variants (Andria et al., 
1981; Suzuki et al., 1984; Galjaard eta!., 1984).1n all types 
of patients, the responsible molecular defect has been at~ 
tributed to the deficiency of a 32 kd glycoprotein, referred 
to as "protective protein.~ which appears to be essential for 
the full biological activity of both ~-galactosidase and 
neuraminidase {d'Azzo et al., 1982). 
In human liver and cultured fibroblasts. active ~-galacto­
sidase is present as a 64 kd monomeric form and as a h'1gh 
molecular weight aggregate (600-700 kd) (Norden et al., 
1974: Hoeksema et al., 1979). In galactosialidosis fibro-
blasts, the residual ~-galactosidase activity is about 10% 
of the normal level and is the result of enhanced intralyso-
somal degradation of the enzyme, which is present only 
in the monomeric form (van Diggelen eta!., 1982; Hoogev~ 
een et al., 1983). 
Studies on the biosynthesis of lysosomal C-galactosi-
dase in cultured fibroblasts have shown that the enzyme 
precipitates with anti-human ~-galactosidase antiserum 
together with two other polypeptides, of 32 kd and 20 kd 
(d'Azzo et al., 1982). Furthermor·e, the majority of active 
~-galactosidase can be resolved with the 32 kd and 20 kd 
proteins '1n the aforementioned high molecular weight ag-
gregate {Hoogeveen et al., 1983). The 32 kd component 
is synthesized as a 54 kd precursor that is also recovered 
extracellularly (d'Azzo et al., 1982). This secreted form, 
taken up by galactosialidosis fibroblasts via the mannose-
6-phosphate receptor, is processed and promotes mul-
timerization of 13-galactosidase monomers, which prevents 
rapid proteolytic degradation of the enzyme (Hoogeveen 
et al., 1981, 1983: Willemsen et al., 1986). Although the in-
volvement of the 32 kd protein in the aggregation of mono-
meric ~-galactosidase became apparent, the biologial sig-
nificance of the 20 kd polypeptide has remained unclear 
until now. 
In concurrent studies on lysosomal neuraminidase, 
Verhe"1jen et al. (1982. 1985) found that in bovine testis and 
human placenta this enzyme copurifies with the ~protec­
tive protein" and ~-galactosidase and that its activity de-
pends on the presence of the ~protective protein:· Taken 
together, these findings strongly suggest that the three 
glycoproteins-C-galactosidase, neuraminidase. and the 
Mprotective protein':....exist in lysosomes as a functional 
complex, but the stoichiometry of this complex is not yet 
understood. 
We have isolated eDNA encoding the "protective pro~ 
tein" to study the primary structure, function, and expres-
sion of this protein as welt as to investigate the molecular 
nature of the mutations in galactosialidosis patients. The 
eDNA clone directs the synthesis of Mprotective protein~ 
precursor, which becomes biologically active after being 
endocytosed and processed in galactosialidosis fibro-
blasts. The amino acid sequence deduced from the eDNA 
reveals that the active ~protective protein" consists of a 
heterodimer of 32 kd and 20 kd polypeptides. These 
components are held together by disulfide bridges. The 
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Agure 1. Separation of Tryptic Poptidcs from the 32 kd Protein: Amino 
Acid Sequences and Oligonucleotide Probes 
The 32 kd protein. purlfled from human placenta. was digested to com-
pletion with trypsin. Resulting peptldes were separated on a reverse-
phase HPLC column using a gradient of 5%-60% acetonitrile (A). The 
numbered peaks. T1-T5, represent peptidos used for automated Ed-
mnn degmdation. Corresponding amino acid sequences are shown in 
{B). Asterisks refer to discrepancies between deduced and predicted 
amino acid sequences; unassigned residues are indicated by the letter 
X. Two amino acid sequences were suitable for synthesi.z:ing oligonu-
cleotide probes. whose sequences are depicted in {C). 
boxypeptidase Y (CPY), a yeast vacuolar protease, and 
the KEX1 gene product. a yeast processing enzyme with 
carboxypeptidase B-like activity. 
Results 
Partial Amino Acid Sequence and 
Isolation of Antibodies 
The high molecular weight complex of 13-galactosidase, 
neuraminidase. and "protective protein" can be isolated 
Ek!m HI Bo.mHI Pvu 11 
5' 
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from human placenta using concanavalin A-Sepharose 
chromatography and affinity chromatography for .B-galac-
tosidase (Verheijen et al., 1985). One of these preparations 
was used in this study to obtain purified 32 kd protein. For 
this purpose the different components of the complex 
were separated by SD8--polyacrylamide gel electrophore-
sis {SDS-PAGE) under reducing and denaturing conditions. 
Electroeluted 32 kd protein was used to raise monospecif-
ic polyclonal antibodies in rabbit. This antibody prepara-
tion, tested in biosynthetic labeling experiments as well as 
on Western blots, recognized only the 32 kd protein and 
its 54 kd precursor. In a separate experiment a gel slice 
containing the 32 kd protein was treated in situ with tryp-
sin, and the released peptides were fractionated by re-
verse-phase high-pressure liquid chromatography (HPLC) 
{Figure 1A). Five of the oligopeptides were subjected to 
automated Edman degradation {Figure 18). TheN-terminal 
sequence of the intact 32 kd protein was obtained using 
the microsequencing method of Aebersold et al. (1986). 
We also determined theN-terminal sequence of the 20 kd 
polypeptide since this protein is consistently present in 
purified preparations of the complex. Two stretches. of 26 
and 28 amino acids, were obtained. 
Isolation of eDNA Clones and Nucleotide 
Sequence Analysis 
Two of the five peptide sequences were used to synthesize 
oligonucleotide probes(Figure 1C). They were made com-
plementary to the mRNA ·In suCh a way that all codon us-
age possibilities were represented. Polyclona! anti-32 kd 
antibodies and two oligonucleotide probes were used in-
dependently to screen a human testis eDNA library in the 
expression vector J..gt11 (Young and Davis, 1983). Both 
screening procedures yielded several recombinant 
clones, the longest of which, J..Hu54. contained an insert of 
1.8 kb. This clone was recognized by the antibodies as 
well as by the two oligonucleotide probes. These findings 
supported the identity of this eDNA. 
The 1.8 kb insert. subcloned into pTZ19 (pHu54), was 
subjected to restriction endonuclease mapping (Figure 2). 
The insert was sequenced using the dideoxy chain-
termination method of Sanger et al. (1977). Figure 2 de-
picts the nucleotide sequencing strategy used. The com-
plete sequence of the pHu54 clone is shown in Figure 3A. 
The eDNA contains 1825 nucleotides. A potential ATG 
translation initiation codon is encountered only 6 nucleo-
tides from the 5' end of the eDNA. This ATG is the begin-
3' 
FlgurO 2. Partial Restriction Map and Se-
quencing Strategy of the Hu54 eDNA Clone 
All the restriction sites used for subcloning and 
sequencing are shown. except for Haelll. 
which has multiple restriction sites. Arrows In-
dicate the extent and direction or sequenc1ng 
reactions. Tho hatched box on the lowermost 
arrow Indicates a location where synthetic oli-
gonucleotides other than the universal primer 
were used. Hatched bar, 5' noncoding region·, 
open bar. codmg region; solid bar. 3' untrans-
latod region. 
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OOOOAG ATC ATC eGA CCC OCG CCO CCC CCC CTG TTC CTG CTG CTC CTG CTC CTG CTC CTG CTA GTG TCC TOO CCC TCC GOA CCC GAO CCA 90 
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AOC TCA CTA OAT GOO CTC CTC ACA GAG CAT CCC CCC TTC CTG GTC CAG CCA GAT OCT CTC ACC CTC OAG TAG AAC CCC TAT TCT TOO AAT $0 
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121 Vol AlnOin Ser Aon Pho Olu A In Leu Gin A&~ Pne Pho ArQ Leu P~e ProGru Tyr Lyo Aon Aon Lys Leu P~c Leu Thr ClyGiu Ser 
TAT OCT COC ATC TAC ATC CCC ACC CTC CCC CTG CTG OTC ATG CAG OAT CCC AGC ATG AAC CTT GAG COO CTG OCT GTG GGC AAT GGA CTC 6:)0 
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CCC CCC TCC ACC AAC ACA ACA OCT OCT TCC ACC TAG CTC AAC AAC CCC TAC OTC CCC AAG CCC CTC AAC ATC CCC OAG GAG CTC CCA CAA 1000 
:JOt Pro Pro Cys Thr[A2JLTriTTh71Aio Alo S<>r TO< Tyr Leu Aon Aon ProTyr Vol Arg Lyo Ala Leu A~n lie ProC1v Oln Leu Pro Gin 
TCC GAG ATC TCC AAC TTT CTG CTA AAC TTA GAO rAC CCC CGT CTC TAC CGA AGC ATG AAC TCC GAO TAT CTG AAC CTC CTT ACC TCA CAC 1170 
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TTT CTC ACC ATC AAC OGC CCC CCC GAG ATO CTT CCC ACC CAC AAG CCC CTC CCT CCC TTC ACC ATG TTC TCC CGC TIC CTC AAC AAC GAO 1440 
421 Phe L<>u T h r I I e l yo C I y A I o C I y t-1 • o Mel V<> I Pro T h r A5p Ly5 PrO Leu A I o A In Phe Tn r M<>l P~<> Ser A rg P"" Leu A on ly~ C In 
CCA TAG TGA TCA CCACACCAACCAGCTCCACGGCCTGATGGAGCCCCTCCCAGCCTCTCCCGCTAGGACAOTCCTGnCTAAGCAAACTCCCCCTGCACCCGGCTTCTOCCGCCA 1 &.~ 
451 Pro Tyr ••• ••• 
CCACTOCCCCCTTCCCACAOCCCTGTACATCCCAGACTCOCCCCACCCTCTCCCATACAGACCCTCCCCGCAAGTTAOCACTTTATTGOCCCAOCACTTCCTCAATCGCCTCCCCTCCC 1674 
CCCTTCTCTGCTTAAACAATGCCCTTTATGATOCACTGATICCATCCCAGGAACCCAACAGACCTCACOACACCCCACAGOCACCTGCTCCACCGACTCTAATTGATAGATTGATI ATC I 793 
0AA TTAAATTCGCTACACCTICAAAAAAAAAA 
B 
Figure 3. Nucleotide and Predicted Amino Acid Sequences of the Hu54 eDNA 
(A) Tho predicted amino acid sequence Is shown, with amino acids -28 to -1 representing the signal sequence and amino acids 1 to 452 represent· 
lng the precursor polypeptide of the "protective protein:' Tryptic peptldes (thin underlines) and N-terminal sequences (thick underlines) of the 32 
kd and 20 kd proteins are marked. Pote'ltlal N-Tinked glycosylation sites are boxed. A putative polyadenylatlon signal in the :3' untranslated region 
Is underlined. 
(B) Alignment of the amino acid sequences of the "protective protein" precursor (HU54). yeast CPY (Valls et al., 1987). and the KEX1 gene product 
(Dmochowska et al., 1987). Identical residues In the proteins are boxed. The asterisk designates the active--site serine residue of CPY. Numbers 
on the left refer to positions of the amino acids within the sequences. 
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ning of an open reading frame of 1440 nucleotides inter-
rupted by two consecutive stop codons, and it is flanked 
at the 3' end by a363 nucleotide untranslated region. The 
nucleotide sequence terminates with a short poly(A) tail. 
and a potential polyadeny!ation signal (ATTAAA) is found 
at position 1796. 
The putative ATG initiation codon is in a context that is 
not optimal for ribosome binding and initiation of transla-
tion (Kozak, 1986). To establish the usage of this ATG, 
pHu54 was transcribed in vitro. The resulting mANA. 
translated in a rabbit reticulocyte lysate system, gave rise 
to a primary product of 54 kd immunoprecipitable with 
anti-32 kd antibodies. The size of this molecule correlated 
well with that of the protein immunoprecipitated after 
translation of total or polysomal RNA from normal fibro-
blasts (data not shown). These results suggest that the 
eDNA contains the entire coding region fOr the ~protective 
protein~ precursor. 
Predicted Amino Acid Sequence of 
the "Protective Protein" and Homology to Yeast 
Carboxypeptidase Y and KEX1 Gene Product 
The open reading frame of 1440 nucleotides encodes a 
protein of 480 amino acids. Four of the five tryptic peptides 
are found in the amino acid sequence deduced from the 
Hu54 eDNA (Figure SA). Few discrepancies exist between 
the primary structure predicted here and the amino acid 
sequencing data (Figure 1C). These include lle-238, Gly-
240, Ser-243, and Lys-283. One of the tryptic peptides (T4) 
could not be located within the predicted amino acid se-
quence. The localization of the N-terminus of the 32 kd 
protein at residues 1-26 (Figure 3A. indicated with a thick 
line) allows for the assignment of a signal sequence of 28 
amino acids immediately preceding the 32 kd polypep-
tide. It contains the three domains-basic N-terminal, hy-
drophobic central, and polar C-terminai regions-typical 
of signal sequences (von Heijne, 1986). Moreover, the ala-
nine and glycine residues at positions -1 and -3 conform 
to statistically determined rules for amino acids at those 
positions with respect to signal sequence cleavage sites 
(von Heijne. 1986). Surprisingly, the N-terminus of the 20 
kd protein is also located within the predicted amino acid 
sequence at residues 299-326 (Figure SA). Thus, the pri-
mary structure of the Mprotective protein~ includes a signal 
sequence of 28 amino acids followed by 298 and 154 
residues constituting the 32 kd and the 20 kd domains, 
respectively. 
There are two potential N-linked glycosylation sites, at 
positions 117 and 305. The predicted molecular mass of 
the Mprotective protein~ precursor is 54,496 daltons, which 
is reduced to 51,421 daltons after removal of the signal se-
quence. Assuming glycosylation at the aforementioned 
residues and therefore addition of approximately 4,000 
daltons, the estimated molecular mass of the precursor 
molecule will be 55 kd. This corresponds to the size ex-
perimentally calculated after SDS-PAGE. 
Searches of different protein data bases demonstrated 
homology between the Mprotective protein~ and the yeast 
vacuolar protease CPY. The gene for CPY has recently 
been cloned and sequenced (Valls et al.. 1987). We have 
73 
1 z s 4 
Figure 4. Functional State of the "Protective Protein" in the Purified 
Complex 
Purified protein components ot the complex were either reduced and 
denatured by boiling In SDS sample buffer In the presence of 20 mM 
dlthlothreltol (+.lanes 1 and 3), or simply boiled without reduction(-. 
lanes 2 and 4). Samples were resolved by SOS-PAGE. One part of the 
gel was stained for total proteins with Coomassie brilliant blue (lanes 
1 and 2); the other part was subjected to Western blotting. Tho nitrocel-
lulose filter was incubated with antl·32 kd antibodies and 1251-protein 
A. Radiolaboled bands were visualized by autoradiography (lanes 3 
and 4). 
used the sequence of the mature form of CPY, residues 
112-532 (Valls et al., 1987), for alignment with the "protec-
tive protein~ {Figure 38). On the other hand, Dmochowska 
et al. (1987) have reported sequence homology between 
CPY and another yeast protein, the KEX1 gene product. 
We therefore also compared the Mprotective protein" se-
quence with residues 34--489 of the KEX7-encoded pro-
tein (Figure 38). Identity is predominantly confined to the 
N-terminal portion of all three proteins. This region is 
flanked by a sequence tract that does not show any signifi-
cant similarity. Homology among the three proteins is 
again found over a stretch of about 100 amino acids. posi-
tioned at the C-termini of Hu54 and CPY and residues 
390-489 of the KEX1 gene product. A conserved region 
of six amino acids (Giy-Giu-Ser-Tyr-Aia-G!y), present in all 
three proteins. spans the serine residue shown to be in the 
active site of CPY (Hayashi et al., 1973) and possibly of the 
KEX1 gene product (Dmochowska et al., 1987). Two other 
regions, also identical. one of ten amino acids (Trp-Leu-
Asn-Gly-Gly-Pro-Giy-Cys-Ser-Ser) including a Cys resi-
due, and one of four amino acids (His-Met-Val-Pro) con-
taining a His residue, are positioned at the beginning and 
the end of the three aligned sequences {Figure 38). These 
observations imply that the "protective protein" might func-
tion as a carboxypeptidase. 
Nine cysteines within the predicted amino acid se-
quence of the "protective protein" are present, four of 
which cluster between residues 212 and 228. This sug-
gests intramolecular covalent binding by disulfide bridges 
between the 32 kd and 20 kd polypeptides. To test this hy-
pothesis, the different components of the purified com-
plex (13-galactosidase, neuraminidase. and "protective pro-
tein") were fractionated by SDS-PAGE under reducing and 
nonreducing conditions (Figure 4). Proteins were either 
directly stained with Coomassie blue or Western blotted 
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Figure 5. Northern Blot Analysis of Fibroblast RNA 
Samples oltotal fibroblast RNA {15 IJ.9) from a normal 'md'IVIdual. the 
E.L (Early tnt.) and L.l. (Lo.to lnl.) galactosialidosls patients, and the 
parents of the E.l. patient wore fractionated on a formaldehyd0-
agarosegel and probed with the Hu54cDNA Ribosomal ANA markors 
are indicated. Exposure t1me was 24 hr. 
and probed with anti--32 kd antibodies. In the presence of 
the reducing agent, 32 kd and 20 kd polypeptides are visi-
ble in the Coomassie blue-stained gel, whereas a 54 kd 
form is detected under nonreducing conditions (Figure 4, 
lanes 1 and 2). Both the 32 kd and 54 kd proteins react 
with the antiserum (Figure 4, lanes 3 and 4). We conclude 
from these results that the 32 kd and 20 kd components 
of the "protective proteinH are held together by disulfide 
bridges and function as a heterodimer. 
RNA Hybridization Studies 
To determine the size of the "protective protein"' transcript 
as well as its abundance in galactosialidosis patients, total 
RNA was isolated from normal cultured fibroblasts and 
from fibroblasts of the l.l. galactosialidosis patient, the 
E. I. galactosialidosis patient, and the parents of the latter. 
A Northern blot containing these RNAs was hybridized 
with 32P-labeled Hu54 eDNA (Figure 5). In normal fibro-
blasts an mANA species of about 2 kb is present. This im-
plies that the 5' untranslated region measures about 200 
bp. The 2 kb mANA is not evident in the E. I. galactosia!i-
dosis patient. whereas it is present in normal amounts ·m 
fibroblasts of the U. galactosialidosis patient. When 10 
,_.g of poly(A)+ ANA was used, traces of the 2 kb message 
could be seen in the E. I. galactosialidosis patient, but only 
upon long exposures of the autoradiographs {data not 
shown). The parents of this patient have drastically re-
duced amounts of the 2 kb mANA. To make certain that 
equal amounts of the dmerent RNA samples were present 
on the Northern blot. the filter was rehybridized with a 
probe recognizing the glyceraldehyde-3-phosphate de-
hydrogenase mANA, which is abundant in fibroblasts 
(Benham et a!.. 1984). In all lanes, approximately the 
same amount of this 1.2 kb message was detected (data 
not shown). These results provide additional proof of the 
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identity of the eDNA clone and they also show different 
mutations in the two clinical forms of ga!actosialidosis 
tested. 
Transient Expression of Hu54 eDNA in C0$-1 Cells 
The Hu54 eDNA was cloned in two orientations into a 
derivative of the mammalian expression vector pCD-X 
(Okayama and Berg, 1983). In one construct, pCDHu54-
sense, the 5' end of the eDNA was oriented toward the 
SV40 promoter, whereas in the pCDHu54-antisense con-
struct the orientation of the eDNA was reversed. Transfec-
tion experiments were carried out on C0$-1 cells (Giuz-
man, 1981), since transient expression of exogenous DNA 
in this cell type has proved to be successful in previous 
studies. 
The pCDHu54-sense and -antisense constructs were 
transfected separately. Two days after transfection, newly 
synthesized proteins were labeled with [3SS]methionine 
in the presence of 10 mM NH4CI to induce maximal 
secretion of lysosomal protein precursors (Hasilik and 
Neufeld, 19$0). Radiolabeled proteins from cell lysates 
and medium concentrates were immunoprecipitated with 
anti-32 kd antibodies. The results are shown in Figure 6. 
Untransfected C0$-1 cells contain an endogenous 54 kd 
protein that is barely detectable by ar.ti-32 kd antibodies 
and is partially secreted into the medium (Figure 6,1anes 
1 and 2). Whether this protein represents the C0$-1 cell 
equivalent of the "protective protein~ precursor is at pres-
ent not clear: After transfection of the cells with the 
pCDHu54-sense plasmid, a large amount of the 54 kd 
precursor is synthesized (Figure 6, lanes 3 and 4). This 
precursor protein is recognized by the antibodies and it is 
present in both cells and medium.lts est"1mated molecular 
weight correlates with that observed tor the glycosylated 
"protective protein" precursor immunoprecipitated in hu-
man cells. The synthesis of this precursor molecule is not 
accomplished in C0$-1 cells transfected with the an· 
tisense construct (Figure 6, lanes 5 and 6). 
The eDNA--derived 54 kd precursor protein is apparently 
not processed to 32 kd and 20 kd polypeptides "1n C0$-1 
cells. Although the experiments illustrated in Figure 6 
were performed in the presence of NH4CI, similar results 
were obtained in the absence of this reagent (data not 
shown). These findings demonstrate that the pCDHu54-
sense construct, when transfected into C0$-1 cells, directs 
the synthesis of the 54 kd ~protective proteinH precursor, 
which is also secreted into the medium. 
Uptake and Processing of COS-1 Cell-Derived 
54 kd Precursor by Human Fibroblasts 
To show that the eDNA-encoded precursor yields a biolog-
ically active ~protective protein," uptake studies were per-
formed. Medium from [35S]methionine-labe!ed COS-1 
cells, transfected with either of the two pCDHu54 con-
structs, was collected and concentrated. Aliquots of each 
of the different medium concentrates were added to the 
medium of cultured fibroblasts from a normal individual. 
the E. I. galactosialidosis patient, and the L.l. galactosiali-
dosis patient. After a further 3 days, immunoprecipitation 
was carried out on cell extracts and medium concentrates 
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Figure 6. Transient Expression of pCOHu54 in C0$-1 Cells 
Hu54cDNA was cloned In two orlentatlonslntotho mammalian expres-
sion vector pCD-X. The resulting pCDHu54 constructs were trans-
fected Into C0$-1 cells. Control cells wore treated In the same manner 
as translected cells but no DNA was added. After 48 hr. cells were in-
cubated with flf>S]methionine for an additional 16 hr In the presence 
of 10 mM NH4CI. Labeled proteins from cells (C) and media (M} wore 
lmmunoprecipltated with antl-32 kd antibodies, analyzed on a 10% 
polyacrylamide gel under reducing and denaturing conditions, and 
visualized by fluorography. Molecular size markers are indicated at 
left. Exposure time for lanes2-4 was 24 hr; lanes 1, 5. nnd 6 were ex-
posed three times as long. 
using anti-32 kd antibodies. Media collected fr'?m the 
three different strains after 72 hr still contain 54 kd precur-
sor protein (Figure 7A, lanes 1, 3. and 4). This precursor 
form is absent in the medium of galactosialidosis fibro-
blasts containing proteins secreted by C0$-1 cells origi-
nally transfected with the antisense plasmid (Figure ?A. 
lane 2). The 54 kd precursor derived from COS-1 cells is 
endocytosed by all three eel! strains and it is rapidly 
processed into an immunoprecipitable 32 kd protein (Fig-
ure?A,Ianes 5. 7, and 8). The 20 kd polypeptide is not rec-
ognized by the anti-32 kd antibodies used in this ex-
periment. 
The predicted amino acid sequence of the 54 kd precur-
sor protein (Figure 3A) has potential glycosylation sites at 
two Asn residues. one within the 32 kd and one within the 
20 kd polypeptide. These two components of the "protec-
tive prote-In" ex·Jst as a heterod'1mer (F1gure 4). They can 
only be visualized separately after reduction and by Using 
an antiserum originally raised against the total complex 
(d:Azzo eta!., 1982). The use of the two potential glycosy-
lation sites in vivo could be demonstrated by performing 
uptake experiments similar to those described above but 
using anti-complex antiserum. Galactosialidosis fibro-
blasts of the E.!. type were used as recip-Ient cells. Three 
days after uptake of COS-1 cell-derived 54kd precursor, 
immunoprecipitation was performed followed by digestion 
with glycopeptidase F. an enzyme that cleaves all types 
of Asn-bound N-glycans (Plummer et aL. 1984; Tarentino 
et al.. 1985). As shown in Figure 78, the 32 kd and 20 kd 
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Figure 7. Uptake, Processing, and Glycopoptidase F Treatment of 
COS-1 ~11-Derlved "Protective Protelr'l" Precursor in Human Flbro-
blort; 
(A) Uptake and process1ng. 355-labeled 54 kd precursor protein, pro-
duced by C0$-1 coils transfected with pCDHu541n the sense orienta-
tion, was added to culture medium of normal fibroblasts and fibroblasts 
from the E.l. and LL galactosialidosls patients. After72 hr, labeled pro-
to·ms from media and cells woro lmmunoprec"•pltated with antl-32 kd 
antibodies, separated by 12.5% SDS-PAGE, and visualized by fluorog-
raphy. Lanes 1 and 5. E. I. fibroblasts; lanes3and 7, r'!Ormal fibroblasts: 
lanes 4 and 8, L.L fibroblasts. Lanes 2 and 6 represent the control ex-
poriment In which proteins sec•eted by COS-1 coils transfected with 
pCDHu54-antisense wore fed to E.l. galactoslalidosls fibroblasts. Mo-
lecular sizes wore calculated by comparison with protein markers. 
(B) Glycopeptidase F treatment. C0$-1 cell-derived, labeled 54 kd 
precursor was fed to E.l. galactoslalidosis cells. lmmunoprecipito.tion 
was carried out with anti-complex antiserum (lo.no 1}. Part of the lmmu-
noprecipltated material was digested with glycopeptidase F (lane 2). 
Samples were analyzed as In (A). 
proteins undergo deglycosylation. resulting in a shift in 
apparent mass of about 2000 daltons (lanes 1 and 2). 
Thus. glycosylation of the 54 kd precursor in C0$-1 cells 
takes place at the two predicted Asn residues. From these 
data we conclude that the cos-1 cell-derived 54 kd pre-
cursor contains all signals necessary for uptake by human 
fibroblasts and intracellular processing. 
We finally tested whether the processed. eDNA-encoded 
"protect.Jve protein" was able to restore lysosomal ~-galac· 
tosidase and neuraminidase activities in both mutant cell 
types. As shown in Table 1, C0$-1 cell-derived 54 kd pre-
cursor, taken up and processed by E. I. and LL galactosi-
alidosis fibroblasts. restores both enzyme activities. In the 
L.l. cells the relative increase in neuraminidase activity is 
less evident because of the higher endogenous residual 
activity. To rule out a possible effect of other secreted 
COS-1 proteins rather than the 54 kd precursor. galac-
tosialidosis cells were also cultured for the same period 
of time in conditioned medium from C0$-1 cells originally 
transfected with the antisense plasmid. Table 1 shows that 
lkJa!actosidase and neuraminidase activities in these fi-
Table 1. Restoration of Enzyme Activities in Galactosialidosls Fibroblasts after Uptake of C0$-1 Cell-Derived ~Protective Protein~ Precursor 
Addition of COS-1 
Ceil-Derived Proteins 
Transfoctlon In 
Activity (nmo1ihr per mg of protein) 
Ceil Strain C0$-1 Cells (\-Galactosidase Neuraminidase 
E.l. Galactoslalidosls pCDHu54-sonse 




L.l. Galactosialidosls pCDHu54-senso 1'7 
" pCDH54-antisense 56 5 
60 6 
Normal + pCDHu54-sense = 60 294 104 
Proteins secreted by C0$-1 cells, aftertransfectlon with pCDHu54-senso or -antisense. were added to the medium of normal fibroblasts and fibro-
blasts from E.L and Ll. galactosialidosls patients. After 72 hr, cells wore harvosted by trypsinization, and enzyme activities were measured In 
cell homogenates using synthetic 4-methy1umbe!liferyl substrates. 
broblasts do not increase. The presence or absence of 
proteins derived from cos-1 cells in the medium of nor-
mal cells does not cause any significant difference in en-
zyme activities. The levels of other lysosomal enzymes 
tested as internal controls in the different cell homage-
nates remain unchanged (data not shown). 
Discussion 
We have isolated and characterized the eDNA encoding 
the 54 kd precursor of the Kprotective pr01einM known to be 
deficient in patients with the autosomal recessive disease 
galactosialidosis. In normal human fibroblasts. the eDNA 
recognizes an mRNAo1 approximately 2 kb that is not evi-
dent in fibroblasts of the E.L galactosialidosis patient. Par-
ents of this patient. who are consanguineous (Kieijer et al., 
1979) and therefore likely to carry the same allelic muta-
tion, have markedly reduced amounts of the 2 kb mRNA 
These data demonstrate heterozygosity for the Kprotective 
proteinft deficiency, for which no direct enzymatic assay is 
available. The U. patient has a normal amount of the 2 
kb mRNA species. This is consistent with previous data 
from immunoprecipitation studies that established the ab-
sence of cross-reacting material for the Kprotective pro-
teinft in fibroblasts of the E. I. patient, but the presence of 
a normal amount of precursor molecules in cells of the Ll. 
patient (d:Azzo et al., 1982: Palmeri et al., 1986). 
TheN-terminal sequences of the 32 kd and 20 kd poly-
peptides are found in the predicted amino acid sequence 
of the Kprotective protein" precursor. From their locations 
we could infer that the two proteins are positioned next to 
each other within the precursor molecule and we could 
demonstrate that, after the initial cleavage of the precur-
sor, the two polypeptides remain held together by disulfide 
bridges. These findings clarify the presence of the 20 kd 
component in purified complex preparations and show 
that it is an integral part of the mature "protective protein:· 
The latler is a heterodimer of 32 kd and 20 kd polypep-
tides. 
The predicted molecular masses of the glycosylated 
precursor (55 kd) and the 20 kd component correlate well 
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with their estimated sizes after SDS-PAGE. There is, how-
ever, a difference of 3-4 kd between the predicted size 
(35.5 kd) and the estimated size of the 32 kd polypeptide. 
One explanation may be that C-terminal processing of the 
32 kd component takes place after initial cleavage of the 
precursor between residues 298 and 299 (Arg-Met). Con· 
versely, N-terminal processing of the 20 kd component 
may occur after cleavage of the precursor molecule some-
what before residue 299. The proteolytic event, if it occurs, 
must be confined to residues 284-298, accounting for 
about 1.7 kd, since residue 284 is the G-terminus of tryptic 
peptide T1. 
The Hu54 eDNA directs the synthesis in C05-1 cells of 
the ~protective protein~ precursor, and the protein is also 
secreted in substantial amounts. COS-1 cells are not able 
to process this form intracellularly into 32 kd and 20 kd 
polypeptides. Nevertheless. the presence of these com-
ponents has been shown in other mammalian tissues, 
e.g., bovine testis (Verheijen et al., 1982) and porcine 
spleen and testis (Yamamoto et al., 1982; Yamamoto and 
Nishimura, 1987). At present we do not know whether 
COS-1 cells fail to recognize the processing site of human 
54 kd precursor or whether the transfection procedure and 
subsequent production of the precursor molecule some-
how interfere with this cleavage event. In contrast, correct 
intracellular processing of COS-1 cell-derived 54 kd 
precursor takes place in normal human fibroblasts as well 
as in both E. I. and U. galactosialidosis cells. This result 
implies that this precursor protein acquires all molecular 
characteristics for further posttranslational modifications. 
The eDNA-encoded precursor also yields a biologically 
functional ~protective protein~ capable of correcting a-ga-
lactosidase and neuraminidase activities after being en-
docytosed and processed by mutant fibroblasts. This in-
direct approach of transient expression in C05-1 cells and 
uptake by deficient fibroblasts offers several opportunities 
for testing the different functions of the "protective pro-
tein.~ For instance, expression of in vitro mutagenized 
cDNAs may prove useful for determining the structural do-
mains in the ~protective protein~ involved in the associa-
tion with a-galactosidase and neuraminidase. 
The most striking observation in this report is the homol-
ogy of the "protective protein" to yeast CPY and the K£X1 
gene product CPY is a vacuolar protease involved in the 
degradation of small peptides (for review see Jones, 
1984). It is synthesized as a larger. inactive precursor 
(Hasi!ik and Tanner, 1978) that is converted to the mature, 
active form prior to or upon delivery to the vacuole (Hem-
mings et aL, 1981). The K£X1 gene product in yeast is in-
volved in the proteolytic processing of killer toxin and 
a.-pheromone precursors, probably at the Golgi stage in 
the secretory pathway (Dmochowska et aL, 1987). It com-
pletes maturation of subunits of these proteins by the 
removal of cf1bas·1c am·lno acid res·1dues from C-terminL 
This proteolytic step is essential for the activation of ma-
ture killer toxin and a.-pheromone. The carboxypeptidase 
B-like activity of the K£X1 product is exerted only after 
cleavage of the precursor molecules by an endopepti-
dase. 
Homology between CPY, the KEX1 gene product, and 
the "protective protein" is extensive, and the stretch of 
amino acids that spans the active site serine in CPY 
(Hayashi eta!., 1973) is completely identical in the three 
proteins. Dmochowska et a!. (1987) have demonstrated 
that mutation of this serine to alanine in the KEX1 gene 
product impairs its activity, strongly suggesting that KEX1 
is. like CPY, a serine protease. It is of interest that the two 
proteases can apparently catalyze similar reactions using 
a conserved active site but are involved in different proteo-
lytic pathways and function in different subcellular com-
partments. 
The conserved stretch of six amino acids including the 
active-site serine is located within the 32 kd polypeptide 
of the "protective protein:· The homology suggests a puta-
tive protease activity for the "protective protein:' Moreover. 
not only is the "serine domain" completely identical in the 
three proteins, but there are also two other identical 
stretches, one containing a cysteine and one a histidine 
residue. A sulfhydryl group as well as a histidine residue 
has been suggested to contribute to the enzymatic activ-
ity of CPY (Hayashi et al., 1973; Kuhn et at., 1974). It is 
noteworthy that, in the case of the "protective protein;· His-
429 is located in the 20 kd polypeptide. This implies that 
this component might also be involved in the putative pro-
tease activity of the "protective protein:· which supports 
the proposed model of the heterodimeric state of its ma-
ture form. We can speculate that this protease activity is 
responsible for specific proteolytic modifications of p-ga-
lactosidase and neuraminidase at their C-termini, result-
ing in the stabilization of the former and in the activation 
of the latter enzyme. The "protective protein" could there-
fore be the first example of a processing enzyme with car-
boxypeptidase 8-like activity in man. 
The characterization of the eDNA encoding the "protec-
tive protein" has enabled a better understanding of the 
protein's primary structure and possible mode of action. At 
the same time, the sequence homologies revealed here 
lead us to speculate on the paradox of a protective func-
tion named to a potential proteolytic activity. Studies of the 
tertiary structure of the "protective protein" and its interac~ 
tion with !}-galactosidase and neuraminidase will become 
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feasible once the genes coding for the latter two compo-
nents are cloned. 
Note: We have now established that cos-1 cell-derived 
"protective protein" precursor, taken up by untreated cos-
1 cells, is correctly converted into the heterodimeric form. 
This implies that the impaired processing of the precursor 




Human skin fibroblasts from normal Individuals and a patient with the 
E.l. form of galactoslal"ldosis (Kieljer et al.. 1979) wore obtained from 
the Rotterdam Cell Aepository(Dr. M. F. Nlermeijer). Cells from the pa· 
tient with the L.l. form of galactosialldosis (Atldrla et al., 1978) were 
provided by Dr. G. Andria. Dept. of Pediatrics. University of Naples, 
Italy. Fibroblasts were maintained In Dulbecco's modified Eagle's 
medium-Ham's F10 medium (1 :1 vollvol) supplemented with antibiotics 
and 10% fetal call serum. 
Protein Sequence Analysis 
The complex of ~alactosidase, neuraminidase. and "protective pro-
tein" was purified from human placenta as previously described 
{Verholjen ot aL, 1985). Tho different components were soparated by 
SDS.PAGE under reducing and denaturing conditions according to 
Laemmli (1970) with minor modifications (Hasilik and Neufeld. 1980). 
The 32 kd protein band was digested in situ with TPCK-trypsln ryvor-
thington Diagnostic Systems Inc., U.K.). Tryptic peptides were traction· 
ated by HPLC (y'Jaters 6000 System) using a Du Pont Zorbax C8 4.6 
mm x 25 em reverse--phase column (Anachem Ud., U.K.) and a 
5°/0-60% gradient of acetonitrile In 0.1% trifluoroacetlc acid; detection 
was at 216 nm. 
Sequence analysis of peptide fractions was performed by auto-
mated Edman degradation on an Applied Biosystems 470A gas-phase 
peptide sequenator (Hunkapltler and Hood, 1983). PTH-amlno acids 
were analyzed on-line using an Applied Blosystems 120A analyzer 
{Southan et aJ .. 1987). For N-termlnal sequence analysis, approxe. 
mateiy SQ-100 11g of the purified complex was separated as above and 
the protein components were blotted against lmmobllon PVrN transfer 
membranoo (MIIIlpore Corp.) as described byTowbin etai. {1979). Filter 
piecoocontalning either the 32 kd or the 20 kd protein were cutout and 
used as starting material lor automated Edman degradation (Aeber· 
sold et al., 1986). Amino acid sequencing was performed at the 
Biotechnology instrumentation Facility (University of California. 
RiverSide). 
eDNA Ubrary Screening 
A human testis eDNA library in A.gt11 (Young and Davis, 1983; Cion· 
tech, Palo Alto, CA), consisting of 1 x 106 independent clones with In-
sert sizes ranging from 0.7 to 3.3 kb, was plated out at a density of s 
x 104 PFU per 90 mm plate and screened with anti-32 kd anti-
bodies as previously described (Huynh et al., 1985). The same library. 
plated out at a density of 2 x 10~ PFU per 22 x 22 em plate, was 
screened with oligonucleotide probes labeled at the 5' end with 32p 
using (y-32?}ATP and polynucleotide kinase (Maniatis et al., 1982). 
The probes were synthesized on an Applied Blosystems381A ollgonu· 
cleotide synthesizer. Hybridization and washing conditions were as de-
scribed by Wood et al. (1985). 
DNA Sequencing 
The Hu54 eDNA Insert and Its restriction fragments were subclonod 
into the plasmid vectors pTZ16 and p'TZ19. Nucleotide sequencoo on 
both strands were obtained by the dideoxy chain-termination method 
(Sanger et al.,1977). M13 universal reverse primer as well as synthetic 
oligonucleotides were used. SequenCQ data were analyzed using the 
program of Staden (1986). Homology searches of the EMBL {release 
14.0; 1988). NBRF Protein (release 14.0; 1987), and SWISS-PROT (re--
lease 5.0; 1g87) data bases were performed using the program of Lip-
man and Pearson {1985). Protein alignment was done with the se--
quenC<J analysis sofware package of the University of Wisconsin 
Genetics Computer Group (Devereux et aJ., 1984). SequenC<Js have 
been deposited in the EMBUGen6;1nk data base {accession no. 
J03159). 
Northern Blot Analysis 
Total RNA was Isolated from cultured fibroblasts according to the pro-
cedure of Auffray and Rougoon {1980). RNA samples were eloctropho-
resed on a 0.8% agaroso gel containing 22M formaldehyde (Maniatis 
etal., 1982) and blotted onto a nitrocellulose filter. Tho filter was hybrid-
ized with tho eDNA probe labeled according to the procedure of Fein-
berg and Vogelsteln (1983). 
Transient Expression of eDNA In C0$-1 Colis 
The 1.8 kb Hu54 eDNA EcoRI insert was subcloned In two orientations 
in a derivative of the mammalian exprc--....slon vector pCD-X (Okayamn 
and Berg, 1983) in which the Psti-BamHI fragment3' of the SV40 pro-
moter was substitute-d by a polyllnker containing an EcoRI site (a gilt 
from N. Helsterkamp, University of Southam California). COS-1 cells 
(Giuzman, 1981) were maintained In the same culturing medium as hu-
man fibroblasts but supplemented with only 5% fetal calf serum. Two 
days beforetranslection. cells were sooded in 100 mm Petn dishes and 
grown to 30010 conlluoncy. 
Transfoctions with pCDHu54 constructs and biosynthetlc labeling 
with FS]methlonino were performed according to the method of van 
Heuvel etal. (1986) except that cells were incubnted In methlon"me-4reo 
mo-dium lor 1 hr before labeling. Tho latter was carrlo-d out for 16 hr 
in tho presence or absence of 10 mM NH~CI (Hasllik and Neufeld, 
1980). Tho preparation of cell extracts and medium concentrates and 
the lmmunopreclpltatlon of the "protective protein" and its precursor 
were poliormed as reported earlier (Proia et al., 1984). Staphylococ-
cus aureus cells. used to precipitate antigen-antibody complexes. 
were treated before use as recommended by the supplier, thereby In-
troducing reducing agent in the immunopreclpitation assay. Immune-
precipitated proteins wore resolved by SD8-PAGE under re-ducing and 
denaturing conditions. Radioactive bands were visualize-d by fluorog-
raphy of gels Impregnated with En3Hance (New England Nuclear). 
Apparent molecular weights were calculate-d by comparison with con-
ventional marker proteins. 
Uptake Studies in Human Cells 
Medium (5 ml) from translocted and 358-laboled C05-1 cells cultured 
·In 25 cm2 flasks was concentrated 2000-lold by ommonlum sulfate 
precipitation and was desalte-d afterward through a Sephadcx G-50 
column (Proia et al., 1984). This concentrate-d material {250 J.d) was 
divided into two allquots. Each aliquo: was added to fresh medium of 
confluent human fibroblasts plate-d in 60 mm dishes. The cell strains 
used wore from a normal individual and from the E.l. and Ll. galac-
toslalldosis patients. Alter an additional 3 days of subculture, coli ex-
tracts and medium concentrates wero prepared for lmmunoprecipita-
tion analysis as describe-d by Proin et al. (1984). Samples were 
Incubate-d with antl-32 kd antibodies for 16 hr at room temperature and 
were subsequently treate-d with & au reus suspenSion (10% wttvol) for 
30 min on ico. lmmunopreclpltato-d radlolabeled proteins were sepa-
rated by 805-PAGE and visualized by fluorography as above. In paral-
lel experiments, Identically treate-d cells wore harvested by trypsiniza-
tion and homogenized byvortexlng In double-distilled water (Galjaard, 
1980). Enzyme activities wore measured In cell homogenates with ar-
tificial 4-methylumbolliferyl substrates using standard assay condi-
tions (Galjaard, 1980). Total protein concentrations were determ·med by 
the method of Lowry (1951). In some instances, immunopreclpltatlon 
of radio labeled proteins was carried out using nn antibody preparation 
recognizing tho components of the complex. Including the 20 kd poly-
peptide (d'Azzo et al., 1982). lmmunoprecipltated material was divide-d 
into two aliquots: one was left untreated, and the other was subjected 
to glycopeptldase F digestion for 16 hr at 37"C using conditions recom· 
mended by the supplier. Treated and untreate-d proteins were resolved 
and visualize-d as described above. 
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Alternative Splicing of $-Galactosidase mRNA Generates the Classic 
Lysosomal Enzyme and a $-Galactosidase-related Protein* 
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From the Department of Cell BWlogy and Genetics, Erasmus University, Rotterdam, The Netherlands 
We have isolated two cDNAs encoding human lyso~ 
somal ,8-galactosidase, the enzyme deficient in G:-u~ 
gangliosidosis and Morquio B syndrome, and a p~ga~ 
lactosidase-related protein. In total RNA from normal 
fibroblasts a major mRNA of about 2.5 kilobases (kb) 
is recognized by eDNA probes. A minor transcript of 
about 2.0 kb is visible only in immunoselected polyso-
mal RNA. A heterogeneous pattern of expression of the 
2.5~kb J3-galactosidase transcript is observed in fibro-
blasts from different G11u-gangliosidosis patients. The 
nucleotide sequences of the two cDNAs are extensively 
colinear. However, the short eDNA misses two noncon~ 
tiguous protein-encoding regions (1 and 2) present in 
the long cDN A. The exclusion of region 1 in the short 
molecule introduces a frameshift in its 3 '-flanking se-
quence, which is restored by the exclusion of region 2. 
These findings imply the existence of two mRNA tem-
plates, which are read in a different frame only in the 
nucleotide stretch between regions 1 and 2. Sequence 
analysis of genomic exons of the /3-galactosidase gene 
shows that the short mRN A is generated by alternative 
splicing. The long and short cDNAs direct the synthesis 
in COS-1 cells of /3-galactosidase polypeptides of 85 
and 68 kDa, respectively. Only the long protein is 
catalytically active under the assay conditions used, 
and it is capable of correcting /3-galactosidase activity 
after endocytosis by G:.u-gangliosidosis fibroblasts. 
The subcellular localization of cDNA~encoded /3-galac-
tosidase and /3-galactosidase-related proteins is differ-
ent. 
Acid {3-o-galacwsidase (EC 3.2.1.23) is the lysosomal hy-
drolase that cleaves P-linked terminal galactosyl residues from 
gangliosides, glycoproteins. glycosaminoglycans. as well as a 
variety of artificial substrates (reviewed in Refs. 1. 2). The 
gene coding for the human enzyme has been localized on 
chromosome 3 (3). Mutations in the iJ·galactosidase locus 
cause deficient or reduced enzyme activity and pathological 
accumulation of undigested metabolites in lysosomes. The 
resulting metabolic storage diseases are G1.,}·gangliosidosis 
-The costs of publication of this article were defrayed in part by 
the payment of page charr;cs. This article must tberefore be hereby 
marked "aduertisenwnt" in accordance with 18 U.S.C. Section 1734-
solely to indicate this fact. 
The nucleotide seqw:ru:e(s) reported in this paper has been submitted 
to the GenBankT'M/EMBL Data Ban.k with accessWn nu.m.bcr(s) 
J05!24. 
+To whom concspondence and reprint requests should be sent: 
Dept. of Cell Biology and Genetics. Erasmus University. P. 0. Box 
1738,3000 DR Rotterdam, The Netherlands. Fax: (0)10-4087212. 
1 The abbreviations used are: G:.t1, If'NeuAc·GgOse.Cer; SDS· 
PAGE, sodium dodecy\ sulfate-polyacrylamide :;cl clecnophoresi!'.: 
HPLC. high pressure liquid chromatography; hp. base pairs, kb, 
kilobo.scs. PCR. polymerase chain reaction. 
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and Morquio B syndrome (4-6). Among G:.n·gangliosidosis 
patients different clinical phenotypes have be<ln described 
that are classified as severe infantile, juvenile or mild infan· 
tile, and adult forms with residual ,8-galactosidase activity 
ranging from <1 to 15% of normal levels (reviewed in Refs. 
1, 7). 
The biosynthesis and processing of iJ·galactosidase have 
been studied in normal and mutant human fibroblasts. The 
enzyme is synthesized as an 85·kDa precursor, which is post-
translationally processed to the mature lysosomal form of 64 
kDa (8). In cells of an infantile and an adult G:-wgangliosi· 
dosis patient, the pre<:ursor protein was found to be synthe· 
sized in a low amount, but no mature form could be detected 
{9). In a Morquio B cell strain, synthesis and processing of p. 
galactosidase proceed normally {9). 
Lysosomal /3·galactosidase has been purified to apparent 
homogeneity from various sources and species {reviewed in 
Ref. 2). In mammalian tissues (10. 11) as well as in human 
cultured fibroblasts (12) the majority of the active enzyme is 
present in a high molecular weight uggregate, and only a sr::~.all 
fraction of the enzyme is found as monomeric 64-kDa poly-
peptide. It has been demons':rated that the aforementioned 
uggregate includes other glycoproteins: the heterodimeric 32-
20-kDa "protective protein" (8. 13-15) and, under certain 
experimental conditions. the lysosomal neuraminidase (16). 
It is likely that these three glycoproteins, /3-galuctosidase-
neuraminidase-protective protein, form a specific complex 
within lysosomes since they copurify, by virtue of their asso· 
ciation, and they influence each other's activity and stability 
{16, 17). Recently, Oshimn et aL (18) have published the 
sequence of the lysosomal iJ·galactosidase, deduced from its 
eDNA. 
We report on the cloning, sequence, and expression of two 
distinct cDNAs encoding the classic lysosomal form of the 
enzyme and a /3-galactosidase-related protein with no enzy-
matic activity and a different subcellular localization. We 
provide evidence that the latter derives from alternatively 
spliced precursor mRNA. 
EXPERIMENTAL PROCEDURES 
Malerials-Restriction endonudeases wexe purcha.sed from the 
following companies: Boehringer Mannheim, Bethesda Resetl..l'ch 
Laboratories (BRL), New England Biolabs, Pharmacia LKB Biotec· 
no logy Inc., and Promega Biotec. DNA polymerase, Klenow ira:;ment, 
wa.s from PromeJ;s Biot~. T, polynucleotide kinase, avian myelo-
blastosis virus reverse transcriptase, Ml3 rever.l<' sequencin~ primer, 
deoxy and dideoxy nucleotid('S, pTZlS and pTZ19 plasmid vectors 
were obtained from Pharmacia LKB Biotechnology Inc. T. D)J"A 
ligase wa.s from BRL. The sequenase and tbe sequencinr: kit were 
purchased from United States Biochemical Corp. Taq polymerase 
was .from Cetus Corp. Immunopreeipitin (formolin·fixed Sw.phyloccus 
aureus cells) and prcstained molecular weight =kers were from 
BRL. Raclionucleotides were obtained from Amersham Corp.: [cr-l2P] 
dA TP and [a·:\"P]dCTP, 3000 Ci/mmol; h·nP]dA TP, 6000 Ci/mmol; 
20656 Alternative Splicing of {3-Galactosida.se mRNA 
[<1·"'S]d.ATPC<S, >1000 Ci/mmol; [~]methionine, >1000 Ci/mmoL 
All other reagents were from stnndard commercial suppbe:rs, if not 
specified otherwise. • 
Cdl Culture-Human skin fibroblasts from normal individuals. 
four patient~ with GM,-gangliosidosis. and one obligated heterozygote 
were obtained from the European Human Cdl Bank, Rottcrdnm (Dr. 
W. J. Klever). Fibrobklsts were culture<! in Dulbecco's modified 
Eude's medium/Ham's FlO medium (1:1 v/v) supplemented v.i.th 
antibiotics and 10% fetal bovine serum. COS-1 cem wert grown in 
the same medium supplemented with 5% fetal bovine serum. 
Protein Sequence Ana/ysi..~-Human placental $-galactosidase was 
purified tor:ether with neuraminidase and protective protein, O$ de-
scribed previously (17). The different C1lmponents were sepi.U'ated by 
SDS-PAGE, under reducing conditions according to Hasilik and 
N0ufcld {19). The 64-kDa ,iS-galactosidase band was digested in situ 
with tosylphcnylalanyl chloromethyl ketone-ueawd trypsin {Wor· 
thingr,on Diagnostic Systems Inc .. United Kingdom). Tzypticpeptides 
were fractionated by HPLC (Waters 6000 System) and Sl:.'quenced by 
automated Edman degradation on an Applied Biosystems 4i0A gas-
phase peptide scquenator o.s described previously {15 ). For N-terminal 
sequence ano.lysis, approximately 50-100 1-'g of the purified complex 
WO.F separnted as above, and the protein components were blotted 
ago.inst Immobilon PVDV transfer membranes (Millipore Corp.). A 
filter piece containing the 6-<-kDa protein was excised and use'd as 
starting material for automated Edman de(i:f:ldation (20). 
eDNA Library Screening-A human testis eDNA librazy in Agtll 
{Clonteeh, Pclo Alto. CAl, consisting of 1 X 106 independent clones 
with insert sizes ranging from 0.7 to 3.3 kb, was plated out at a 
density of 5 x 10• plaqu0-formingunits per 90-= plate and screened 
with anti-,6-golactosidasc antibodies as described previously (21). 
Antibody-positive clones were rescreened with oligonucleotide probes 
labeled at the 5' end with a:-p using "r-._"1> and polynucleotide kinase 
(22). The probes were synthesized on an Applied Biosystems 381A 
oligonucleotide synthesizer. Hybridization and washing conditions 
were as described (23). 
DNA Sequencing-HI]Ga(S) and H,6Ga(L) cDNAs and their re· 
striction fragments were subcloned into plasmid vectors pTZ18 and 
pTZ19. Nucleotide sequences on both strands were obtained by the 
dideoxy chain termination methods of Sanger ct aL (24). for single-
stranded DNA, and of Ml.ll"PhY and Kavanagh (25), for double· 
stranded DNA. Ml3 universal reverse primer and a synthetic oligo-
nucleotide were used. Sequence data were nnalyzed using the program 
of Staden (26). 
Isolation and Sequencing of Genomic ,6-Galactosidase A C!.oncs-A 
human EMBL-3 A library (kindly provided by Dr. G. Grosvcld. 
Erru;mus University. Rotterdam), derived from DNA of leukocytes of 
a chronic myeloid leukemia patient. was s~ned with the 5' 8.50-bp 
EcoRl fragment of eDNA clone HBGa(L}. The insertS of three over-
lapp in~; A clones were subcloned into the plasmid vector pTZ18. 
Sequences of genomic exons were determined by the chain termina-
tion method on double-suanded DNA, using synthetic oligonucleotide 
primers derived from the ,8-golactosidase eDNA sequence. 
RNA Isolation o.rui Northern Blot Hybridi;;o.tion-Totnl RNA was 
isol£1ted from cultured fibroblasts as described (2i). Polysomal 
mRNA, immunoselected using antibodies :raised against purified pla-
cental complex, wns obtained following the procedure of Myerowitz 
and Proin (28). RNA samples were electrophoresed on a 1% agarose 
~;el containing 0.66 M formaldehyde as described (29) and blotted 
onto nylon membranes (Zetll·Probe). The filter was hybridized with 
the eDNA probe lnbeled according to the pr~dure of Feinberg and 
Vogelstein (30). 
Polymerase Chain &action-10-1.5 J.<J!. of total RNA and about SO 
ng of polysomal R..l\!A were reverse transcribed into single-stranded 
eDNA using two nntisense oligonucleotide primers and avian myelo-
blastosis virus reverse transcriptase. Subsequently. partial cDNAs 
were amplified in the presence of a third sense primer and Taq 
polymernse ns described {31), using a programmable DNA incubntor 
(BioExcellcnce). Amplified material WIIS separated on 2% agarose 
gel~ and blotted onto Zeta-Probe membranes. Filters were hybridized 
usinb either type-sp~>Cific oligonucleotide probes or a 90·bp Psti DNA 
fragment. These probes were labeled as mentioned above. 
Transient Expres.~ion of 8-Go.lactosidase cDNAs in COS-1 Cel!s-
Subcloning of the two cDNAs into n derivntive of the mammalian 
expres»ion vector pCD-X and conditione of transfections of 
pCDH,BGa constructs to COS-1 cells were a.s described previously 
(15). Labeling with Cc'S]methionine was carried out in the presence 
or absence of NH,Ci (19}. Rndiolabeled eDNA-encoded .8-galactosid-
ase proteins were immunoprecipitated from cell extracts and medium 
concentrates according to the method of Proia ct ol. (32). Immune· 
precipitated proteins were resolved on SDS-PAGE under reducing 
conditions. Radionctive bands were visualized by fluorog:rnphy of gels 
impr-egnated with Amplify (Amersham Corp.). Apparent molecular 
weights were calculated with conventional marker proteins. !S·Galac-
tosidase activity in COS-1-transfectcd cells was measured with arti-
ficial 4-metllylumbelliferyl substrate using standard assay conditions 
(7). 
Uptake Suui.ies in H= Cell.s-The preparation of conditioned 
media used in uptake studles and the experimentol conditions were 
as reponed (15). Human :recipient cells were from an infantile GM,-
gangliosidosis patient (Fig. 5, patient li}, They were seeded on 6-well 
plates 4 days before addition of conditioned media. The uptake was 
carried for a further 3 days. Cells were harvested by trypsinization 
and homogenized by vortexing in double-distilled water. Enzyme 
activities were measured in cell homogenates using 4-meth-
ylumbelliferyl substrates (7). 
Indirect lrnnu.moflu,or=cnce-For light microscopy, COS-1 cells 
. were transfectcd with pCDH.BGa constructs as above, but omitting 
the labeling step. Twelve hours before harvesting, transfected cells 
were reseeded nt n low density on coverslips. Fixation and immune-
labeling were performed according tO Ref. 33 using anti-,6-ga.lnctosid-
ase antibodies and goat nnti-(ro.bbit lgG) conjugated with fluorescein 
in the second incubation step. 
RESULTS 
Partial Amino Acid Sequence and Isolation of Antibodies-
The ,8-galactosida..<:e, neuraminidase, protective protein com-
plex was purified from human placenta, and its components 
were separated by SDS-PAGE under reducing conditions. The 
64-kDa ,8-galactosidase, electroeluted from the gel, was used 
to raise monospecific polyclonal antibodies in rabbit. This 
antibody preparation, tested in biosynthetic labeling experi· 
ments and Western blots, precipitates both mature and pre· 
cursor forms of ,8-galactosidase (data not shown). In addition, 
a gel slice containing the 64·kDa protein was digested in situ 
with trypsin. and the resulting peptides were fractionated by 
reverse-phase HPLC. Five of the oligopeptides were subjected 
to automated Edman degradation, but only three of them gave 
an unambiguous amino acid sequence (Fig. lA). We also 
sequenced the N terminus of intact mature 64-kDa ,B·galac· 
tosidase. A stretch of 18 amino acid residues was obtained in 
this case (Fig. lA, N-ter). 
Isolation and Characterization of eDNA Clones-One tryptic 
peptide sequence (T3) and the N·terminal sequence were used 
to synthesize two oligonucleotide probes complementary to 
the mRNA (Fig. 1B). Probe 1, a unique 45-mer, was con· 
structed on the basis of codon usage frequencies in mamma-
lian proteins, whereas probe 2, a 17·mer, was degenerated A 
human testis Agtll eDNA expression library was fll'St 
screened with anti·,B·galactosidase antibodies. Several recom-
binant clones were isolated and rescreened with both oligo-
nucleotide probes. One clone, AH,8Ga39, with a total insert 
size of 1. 7 kb, carried an internal &oRI site which released, 
upon digestion with EcoRI, two fragments of 500 and 1200 
bp, hybridizing with probe 2 and :i, respectively. These results 
supported .the identity of the eDNA and defmed its orienta-
tion.. Partial nucleotide sequencing of this eDNA revealed the 
presence of a putative ATG translation start codon, but the 
absence of a polyadenylation signal. In vitro translation of 
total RNA from cultured fibroblasts established a molecular 
mass of about 73 kDa for the non-glycosylated ,8-galactosidase 
preproform. ~Therefore, AH,8Ga39 could not contain the entire 
coding region of ,8-galactosidase precursor. Rescr~n.ing of the 
library with this eDNA probe yielded a clone, AH,BGa(L), that 
consisted of a 5' EcoRI fragment of 850 bp and a 3' fragment 
of 1550 bp. Both cDNAs were subcloned into pTZ18 and 
pTZ19, subjected to restriction endonuclease a.Ildlysis, and 
2 G. T. J. van der Horst, unpublished dnta. 
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Fie. 1. Partial amino acid sequences of placental .B·galac· 
tosidase and oligonucleotide probes. A, Tl-T3 are the amino acid 
sequences of three tryptic peptides derived from purified humnn 
placental ,8-galactosidase. N·ter indicates the amino terminal se-
quence of the mature protein.AsterWkrefers to a discrepancy between 
chemically derived and predicted amino acid sequence~ unassigned 
residues are_ indicated by X. Amino acids nre identiiied by the single-
letter code. B, T3 and part of N-ter were used to synthesize oligonu-




FIG. 2. Composite restriction maps and sequencing strategy 
of HPGa eDNA clones. All restriction enzyme sites in the cDNAs 
used for subcloning are shown. Arrows indicate the direction and 
extent of sequencing reactions. Cross-hatched boxes represent the two 
protein-.:::oding regions not present in the short ~-galactosidase eDNA. 
Broken arrows indicate seq,uencing reactions used for the short don~J. 
Arrows startinl:" with a uerticallin.c represent 5' or 3' seq,uences of 
independent cDNAs. The arrow starting with a solid sqWli"C box was 
a sequence reaction primed with a synthetic oligonucleotide. The 
hatched and solid bc.rs at!! the 5'- and 3'-untranslated regions, re-
spectively. 
sequenced using the dideoxy chain termination method (24). 
In Fig. 2 a compendium of the partial restriction maps of the 
two cDNAs is depicted together with the nucleotide sequenc-
ing strategy used. The complete sequences of H,8Ga39 and 
H~Ga(L) are combined in Fig. 3. 
A common ATG translation initiation codon is found at 
the 5' end of both cDNAs (Fig. 3, position 51). This ATG 
represents the beginning of an open reading frame for 
H~SGa(L) of 2031 nucleotides, which is interrupted by three 
consecutive stop codons. and it is flanked at the 3' end by a 
318-nucleotide untranslated region. A putative polyadenyl-
ation signal (AA T AAJ\) is present at position 2379. The 
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sequences of the two cDNAs from their intemal EcoRI site 
toward the 3' end are identical, except that H,8Ga39 misses 
the last 412 nucleotides including 94 bp of coding sequence 
and the 3' -untranslated region with the polyadenylation sig-
naL Although there is no direct proof that the 3' ends of the 
mRNAs specifying the two cDNAs are the same, S1 nuclease 
protection analysis of this region did not reveal the presence 
of differentially spliced transcripts (data not shovm). There-
fore, it is likely ?_.hat H,8Ga39 is a partial eDNA truncated at 
the 3' end. In contrast, a Comparison of the 5' ends of the 
two clones revealed significant differences. The &oRI frag-
ment encompassing the 5' end of H,8Ga39 is 393 nucleotides 
shorter than the corresponding fragment of H,BGa(L). The 
missing sequences comprise two stretches (boxed in Fig. 3), 
one of 212 nucleotides, between positions 295 and 508, and 
one of 181 nucleotides, between positions 602 and 784 (re-
ferred to as regions 1 and 2, respectively). Sequences imme-
diately flanking these regions are completely identical in the 
two clones. If translation starts at the common ATG initiation 
codon, the exclusion of region 1 causes a -1 frameshift 
mutation in the open reading frame of H,8Ga39 which is 
reverted by a + 1 frameshift due to the exclusion of region 2. 
In order to obtain a full length eDNA bearing the short 5' 
end, we have substituted the 3' end EcoRI fragment of 
H,8Ga39 for the H,BGa(L). The resulting eDNA construct. 
H.BGa(S), has an open reading frame of 1638 nucleotides, 
which starts at the same ATG (position 51) and is interrupted 
by the same stop codon as the long eDNA. These surprising 
findings imply the existence of two ,$-galactosidase mRt~A 
templates. encoding proteins that are translated in different 
frames in the 95-nucleotide stretch between the two regions. 
To verify whether these two mRNAs arise by alternative 
splicing, we have isolated genomic A clones spanning the area 
of interest. The entire sequence of the exons encoding nucle-
otides 296-784 in H,BGa(L) eDNA (Fig. 3) was determined. 
In Fig. 4 the exons involved are schematically shown together 
with their exon/intron boundaries. Region 1 in the long eDNA 
is encoded by two exons of 151 and 61 bp, respectively, and 
region 2 by one exon of 181 bp. A separate exon specifies the 
95-bp sequence between these two regions. The exact mapping 
of the different exons within the gene has not been deter-
mined. These results confLrm that the two ,8-galactosidase 
transcripts derive from alternative splicing of the precursor 
mRNA. 
Predicted Primary Sequences oj ,8-Galactosidase and (3-Ga-
lacwsida.se-related Proteins-As shown in Fig. 3, the two 
eDNA clones encode polypeptides of 677 and 546 amino acids, 
respectively, which have the first 82 N-terminal residues in 
common. These are followed. in the predicted sequence of the 
long eDNA-encoded ,8-galactosidase, by two noncontiguous 
sequences (boxed in Fig. 3) of 71 amino acids (residues 83-
153) and 61 amino acids (residues 185-245}, which do not 
occur in the short protein, referred to as P'-galactosidase-
related, because of splicing out of rCf;ions 1 and 2. Conse-
quently, a unique stretch of 32 amino acids is found in the ,8-
galactosidase-related protein (residues 83-I14), which is dif-
ferent from the sequence between regions 1 and 2 (residues 
154-185) in the long molecule. 
A.ll tryptic peptides as well as the N-terminal sequence of 
64-kDa placental ,8-galactosidase are found in the amino acid 
sequence deduced from the cDNAs (Fig. 3, thick line). The 
only disagreement is at residue 1 of T1 where the experimen-
tally determined residue is aspartic acid (Fig. lA), whereas 
the amino acid predicted from the nucleotide sequence of the 
two cDNAs is threonine. Both eDNA-encoded proteins start 
with a putative signal peptide which is characterized by an 
20658 Alternative Splicing of /)-Galactosidase mRNA 
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130 150 170 190 210 230 
ZS 'I'G~~T~~~G~~~TI~C{AT§G~~CCVCfl'CftA"gAT§G~p1fGC{A~~CAMG'1TI?C'f.A'19f"~G~CCfcpC'f. 64 
250 270 290 I 310 330 Jso 
AC'I'GCAAGGACCGCCTccrGMGATCAAGATGGCTr.GGcrGMCGCCATCCAGActrATCTGCC(;r(;(;AAC'ITICATGAGCCCI'GCCCAGGACAG'l'ACCAG'ITITC'I'GAGGACCATGATG 65 II K 0 R 1,. 1.. K M K M A G L N A 1 Q T I Y V P It N F H E p II P G 0 y Q F S E D H D V 104 
370 390 410 ~30 450 470 
TGGAATA'ITITCITCGCCl'GGCTCA'l'CAGCTGGGACTGCTGG'ITATCCI'CAGGCCo:::GGcccrACATCTG!GCAGAG!CGGAAA'rCGCAGGATIACC'l'CCITCGCI'GCTACAGAAAGACT 
E Y F L R L A H E L C L L V I L R P G P Y I C A E II E M G G L l' A V L !,. E K E S 144 
184 
224 
850 870 890 910 930 950 
'rCATCM!TC!'CAATI'C'rATAcrcccrGGcrAGATCAC'TGGGGCCAACCTCAC'TCCACAATCAAGACCGAAGCACTGGCITCCTCCr::tr:rATGATATACI'TGCCCCTGGGCCGAGTGTGA 
134 I N S E f Y T G \1 L D H II G Q P H S T I K T E A V A S S L Y 0 1 L A R G A S V N 304 
970 990 1010 1030 1050 1070 
ACITCTACATC'ITI'ATAGGTGGGACCMTITIGCC!ATTGGAATCGGGCCAACTCAcccrATGCAGCACACCCCACCJIGCI'ACGACTA'rr./.T(;CcCO\crGAGTGAGGCTCCCCACCTCA 
774 L Y 11 F 1 G G T N F A Y 'J N G A N S P Y A A Q P T S Y D Y D A P L S E A G D L T 344 
10'10 1110 1130 1150 1170 1190 
r::r:GAGAAG'J'A'ITITGCI'C'rGCCAAACATCATCCAGMG'ITTGAAAAAG'J'ACCACMGGTCCTATCCCTCCATC!ACACCAAAGTITGCATATGGAAAGGTCACITI'GGMAAGTIAAAGA 27.;. E K Y F A L R N I I Q K F E K V P E G p I P P S T P K F A Y G K V T L E K L K T 334 
1210 12:;{) 1250 1270 1290 1310 
CAGTCCGAGCAGCI'CTGGACATI'CTGTGTcccrCTGCGCCCATCAAAAGCCITIATCCC11'GACATITATCCAGWGAAACJ\GCAITA1'GGC'ITTGTCCl:GTACCGGACAACACTTCCTC 254 V G A A L D 1 L C P S G P I K S L Y P L T F 1 Q V K 0 H Y G l' V L Y R T T L P 0 424 
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AAGATIGCAGCAACCCACCACCTCTCTCITCACcccrCAATGCAGTCCACGATCGAGCATATGTTGcrc;'I'(;GATGGGATCCCCCAGGGAc:TCCTIGAGCG6AACAATG!GATCAC!CTGA 294 0 C S N P A P L S S P L N G V ll 0 R A y V A V D G I p Q G V L E R N N V 1 T -1. N 464 
1450 1470 1490 1510 1530 1550 
ACATMCAG(.GAAAGCTCGAGCCACTC!CGACCITCTGGTAC'.AGMCATGGGACGTCTGMCTA1'Gc:I'GCATATATCAACC.A'ITTTMGGG'ITICCITTCTMCCfGACl'CTCACTI'CCA 
33-1- 1 T G K A G A T L D L L V E N M G R V N Y G A Y I N D F K G L V S N L T L S S N 504 
2170 2190 2210 2230 2250 2270 
TGATIGGAATGTCCAAATGGA/IMCGMTITACCA'tGTGCA'ITTTCACCTGAGGTTICCcrGCATCCCTGCAGTGCCAAAGCGCCACCITCAGGCACCACC!CCMTGTCTGAGGCcrGA 
2290 2310 2330 2350 2370 2390 
CAGCACIIGTMCGTGCATACATATCTGCIIGGGCTGGMTCCMCCITI'MAGGTGGTAGTGIITITITATITTGGMGMTC!ITCITIICC1Ttt1'CITAAATAAAII1TIGTACTCMATG 
Fie. 3. Combined nucleotide and predicted amino acid sequences of .8-galactosidase cDNAs. The 
numbers abo!X' the nucleotide sequence refer to H~Ga(Ll eDNA. Numbel"S on the right and on the kft specify the 
amino acids of the long and short ,8-galactosido.se-predlcted sequences, respeetively. Amino acid sequences 
co:rrespondi.J:l.g to uypt!c JX'ptides and N terminus of the mature pll.lC<'ntnl enzyme nrc indicated with n thick 
underline. Potentinl N-linked glycosylation sites nre indlcated with a thin. urul;:rline. The nucleotide nnd deduced 
amino acid sequences of regions 1 and 2 are boxed. The stretch of 32 amino acid residues in the short protein. 
translated from another frame, because of exclusion of regions 1 and 2, is shown below the conespondinr; sequence 
of the long P-ga.lactosido.se. A putative polyadenylation signnl is indicnted with a double underline. 
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Fie. 4. Exons involved in alternative 5plicing, generating human ,B-galacto5idasc long and short 
mRNA.s. Boxes repre5ent separate exOns: numbers specify their length in base pairs. Interrupted /.in.cs depict 
intronie sequenees of unknown size. The sequences of all exons have been dctermined exeept for the 5' end of the 
left-rMst exon and the 3' end of the right-rMst exon, ns indicated by the uertical zig-zag lines. Sequences are 
identical to the corresponding H£!Ga(L) eDNA sequen~. but only intron/exon boundnries (A to J) are shown. 
Small. crrows specify splicing events generating the long ,8-galactosidnse m.RNA; large arrows indicate the mode of 
splicing giving rise to the smoll,B-galactosidase transcript. 
N-terminal region including a positively charged residue (Arg-
7), a highly hydrophobic core, and a polar C-terminal domain. 
The most probable site for signal peptidase cleavage is Gly-
23 (34). Seven potentialN-linked glycosylation sites are pres-
ent in the predicted primo.ry sequence (Fig. 3. thin line). The 
glycosylation site at position 26 is located immediately after 
the signal peptide. and it is followed by 18 amino acids 
(residues 29-46) that are colinear with the chemically deter-
mined N terminus of the purified placental enzyme. The 
predicted M, of unglycosylated ,$-galactosidase and ,$-galac-
tosidase-related protein, including the signal peptide, are 
76.091 and 60.552, respectively. Their amino acid sequences 
were compared with other sequences present in the NBRF 
(release 19.0. December 31, 1988) and Er-.ffiL (release 18, 
February 1989) data base. No significant homology was found. 
RNA Hybridization Studies-The H,SGa(L) eDNA insert 
was labeled by random priming and used to probe total and 
polysomal. RNA isolated from cultured fibroblasts of normal 
individuals, four G~.wgangliosidosis patients, and one heter-
ozygote. As shown in Fig. 5, an mRNA of about 2.5 kb is the 
major transcript detected in normal fibroblasts. The same 
hybridization pattern was obtained v.ith total human testis 
RNA (data not shown). When immunoselected polysomal 
RNA is applied a faint minor band of about 2.0 kb becomes 
visible. It is clear that this 2.0-kb species is present in a much 
lower amount than the long mRNA. This difference in amount 
is also reflected by the amount of respective eDNA clones 
found in the library (1 versus 12). 
The 2.5~kb mRNA is also detected i:J. total RNA from 
fibroblasts of the adult GM1-gangliosidosis patient (Fig. 5). 
However. the three infantile forms of the disease exhibit a 
very different expression po.ttern. In the fl.rst patient (1), a 
faint broad band is visible. In some gels this band can be 
resolved into two, one of which is slightly larger than 2.5 kb 
(data not shown). The mother of this patient displays a 
hybridizing band of normal size but somewhat less intense. 
There is no dete<:table ,$-galactosidase transcript in the second 
infantile patient (II), whereas in the third patient (III) the 
2.5-kb mRNA is present in a much lower quantity than in 
controls. The Northern blot was rehybridized with a probe 
re<:ognizing the glyceraldehyde-3-phosphate dehydrogenase 
mRNA (3.5). Signals of equivalent intensity corresponding to 
this 1.2-kb message were detected in all samples (data not 
shown). Taken together these results demonstrate that differ-
ent mutations must be involved in apparently similar~~­
gangliosidosis clinical phenotypes. 
Detection of Two mRNA Transcripts by PCR Amplifica-
tion-Since it is diffl.cult to visualize the small mRNA mole-
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Frc. 5. Northern blot analysis of fibroblast RNA. Total and 
polysomnl fibrobl.nst RNA from three normal individuals and total 
fibroblast RNA from nn adult and thr'X' infantile GM1-gangliosidosis 
patients as well as one heterozygote were fra~tionated on a formal-
dehyde-agarose gel nnd probed with the H/3Ga(L) eDNA. Tbe sizes 
of the two P-galactosiduse transcripts are indicated. Exposure time 
was 2 days. 
cule on Northern blots. we decided to use the polymerase 
chain reaction (PCR) to increase the detection level and to 
screen specific regions of ~-galactosidase mRNA(s) for the 
presence or absence of regions 1 and 2. The strategy applied 
in these experiments is depicted in Fig. 6B. Three oligonucle-
otide primers were designed according to distinct complemen-
tary DNA sequences present in the two ,6-galactosidase clones 
(sequences are given in the legend to Fig. 6). Their positions, 
flanking or within regions 1 and 2, were chosen to direct the 
S).'Othesis and amplification of eDNA fragments representa· 
tive for the two different mRNA species. Total RNA from 
cultured fibroblasts and from human testis as well as polyso~ 
mal mRNA from fibroblasts were reverse transcribed into 
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Fie. 6. Detection of two mRNAs for P-galactosidase by PCR 
amplification. A. total (T. Fibr.) and polysomo.l fibroblast (P. Fibr.) 
R..l\!A and total testis (T. Testis) RNA were used to synthesize single· 
stranded cDNAs that were subsequently subjected to 24 rounds of 
amplification. Amplified products were separated on 2% ngarose gels. 
blotted, and hybridized with typ¢·spocific probes. E. coli tRNA was 
included as control. Sizes of the amplified fragments nrc indicated. 
Exposure times were 1 b for lanes 1-5 and 30 min for lanes 7 and 8. 
B. the EcoR1 fragment at the S' end of both cDNAs is shown. Tbe 
triangle..~ represent regions 1 and 2; numbers correspond to the nu· 
cleotide positions at theirS' and 3' ends. Solid bar.~ 1, 2, 3 are the 
primers used for eDNA syntheses and PCRs. Arrows indicate their 
sense and antisense orientations. The sequence of the antisense 
primer 1 is 5' -AAGCATCTGTGATGTTGCTG-3'; of the antisense 
primer 3 is 5'-ACATTI'CAGGAATGTTTTATGTGCT-3'; of the 
sense primer 2 is 5'-TGGAAGGACCGGCTGCTGAA-3'. Cross-
hatched bars designate a 90-bp Psti probe and two 20-mer oligonucle-
otide probes. The sequence of the 5'-oligonucleotide probe is 5'-
CCATCCAGAC/ATTACCTGGC-3': of the 3' probe is 5'-AA-
CAGTGCAG/GCAGCAACAT-3'. 
single-stronded eDNA using either antisense primer 1 or 3. 
The polymerase chain reactions were subsequently performed 
by adding the sense primer 2. Escherichia coli tRNA was used 
in separate reactions as a negative control. Amplified material 
was separated on agarose gels and Southern-blotted. In order 
to unequivocally distinguish between amplified fragments 
originating from the short or the long mRNA, type-specific 
probes were used (Fig. 6B, cross-hatched bars). Two 20-mers 
were synthesized on the basis of sequences of the H{)Ga(S) 
eDNA, which are colinear with the 10 nucleotides flanking 
each end of regions 1 and 2 of H{)Ga(L) (sequences are given 
in the legend to Fig. 6). These 20-mers hybridize, under 
stringent conditions, only to the eDNA fragment derived from 
the short mRNA. On the other hand the eDNA fragment 
specifying the long mRNA is detected by a 90-bp Pstl probe 
present in region 2. As shown in Fig. 6A, fragments of 169 
and 498 bp. representing the short and the long mRNA • 
respectively, are amplified in all samples and are identical in 
the two tissues tested (lanes I-3 and 6-8). The identity of 
much fainter smaller bands present in lanes 6 and 8 is un-
known. No hybridizing bands are visible in the tRNA lanes 
(lanes 4 and 5). It is noteworthy that the aforementioned 
eDNA fragments can also be amplified from polysomal RNA. 
This implies that the short transcript undergoes translation. 
Transient Expression of {3-Galactcsid.ase cDNAs in COS-I 
Cells-H{)Ga(S) and H{)Ga(L) cDNAs were cloned in sense 
and antisense orientations into a derivative of the mammalian 
expression vector pCD-X and transfected separately to COS-
1 cells. After 48 h, normal and transfected cells were incubated 
for an additional 16 h, with r~~s]methionine. In some in-
stances the labeling step was done in presence of NILCl to 
induce maximal secretion of lysosomal protein precursors 
(19). Radiolabeled proteins from cells and media were im-
munoprecipitated with anti-{3-gal.uctosidase antibodies. The 
results are shown in Fig. 7. A {)-galactosidase polypeptide of 
85 kDa is detected intra- and extracellularly after transfection 
of COS-1 cells with pCDH{)Ga(L)-sense construct (lanes I, 2, 
and 7, 8). A protein of 6S kDt.t is synthesized and secreted 
upon transfection with the pCDH{)Ga(S)-senseplasmid (lanes 
3 and 8). Treatment with NILCl does not hove any detectable 
influence. The estimated molecular mass of the large molecule 
(85 kDa) correlates with that observed for the glycosylated (3-
gal.nctosidase precursor immunoprecipitated in human cells. 
The 68-kDa polypeptide is a form that was not noticed pre-
viously. These eDNA-derived proteins are not present in 









Fie. 7. Transient expression of pCDHPGa constructs in 
COS-1 cells. The pCDH.8Gn(L) andpCDH,BGa(S) eDNA constructs 
in the sense (se. lanes 1-3 and 7-9) and antisense (a, lane 4) orien· 
tntions were transfected to COS-1 cells. A mock transfection was 
carried out without the addition of DNA (lane 5). n.L indicates not 
transfected (lane 6). After 48 h cells were incubated with ['3hS]methi-
onine for an additional 16 h with and without NH.,Cl (+ cmd -). 
Labeled proteins from cells and media were immunoprecipitated with 
anti-,8-gn.lactos.id.o.se antl"bodies, analyzed on a 12% SDS-polyncryl-
amide gel. and visualized by fluorography. Molecular sizes were 
calculated by comparison ·,...jth protein markers. Exposure time for 
lanes J--6 was l day and for lanes 7-9 was 1 week. 
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sense construct (lanes 4 and 5). It appears, therefore, that the 
antibody preparation used in these experiments hardly rec-
ogni.2es COS-1 endogenous fJ-galactosidase, since untrans-
fected cells also do not show any cross-reactive bands {lane 
6). As seen in lanes 1 and 2, the eDNA-derived 85-kDa /3-
galactosidase precursor is poorly processed into the mature 
64-kDa form in transfected cells. This is due to the b:ansfec-
tion procedure, as observed before {15). A 5-fold increase in 
/3-galactosidase activity above the endogenous COS-1 values 
is measured only in cells transfected with the pCDH/3Ga(L)-
sense construct {Table I). Using the same assay conditions, 
the /3-galactosidase-related molecule is apparently not active. 
We also tested whether the eDNA-encoded proteins were 
able to correct /3-galactosidase activity in G~u-gangliosidosis 
cells. For this purpose,medium from COS·l cells transfected 
with sense or antisense pCDH/3Ga constructs as well as me-
dium from mock-transfected cells were collected and concen-
trated. Aliquots of the different C(lnditioned media were added 
to the culture medium of fibroblasts from an infantile G~n­
gangliosidosis patient (patient II in Fig. 5). After 2 days of 
uptake, activities were measured in cell homogenates using 5-
methylumbelliferyl substrate. As shown in Table II, COS-1 
cell-derived 85-kDa precursor taken up by G~n·gangliosidosis 
cells corrects /3-galactosidase activity. In a similar uptake 
experiment carried out using radiolabeled secretions from 
COS-1-transfected cells, we could demonstrate that the 85-
kDa precursor and the 68-kDa /3-galactosidase-relatedprotein 
were taken up by the mutant cells, but only the 85-kDa 
precursor was further processed to the mature 64-kDa form 
(data not shown). 
In order to determine the intracellular distribution of the 
two proteins, indirect immunofluorescent staining was per-
formed on transfected cells using anti-.B-galactosidase anti-
bodies and fluorescein-labeled second antibodies (Fig. 8). A 
typical lysosomal distribution as well as uniformly diffuse 
perinuclear labeling of .8-galactosidase is observed in COS-1 
cells transfected with the pCDHP'G.a(L)-sense construct (Fig. 
SA). However, a strong fluorescent labeling restricted to the 
perinuclear region is present in cells transfected with the 
short construct (Fig. 8B). Adjacent untransfected cells react 
poorly with the human antibodies. Taken together, these 
results demonstrate that the long and short cDNAs direct the 
TABl-E I 
Actiuitv of fj-galactosidase in COS-1 ce/k after Cransfection with 
" pCDHf]Ga plasmid DNA:> 











• One milliunit of enzyme activity is detined as the activity that 
releases 1 nmol of 4-methylumbE-Iliferone ~r min. 
synthesis of two proteins, one of which behaves as the classic 
lysosomal /3-galactosidase, whereas the other is not enzymat-
ically active at the pH value and substrate concentration used. 
This ,8-galactosidase-related protein also has a different sub-
cellular localization. 
DISCUSSION 
We have isolated and characterized two distinct eDNA 
clones encoding human lysosomal /3-galactosidase and a /3· 
galactosidase-related protein. In total RNA from normal hu-
man fibroblasts, a major mRNA of 2.5 kb is recognized by 
eDNA probes. A minor transcript of about 2.0 kb is detectable 
only in immunoselected polysomal RNA. The 2.5-kb ,8-galac· 
tosidasE! mRNA is also present in fibroblasts from the adult 
GM1-gangliosidosis patient, but it is either absent or reduced 
in amount in cells from thre<l patients with the infantile form 
of the disease. The pattern of expression of this .8-galactosid· 
ase mRNA in patients I and II is consistent with data from 
immunoprecipitation studies that est::tblished the absence of 
cross-reactive material for $-galactosidase in fibroblasts from 
these patients.2 Apparently, other infantile ~~-gangliosidosis 
patients, not yet analyzed at the molecular level, do synthesize 
/3-galactosidase precursor (36). The adult and the third infan-
tile patient studied here were previously reported to synthe-
size a .a-galactosidase precursor that did not get phosphory-
lated {37), This might still hold true for these two patients. 
but the assumption made by Hoogeveen ct aL (37) that all 
GM,-gangliosidosis variants are phosphorylation mutunts is 
not substantiated by the results presented here. Patients I 
and II. for instance, may represent splicing and/or promoter 
mutants. Obviously, different or even the same clinical phe-
notypes are caused by distinct genetic lesions, and further 
studies are needed to define the clinical and biochemical 
heterogeneity observed in G~wgangliosidosis patients. 
The nucleotide sequences of the two cDNAs comprise open 
reading frames that begin at a common ATG translation 
initiation codon and terminate at the same stop codon. How-
ever, H{:!Ga(L) is 393 bp longer than HtJGa(S). Its nucleotide 
sequence is colinear with the human placental /3-galactosidase 
eDNA recently isolated by Oshima et aL (18). The only 
sequence differences we find are at nucleotide positions 79 (T 
instead of C), 650 (G instead of C), and 651-6.53 (CGC instead 
of GCG), resulting in the following amino acid changes: Leu-
10 instead of Pro-10 and A.rg-201 instead of Ala-201. These 
discrepancies may represent truE! allelic variations and/or 
mistakes introduced by cD:;..J"A cloning procedures. The se-
quence of the short eDNA is virtually identical to the former, 
but it misses two noncontiguous protein-encoding sequences, 
regions 1 and 2, present in the long clone. Furthermore, the 
exclusion of region 1 in this eDNA introduces a frameshift in 
its 3' -flanking sequence which is subsequently restored by the 
exclusion of region 2. These unusual findings imply the exist-
ence of two distinct mRNA templates which, roost remarka-
TABLE II 
Correction of P-galaccosidase activity in G . ..,.,-go.ngliosidosis fibroblasts after uptake of COS-I cell-derived 
{3-galactosida.sc precursor 
Tr=fection in COS-I 
cells 
pCDHPGa {L) sense 
pCDHPGa (Sl sense 
pCDH!SGn (S) sense 
Mock 







Activity in G,,.ganglio~ldosia fibrobla5t5 
;:J-C:alacto5.idase 
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FIO. 8. Immunocytochcmica.lloealiz.ation of P-go.lactosidasc 
proteins in tl:'ansicntly transfectcd COS-1 cells. A. trunsfection 
with pCDHBGa(Ll cDKA construct: B. trnnsfection with pCDH-
tJGn(Sl eDNA construct. 
bly, are read in different frames only in the 95-nucleotide 
stretch between regions land 2. To our knowledge this is the 
first example of such a configuration in a mammalian gene. 
By sequencing genomic !)-galactosidase clones, we could 
demonstrate that nucleotides 296-i84 of the 2.5-kb mRNA. 
spanning regions l and 2 as well as their intermediate se-
quence, are encoded by four separate exons. As shown by the 
sequence of the exon/intron borders, all four exons obey the 
GT/AG rule (38). These results strongly indicate that the 
short mRNA is generated by a differential splicing process 
that involves three exons. An increasing number of genes are 
known to create protein diversity through the use of differ-
ential splicing (reviewed in Ref. 39). Among lysosomal pro-
teins this phenomenon has been observed for human .6-glu-
curonidase mRNA (401. The genomic data also rule out the 
possibility that the shon eDNA is the product of n cloning 
artifact. The amount of the short mRNA. however. must be 
less than 1/,o of the long one. if we consider the signal obtained 
on Northern blots. Therefore, the existence of the two ~}­
galactosidase transcripts was further proven by PCR ampli-
fication of panial eDNA fragments specifying the two 
mRNAs. The short transcript does not seem to be testis-
specific. since it is also detected in fibroblast total and poly-
somal mRNA, indicating that this transcript is actively trans-
lated in fibroblasts. It is not excluded. however, that the two 
mRNAs muy be expressed in differential amounts in other 
tissues. 
The open reading frames of the lonr:: and short .6-galucto-
sidase cDNAs code for 677 and &46 amino acids, respectively, 
with the fLrst 23 residues in common representing a typical 
signal peptide (34}. Both proteins carry seven potential N-
linked glycosylation sites at identical positions. One of them 
is located immediately after the signal sequence and precedes 
the K -terminal ~uence of mature 64-kDa placental $-galac-
tosidase. From its location we can infer that the substantial 
proteolytic processing of the 85-kDa /)-galactosidase precursor 
observed in human fibroblasts (8) as well as in mouse kidney 
cells and macrophages (41, 42) must occur nearly exclusively 
at the C terminus. 
The two cDNAs direct the synthesis in COS-1 cells of 
immunoprecipitable polypeptides, which are also recovered 
extracellularly. The molecular mass of the long protein, 85 
kDa, is in agreement with the apparent siz.e of /)-galactosidase 
glycosylated precursor immunoprecipitated from human fi-
broblasts (8). The 6$-kDa protein derived from the short 
eDNA is a form thnt was not detected previously. Whether or 
not this protein has a defined biological function is not known. 
Although both polypeptides are recognized by the antibodies, 
the P'-gulactosidase·related protein is not catalytically active 
under the assay conditions used. The same holds true for the 
short $·glucuronidase protein (40). Furthermore, even though 
both eDNA-encoded proteins, 85 and 6S kDa, are as efficiently 
endocytosed by GM,-r;angliosidosis fibroblasts, only the 85-
kDa precursor is further processed int~o.cellularly and corrects 
~}-galactosidase activity. 
The subcellular localization of COS-1-derived !)-galactosid-
ase and f)-galactosidase-related proteins is different. The long 
p-galactosidase has a clear lysosomal distribution, whereas 
the short molecule is found only in the perinuclear region. 
The latter is likely to reach the Golgi apparatus, since it is 
secreted into the extracellular space even without the addition 
of NH,CL The differential subcellular distribution of the two 
proteins might explain their distinct catalytic behavior. Fur-
ther studies are needed to define the function and substrate 
specificity of the !)-galactosidase-related protein. It will be of 
interest to analyze the domains that are either missing or 
different in the two polypeptides. 
This work together with our studies on the other compo-
nents of the complex. the protective protein and neuramini-
dase, will enable us to gain more insight in the fine mecha-
nisms of mutual cooperation between these lysosomal glyco-
proteins. 
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The "protective protein" is the glycoprotein that 
forms a complex with the lysosomal enzymes i1·galac-
tosidase and neuraminidase. Its deficiency in man leads 
to the metabolic storage disorder galactosialidosis. The 
primary structure of human protective protein, de-
duced from its cloned eDNA, shows homology to yeast 
serine carbo:;cypeptidases. 
We have isolated a full-length eDNA encoding mu-
rine protective protein. The nucleotide sequences as 
well as the predicted amino acid sequences are highly 
conserved between man and mouse. Domains impor-
tant for the protease function are completely identical 
in the two proteins. Both human and mouse mature 
protective proteins covalently bind radiolabeled diiso-
propyl fluorophosphate. Transient expression of the 
murine eDNA in COS-1 cells yields a protective protein 
precursor of 54 kDa, a size characteristic of the gly-
cosylated form. This eDNA-encoded precursor, endo-
cytosed by human galactosialidosis fibroblasts, is proc-
essed into i 32- and a 20-kDa heterodimer and corrects 
,8-galactosidase and neuraminidase activities. A tissue-
specific expression of protective protein mRNA is ob-
served when total RNA from different mouse organs is 
analyzed on Northern blots. 
Galactosialidosis is a human autosomal recessive disorder 
characterized by a combined deficiency of lysosomal {3-D-
galactosidase (EC 3.2.1.23) and N-acetyl-a-neuraminidase 
(EC 3.2.1.18) because of a primary defect in the protective 
protein (1-3). Different clinical phenotypes exist in patients 
with this di&!ase, ranging from severe infantile forms to 
milder late infantile and juvenile/adult types (1. 4). 
In cultured human fibroblasts the first immunoprecipitable 
form of the protective protein is a glycosylated pre<:ursor of 
54 kDa, which undergoes post-translational processing (3). 
The primary structure of human protective protein has been 
determined recently through eDNA cloning (5). From the 
deduced amino acid sequence we could infer thnt the precursor 
mole<:ule is proteolytically cleaved into a mature heterodimer 
of 32- and 20-kDa polypeptides, held together by disulfide 
bridges (5). 
• The costs of publication of this article wer!.' dcfruycd in pu.rt by 
the payment of puge charges. This article must therefore be hereby 
marked "aducrtiscnu:nt" in accordunce with 18 U.S.C. Section 1734 
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~These authors contributed cqua.Uy to the results described in this 
report. 
§To whom conespondence and reprint requests should be sent: 
Dept. of Cell Biology and Genetics, Erasmus University, P.O. Box 
1738.3000 DR Ronerdum, The Netherlands. Fax: (0110·4087212. 
It was shown earlier that in human cells the protective 
protein associates with lysosomal ,8-galactosidase since it is 
resolved together with the latter enzyme in a high molecular 
mass a&,<>reg-ate {600-700 kDa). This association promotes 
multimerization of ,8-galactosidase monomers, which, in tum, 
stabilizes the enzyme (6). In addition, neuraminidase can be 
purified in an active and stable form together with )3-galac-
tosidnse and the protective protein (7, 8). Although it is likely 
that the catalytic site of human placental neuraminidase 
resides on a 66-kDa polypeptide, the presence of the protective 
protein is essential for expression of neuraminidase activity 
{9). Taken together, these studies indicate that a complex of 
iS-galactosidase, neuraminidase, and protective protein may 
be functionally present in lysosomes. but so far no data on 
the stoichiometry of this con::.plex have accumulated. 
The primary structure of human protective protein (5) 
shares homology with yeast carboxypeptidase Y {10), the 
KEXl gene product (11). and certain plant serine carboxy-
peptidases (12-14). All these proteins have in common three 
conserved amino acid stretches that include the serine and 
the histidine residues essential for their catalytic activitY (15; 
for review see Ref. 16 and references therein). This implies 
that the protective protein might function as a serine protease. 
In order to defme domains involved in the proteolytic 
activity of the protective protein and/or its binding to ,8-
galactosidase and neuraminidase, we have isolated the eDNA 
encoding murine protective protein. Our results show that 
mouse and human eDNA sequences are largely homologous, 
giving rise to almost identical proteins. 
EXPERIMENTAL PROCEDURES 
Materials-Restriction endonuclco.ses were purchased from the 
following cornpanie~: Boehringer Mannhcim, Bethes.da. Research 
Laboratories, New England Biolabs. Pharmo.cia LKB Biotechnology 
Inc .. and Promega Biotec. DNA polymerase, Klenow fragment, was 
from Promel:"l Biotec. Ml3 universal and reverse sequencing primers 
and pTZ18 and 19 plnsmid vectors were obtained from Phormacia. 
The synthetic oligonucle<ltid<'. used for sequence determination. was 
synthesized on an Applied Biosystems 381A oligonucleotide synthe-
sizer. Sequenase and sequencing kit were purchased from United 
States Biochemical Corp. Immunoprecipitin and prcstained mol!'X:u-
lar weight markers were from Bethesda Research Laboratori<:>S. BCA 
protein assay rear:cnts were purcha.scd from Pi<'rcc Chemical Co. [a· 
J 2P]dATP. [a·"'!J>]dCTP (3000 Ci/mmol), [a-'-'S]dATPaS' (>1000 
Ci/mmoll, [""S]mcthioninc (>1000 Ci/mmoD, o.nd ["H]DFP (3.0 Ci/ 
mmol) were obtained from Amc:rsho.m Corp. and DuPont-:-.lew Eng-
lund Nuclear. All other rea~ents were from standard commercial 
suppliers, if not specified otherwise. 
Cell Culture-Fibroblast..~ frorr; an early infantile e;a!actosialidosis 
patient (5} were obtaine-d from the European Human Cell Bunk. 
Rotterdam (Dr. W . . ]. Kleijer). They were maintained in Dulbecco's 
modified Eagle's medium-Ham's F-10 medium (1:1, vfv), supple-
' The ubbreviations used o.re: dATPc.S. deoxyadenosine 5' ·0·(3-
thiotriphosphatel; DFP. diisopropyl t1uorophosphate; SDS. sodium 
dode<:yl sulfate; kb. kiloba..'lefsl. 
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mente-d with 10% fetal bovine serum and antibiotics. COS-1 ce-lls {17) 
were maintained in the so.mc culture medium b1.1t supplemented with 
only 5% few.! bovine serum. 
Isolation. of eDNA C/oncs-Construction of the mouse testis eDNA 
library in AgtlO bas been descri~d previously (18). The mouse brain 
eDNA library was prepared by D. M. according to the same procedure. 
The testi5 eDNA libmry was plated out at a density of 2-3 x 10" 
plaque-forming units/20 x 20-cm plate. Screening was performed 
using the heterologous Hu54 eDNA as a probe (5, 19). Standard 
hybridizat~on and washing conditions were used except that the 
washing temperature was lowered to 60 ·c. Positive ph.a~;es were 
isolated niter two further steps of pln.quQ purification. The 1.2-kb 
inse:rt of clone AT2 wns used to screen thQ brain eDNA Jib:rory, plated 
out as di!SCI'ibed above. This librory was subsequently screened with 
a 5' end fragment of the Hu54 eDNA (nucleotide:> 1-660 (5)). One 
clone (ABl) positive in both hybridizations was selected for further 
investigntion. 
DNA Sequence Analysis-Suitable restriction endonuclease sites 
in the insem of ABl and AT2 were used for subcloningoffragments 
into plasmid vectOrs pTZlS and pTZ19. Nucleotide sequences were 
determined using the dideoxy chain termination method on sins-Je-
stranded D::-TA (20) <1nd double-stranded DNA (21). The reaction 
conditions were modified for use with [o:-3"S]dATPo:S and Sequenase. 
as recommended by the supplier. Sequence data were analyzed with 
the programs of Staden (22) and the University of Wisconsin Genetics 
Computer Group (23). DNA nnd protein ali[:I!ments were done with 
the latter softwnre package. 
Trc.n,s(ectirJf!.$ in COS-1 Cdl:;-A B(Vfi-HI restriction site. sh(l!ed by 
Bl and T2 cDNAs. WM used to construct full-length moW!e protective 
protein eDNA (Mo54). The result:Og composite EcoRl insert was 
subcloned in two orientations into <l deriv~tive of the m<lmmalian 
expression vector pCD-X as descn'bed previously (5). Transfections 
in COS-1 cells. merobolic labeling of transfected cells with r:'"S] 
methionine_ and preparation of cell extrll.cts were performed as re-
ported earlier (5. 24). &creted proteins were concentrated 20-fold by 
(NH.J,SO, precipitation and desalted afterward on a Scpbadex G-50 
column (24). An aliquot (about 1%) was taken for dire<:t analysis on 
SDS-polyacrylamide ~el electrophoresis. The rest of the concentrated 
medium from different transfcction experiments was either used for 
immunoprecipitation (about 25%) or in uptake studies (<lbout 75%: 
see below). Cell extr:lcts and medium concentrates were immunopre-
cipitated with anti-human 32-kDa antibodies and resolved on 12.5% 
poly<lcrylamide gels under reducing conditions (25). Radioactive pro-
teins were visualized by t1uorograpby of dried gels that had been 
treated with Amplify {Amersham Corp.). 
Uptake o( Protcctiuc Protein Prccu.rsors in Human Cdls-Aliquots 
of medium concentrates from transfccted COS-1 cells were ndd~-d to 
the medium of tibroblasts from an early infantile galactosia.lidosis 
po.tient. After 3 days of uptn.ke, cells were processed for either im-
munoprecipitation ano.lysis or enzyme activity assays as reported 
previously {5). The <lnti-human complex antibodies used in these 
experiments Mve been described eo.rlier {3). 
DFP-bindin.g Assay-COS-1 cell&, SC('ded in six-well pln.tes, were 
trnnsfccted with various pCD constructs us described above and 
maintained afterward in normal culture medium for j2 h. The cells 
were then harvested by trypsiniz:J.tion. rinsed 3 X with phosphate-
buffered saline. and homogenized in ice-cold water. Confluent human 
fibrobla-sts from a normal individucl and the early infantile galucto-
sialidosis patient were cultured in six.-w('ll plutes for 6 days and 
harvested as above. Cell lysates were adjusted to 0.01 M :;;odium 
phosphate, pH 6.8. and freeze-thawed once. To these homogenates 3 
.uCi of ['H]DFP was added. and binding of the inhibitor W<lS allowed 
for 1 h at room temperature. Ro.diolabeled proteins were immunopre-
cipitated using the anti-human complex antibodies (3) and subse-
quently visualized by SDS-poly<lcryktmide gel electrophoresis and 
t1uoro(;!aphy. 
Northern Blat Analysis-Adult BCBA mice and fetuses at days 13. 
16, or 19 of gestation were used as sources of tissues for RNA 
extroction. Adult rnic<' w<-re killed by cervical dislocation: tissues were 
removed and immediately frozen in liquid nitrogen. Total RNA was 
extracted using the method of Aul1rny and Rougcon {26). 10-15 .ug of 
RNA from tissues and embryos was dissolved in loading buffer 
contnining ethidium bromide and <lpplied on n 0.8% a,;nrose :;el 
containing 0.66 M formaldehyde 127). After electrophoresis. the RNA 
was visualized by UV illumination at 300 nm undsubsequently blotted 
onto n Zeta-Probe membrane (Bio-Radl (27). Standard hybridization 
and washing conditions were applied (28). 
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RESULTS 
Isolation of eDNA Clones and Nucleotide Sequence Analy-
sis-Humo.n protective protein eDNA Hu54 {5) was used as 
a probe to screen a mouse testis Agt10 eDNA library (18). Out 
of 2-3 X 10~ plaques, six positive clones were isolated, all with 
an insert size of about 900 base pairs which hybridized with 
the 3' end of the Hu54 eDNA (nucleotides 1200-1800) but 
not with a 5' end probe. One clone. AT2 (Fig.1), was selected 
for further analysis, and its insert was used to screen a mouse 
brain AgtlO eDNA library. Out of 1.6 x 106 plaques, 33 
recombinant clones were )detected, one of which (ABl) 
strongly hybridized with a fragment of the human eDNA 
spanning lxtse pairs 1-660 (5). Its insert was mapped relative 
to Hu54 and T2 cDNAs. As shown in Fig. 1, B1 and T2 
overlap partially and share a common BamHI restriction site 
that was used to create a composite eDNA. The total length 
of the two inserts (2.0 kb) was sufficient to contain all coding 
inform.ation for a mouse protective protein having a size of 
54 kDa. 
Bl and T2 cDNAs were subcloned separately and sequenced 
on both strands using the strategy depicted in Fig. L The 
complete nucleotide sequence and predicted amino acid se-
quence are shown in Fig. 2. The mouse protective protein 
eDNA Mo54 is 1987 nucleotides long. It can be divided into 
a 5' -untranslated region, an open reading frame, and a 3'-
noncoding region of 213, 1422, and 352 nucleotides, respec-
tively. In the 5'-untranslated region, a putative translation 
initiation codon is found at position 12. This ATG, however, 
is immedi.utely followed by a stop codon. A second ATG, 
which starts at position 214, is in th<J correct context for 
translation initiation {29) Dnd could therefore represent the 
true initiator. also by comparison with the human eDNA. In 
the 3' -untranslated region, a putative polyadenylation signal 
(ATTAAA) is present at position 1966-1971. 
When Mo54 and Hu54 cDNAs are aligned at the nucleotide 
level, the most striking feature is an identity of72% through· 
out their entire 3' -noncoding regions (Fig. 3). This is not due 
to the presence of an open reading frame shared by human 
and mouse cDNAs. Identity in the coding regions of the two 
cDNAs is 85%. 
Predicted Amino Acid Seq~.~ence of Molt$€ Protective Pro-
tein-The open reading frame of 1,422 nucleotides in Mo54 
eDNA encodes a protein of 474 amino acids (Fig. 2) with a 
predicted Mr of 53,844. The amino acid sequence of mouse 
protective protein is highly homologous to its human coun-
terpart, the identity being 87%. The alignment shown in Fig. 
,. dd=="==="'==' =='=""=""b=,!d· ,. 
FlC. l. Partial restriction map and sequencing strategy of 
full-lt;lngth Mo54 eDNA. Overlapping eloncs, ABl and AT2, were 
isola.ted from mouse brain and testis eDNA libraries. respectively. 
Thei'r position with regnrd to the full-length Mo54 eDNA of 2.0 kb 
(/awer bar) is indicated by the top bars. Restriction &ites used for 
sequencing :;u-e shown. Arrows indicate extent and direction of se-
quencing reactions. The black box on one arrow represents a synthetic 
oligonucleotide used for sequ"'ncing. Hatched bars. 5'- and 3' -noncod-
ing regions. 
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FIC. 2. Nucleotide and predicted 
amino acid sequences of Mo54 
eDNA. The composite nucleotide se-
quence is derived from ABl and i\T2. 
Nucleotides are numbered on the IJ:ft; 
the preclieted amino acid sequence is 
numbered on the right. Residue 1 is the 
first amino acid (alanine) of precursor 
mouse protective protein. The proposed 
proteolytic cleavage s-ites are indicated 
by IX'rtical arrows. N-Linked glyoosyla-
tion sites and the putative polyadenyl-
ation signal are t.IJUU>rlined. Only one of 
the two consecutive stop codons is 
marked by an asU:risk. 
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7<1
1 ~c:;·~~·1flii'-.1"~~rc:F'C"'1cc.rn:FFF@4~1~''T"~~~ l'o< 
lJ:l ~~·~r~~.c;t?'t~~rf7-~tpT'= l!J• 
HU I4Xl !c;A--CCA.CAGCAACC-----ACCTCc:ACGC--CCT<:ATGCACCCCCTCCCJ.GCITCTCC 
", """ ' .. ,,, ''"'"" "'" MO llo40 AGC'ITCCGCTCCAACCCi.'tCCJ.,V.'TCc:'rCAG'l:ACCT!;AT-CACCCCCTCTCCGCCTCTCT 
HU 1:>02 CGCTACCACioCTCCTCTTCTAAG~CCCTGCAGGCGGCITCTGCCGCCAGG;.CT 
. . 1" . . ... ·" '" ' 
M0 1699 C---ACCAGACAGGAGTCCTCCGC!M"I"GC'ICCC=GCAAC"l"CCTc;TA-c;TAAAACT 
HU 1~61 GCCCC--CTICCCJIGAGCCC'ICTACJI"tCCCAGAC"l"GGGCG-CJI(';G(';TC"tCCCA"tACACAG 
"" :J" " "::"' . "" " MO 1755 GCCCJICACTIC!CJICAGCC"tGCTGCA."tCGCJICCC"tGCGCCTClGGGCG"l"CACA.--CACAG 
HU 1618 CC"I"GGGGGCMGTI"AGCI<C:T":""tATitCCCCA.CGAmt:CTGAA"tGGGG"l"GCCCTCGCCCC 
"'" "'" .,,,. ' '""'""" " MO 1813 CC!ACGACCAACTCAGCI<C"tn'(;"l'l"CCGGCCATCG--------"tCGCCTGCCC""tCACCTC 
HU 1678 Tl"C"t-GTCCTTAAACM.TGCCCl"ITA"tCATCCACTCATl"CCA.TCCCJICCAACCCAACI\GA 
"" 1:::1 ::· •••• ,, "'"'"' 
HO 1865 CCCGAC"l"GCATAAA-----------------AAC"tCH--CCJICCCCJICW\CCCCAACIICA 
HU 1 7~ 7 CC!CI\CGACJICCCCACJic;cc;.CCTCCTCCACGCI\CTC'tAA"tl'(:ATAGAT ---TCATTAtC 
"' " • '" .. ::' "' ' ...•. '1! ' ' 1" " 
MO 1906 CCT-ACAGAAACCO.-A(;GACC(;CGC'tGGATGGJ\TI"CTAATTCATG(;TT(;AC"tAATTC"tC 
HU 179~ CAATTAAATT=ACACCTTCAA 
' MO 196-4 GAATTAAATCCGCtATACCTTCCA 
F'Ic. 3. Comparison of mouse and human protective protein 
cDNAs at their 3' -untranslatcd regions. Identical nuclcotides 
arc indicated by double dots. Numbers to the left refer to tho position 
of the fust nucleotide in that line. within mouse (MO) and human 
(HU) eDNA sequences. 
4 reveals that only two gnps need to be introduced in the 
Mo54 sequence in order to obtain maximal similarity. There-
fore, it is likely that proteolytic processing in the mouse 
preprofonn OCCUIS in a similar fashion as in its human hom-
ologue. Based on this assumption, the most probable site for 
signal peptidase cleavage is between alanines -1 and+ 1 (Fig. 
2). Moreover, the amino acids surrounding these residues 
conform best to the consensus sequence for the peptidase 
cleavage site (30). Thus, mouse protective protein can be 
FIG. 4. Alignment of predicted amino acid sequences of 
m.ouse and human prcproforms. Identical residues are boxed; 
n~.Lmbers above and below the ~que:cces refer to am.ino acid positions. 
divided into three major domains: a signal sequence of 23 
amino acids (-23 to -1 in Fig. 2), and a 32-kDa and a 20-
kDa component of 297 and 154 residues, respectively. Their 
identity with the corresponding sequences in the human pro-
tein is 70% (signal sequence), 88% (32 kDa), and 91% (20 
kDa). 
Domains that are implicated in the protease activity of 
known serine carboxypeptidases isolated from yeast and 
plants are maintained in mouse and humnn protective pro-
teins. These domains, spanning amino acids 53-62, 148-153, 
and 427-431 in the mouse protein (Figs. 2 and 4), include the 
essential residues Cys00 , Ser1w, and His•za. The corresponding 
serine residues in different yeast carboxypeptidases have been 
:Proven to be present in the active site (11, 15, 31). 
Two potential glycosylation sites are present in the mouse 
protective protein (underlined in Fig. 2) which are located at 
positions identical to the human protein. 
A notable difference between Mo54 and Hu54 predicted 
amino acid sequences ic: the presence of 2 extra cysteines in 
the mouse protective protein, which are found at the amino 
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and carboxyl termini of 32- und 20-kDa polypeptides, respec-
tively. 
Expression of Mo54 eDNA. in COS-1 Cells and Uptake of 
eDNA-encoded Precursor by Human Cells-In order to dem-
onstrate that the Mo54 sequence encodes a functional protec-
tive protein, the eDNA was cloned in two orientations 
(pCDMo54 sense and antisense) into a derivative of the 
mammalian expression vector pCD-X and transfected into 
COS-1 cells (5). For comparison. parallel transfections were 
performed using pCDHu54 constructs (5). Transient expres-
sion was detected 2 days after transfection by [~S]methlonine 
labeling of newly synthesized proteins in the presence of 10 
mM NH.,Cl to induce maximal secretion of lysosomal protein 
precursors (25). Radiolabeled proteins from celllysates and 
medium concentrates were immunoprecipitated using anti· 
human 32-kDa antibodies. As shown in Fig. 5, the Mo54 
eDNA dixects the synthesis in COS-1 cells of a protein of 
about 54 kDa which is partly secreted into the medium (Fig. 
5, lanes 1 and 5). This polypeptide appears somewhat bigger 
than its human counterpart (Fig. 5, larv:s 3 and 7), and it 
seems to be synthesized in less amount. However, when a 
small aliquot of total secreted proteins from transfected COS-
1 cells was directly analyzed by SDS-polyacrylamide gel elec-
trophoresis, it became clear that the quantity of mQI,lSe pro-
tective protein precursor presen~ in the medium is comparable 
to that of its human counterpart (Fig. 5, lanes 9-12). Appar-
ently, the anti-human 32-kDa antibodies precipitate the 
mouse prote<:tive protein to a much lesser extent. COS-1 cells 
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FIC. 5. TrnilSient expression of mouse and human cDNAs. 
COS-1 cells were transfected with pCDMo54 and pCDHu54 sense 
($) and antisense (A) constructs. After transfection, newly synthe-
sized proteins were labeled with ["'S]methionine in the presence of 
10 mM NH.Cl. Labeled proteins from cells and media were i.mmuno-
preeipituted using anti-human 32-kDa antibodies (lanes 1-8). Small 
aliquots of ~creted proteins were kept for direct analysis (lanes 9-
12). Molecular size murkers lll:e indicated at left. Exposure time for 
lanes I-4 wns 16 b: for lanes 5-S, 48 h; and for lanes 9-12, 72 h. 
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immunoprecipitablc products (Fig. 5, lanes 2, 4, 6, and S). 
Previous experiments have demonstrated that the Hu54 
eDNA-encoded precursor, secreted by COS-1 cells, is endo-
cytosed by human galactosialidosis fibroblasts, resulting in 
correction of .8-galactosidase and neuraminidase activities in 
these cells (5). To compare the biological activity of mouse 
and human protective proteins, similar uptake studies were 
performe!l using early infantile galactosialidosis fibroblasts as 
recipient cells. Secreted proteins from cos~ 1-transfected cells 
were concentrated and added to the medium of confluent 
human fibroblasts. After 3 days of uptake, cells were harvested 
for either immunoprecipitation analysis or enzyme activity 
assays. As shown in Fig. 6, COS-1 cell-derived mouse protec-
tive protein precursor is endocytosed and processed intracel-
lularly to a 32- and 20-kDa heterodimer (Fig. 6, lane 1). The 
mouse 32-kDa polypeptide is bigger than its human homo-
logue, whereas the two 20-kDa forms are similar in size (Fig. 
6, lanes 1 and 3). The anti-human complex antibodies used 
in this experiment also show a reducOO affinity for the mouse 
prote<:tive protein components. Taken together, the data on 
sequence homology, transient expression, and uptake suggest 
that mouse protective protein is synthesized, proteolytically 
processed, and glycosylnted in a way comparable to the human 
protein. 
In fact, eDNA-encoded mouse protective protein precursor 
54 -
32- • . 
20- • 
2 3 4 
FIG. 6. Uptake of COS-1 cell-derived mouse and human 
protective protein precursors by human cells. Labeled proteins, 
se«eted by trnnsfeeted COS-1 ~lls. were ndded to the medium of 
fibroblnsts from an early infantile gnl<lctosialidosis patient. After 3 
days of uptake. cells were lysed and proteins immunoprecipitated 
Uf:>ing anti-human complex antibodies. Four sepnrate uptake experi-
mei:tts were performed by ndding concentrated medium from COS-1 
~lls transfected with pCDMc54 sense {lane Jl. pCDMo54 antisense 
(lane 2). pCDHu54 sense {lane 3), and pCDHu54 antisense (lane 4). 
Molecular sizes were calculated by compari:;on with protein markers. 
Exposure time was 10 &ys. 
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can substitute for its human counterpart since it is nble to 
correct iS-galactosidase and neuraminidase activities after en-
docytosis by early infantile galactosialidosis cells (Table.!). 
The increase in P-galactosidase activity is comparable irre-
spective of the fact that mouse or human protective proteins 
are used. On the contrary, correction of neuraminidase activ-
ity seems to depend upon which protein is added to the culture 
medium. 
Protective Proteins Bind to the Serine Protease Inhibitor 
DFP-From our data it is clear that mouse protective protein 
preserves one of the biological functions of the human protein, 
namely the interaction with iS-galactosidase and neuramini-
dase. Given the high degree of homology with certain known 
serine carboxypeptidases. we investigated whether both 
mouse ll.nd human protective proteins are a member of this 
family of enzymes. In general, serine proteases can be distin-
guished from other proteases by their sensitivity to the inhib-
itor DFP. 
We made use of [3H]DFP to detect directly the binding of 
this inhibitor to the two protective proteins. Experiments 
were performed using COS-1 cells transfected withpCDMo54 
or pCDHu54 plasmids. As already seen in Fig. 5, protective 
protein precursors are synthesized intracellularly in large 
amounts. but they are very poorly or not at all proteolytically 
processed. Using slightly different experimental conditions, 
partial proteolytic cleavage of the precursor molecules to their 
respective mature forms can be observed (data not shown). 
Unlabeled cell extracts of COS-1 cells transfected with the 
aforementioned sense or antisense constructs were incubated 
with (3H]DFP. Human fibroblasts from a normal individual 
and the early infantile galactosialidosis patient were treated 
in the same way. Radiolabeled proteins were immunoprecip-
itated afterward with anti-human complex antibodies, re-
solved by SDS-polyacrylamide gel electrophoresis. and visu-
alized by fluorography. 
As shown in Fig. 7. only the 32-kDa component of hetero-
dimeric mouse and human protective proteins binds [~H]DFP. 
After transfection with pCDHu54, a large amount of radiola-
beled 32-kDa polypeptide is immunoprecipitated with anti-
human complex antibodies (Fig. 7.lane3). As observed before 
(Fig. 6), the mouse 32-kDa form is bigger in size and is 
precipitated less efficiently with these antibodies (Fig. 7, lane 
1). The faint band visible throughout lanes 1-4 represents 
endogenous COS-1 mature protective protein which is of the 
same size as the human protein. The eHJDFP labeling 
method is sensitive enough to detect human 32-kDa protective 
protein in normal fibroblasts (Fig. 7, lane 5), and it is highly 
specific since no labeled protein can be seen in the early 
TABLE I 
Correction of $-galactosidase and neuraminidase activities in 
galactosialidosis fibroblc:sts after uptake o{ COS-I ceU-deriued hwnc.n 








Addition of Activity in galactooialidosio 
COS-1 C<!ll-derived fibroblnsw 
proteins tJ·Gnlactooidase Neu=inid~ 
milliwtit.<"/mg microunit.<"/mg 
prot£in proeein 
+ 4.9 147 
+ 5.0 250 
+ 1.1 0 
+ 1.0 13 
+ 1n 10 
0.9 8 
• One milliunit of enzyme activity is defined ns the activity that 
releases 1 nmol of 4-methylumbelliferone/m.in. 
~One microunit of enzyme activity is delmcd as the activity that 
















FIG. 7. La.belin' of prot«tive proteins with rHJDFP. Cell 
extracts of COS-1 cells transfected with pCDMo54 sense (lane I) or 
antisense (lane 2), and with pCDHu54 sense (lane 3) or antisense 
{lane 4) ns well ns extracts of normal (N.lane 5) and ~actosialidosis 
(GS,lane 6) fibroblasts were incubated with ["H]DFP. Labeled-pro-
teins were immunoprecipitated with anti-human compleX antibodies, 
resolved on a 12.5% SDS·polyacrylumide gel, and visualized by fluo-
rography. Moleculur size markers o.re indicated at left. Position of the 
32-kDa components is indicated at right. Exposure times for lanes 1-
4 was 4S h and for lanes 5 and 6, 6 days. 
infantile galactosialidosis fibroblasts (Fig. 7, lane 6). It is 
noteworthy that the respective precursor forms cannot bind 
the inhibitor. From these results we cll.n infer that mouse lllld 
human protective proteins function also as serine proteases, 
and they are nctive after conversion to their heterodimeric 
state. 
Tissue-specific Expression of Mouse Protective Protein 
mRNA-To determine the size and abundance of mouse 
protective protein mRNA, we analyzed total RNA isolated 
from several mouse tissues on a Northern blot. Samples were 
applied in equal amounts, and the blot was hybridized using 
the complete Mo54 eDNA as 11 probe. As shown in Fig. 8, all 
tissues investigated contain a proteetive protein transcript of 
about 2.0 kb. Thus, the composite Mo54 eDNA is probably 
full-length. In spleen, brain, heart, and ovarium, <.transcript 
of slightly longer size is also detected (Fig. 8, l.an.r:s 2, 4, 7, and 
11). In two of these tissues, brain and heart, this mRNA is 
present in nearly equal amounts as the major 2.0-kb species. 
Faint bands of much bigger size, visible only in few of the 
samples, may represent pre<:ursor mRNA. A tissue-specific 
expression of the 2.0·kb protective protein mRNA is observed, 
with high amounts present in kidney and placenta and low 
amounts in testis (Fig. 8, lanes 6, 10. and 12). The latter result 
explains the low yield of recombinant phages isolated from 
the testis eDNA library. 
Mouse Protectiue Protein 4683 
FIG. 8. Expression of protective 
protein mRNA in different mouse 
tissues. Total RNA was isolated from 
different mouse tissues and embryos at 
indicated duys of gestation. Samples of 
10-15 p.g were fractionated on a formal-
dehyde-agarose gel. transfened to Zeta· 
Probe membrnnes, and probed with the 
composite Mo54 eDNA. Ribosomal R~A 
markers are indicated. Exposure time 
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The purpose of the work presented here was to characterize 
the mouse counterpart of human protective protein in order 
to gain insight in the primary structure of the protein and to 
select out conserved domains responsible for its function(s). 
We have isolated a full-length mouse eDNA encoding a bio-
logically functional protective protein. 
At the amino acid sequence level. mouse and human pro-
teins are highly homologous. ':'his stringent conservation 
agrees with a multifunctional ro:e for the protective protein. 
namely stabilization of /3-galactosidase. activation of neura-
minidase. and a putative protease activity that might relate 
to the other two functions. The mouse protective protein 
contains 2 extra cysteines located at the amino terminus and 
carboxyl terminus of 32- and 20-kDa components, respec-
tively. These residues might be responsible for the formation 
of another disulfide bridge that, in turn, could influence the 
folding of the protein. The remainingcysteines are in identical 
positions in mouse and human protective proteins. Since their 
total number is uneven, at least 1 free sulfhydryl group should 
be present in both protective proteins. The mouse 54-kDa 
precursor as well as the mature 32-kDa component are bigger 
in size than the corresponding human forms. The simplest 
explanation is that differences in amino acid composition 
cause retarded electrophoretic mobility. Nonetheless. we can~ 
not exclude that signal sequence cleavage occurs amino·ter· 
minal to the predicted site, since am.ino~terminal sequencing 
of mouse precursor protein has not been performed. 
We have shown that both mouse and human protective 
proteins can bind the inhibitor DFP. These results strongly 
suggest that these proteins are either serine proteases or 
esterases, although direct inhibition studies with DFP could 
not be performed since an enzymatic assay for the protective 
protein is not yet available. Radiolabeled DFP can bind only 
to the 32-kDa and not to the 20-kDa component of the mature 
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heterodimer. This conforms with the location of the serine 
active site within the 32-kDa part of the polypeptide. Fur-
thermore. the results indicate that the precursor molecule is 
not proteolytically active, hence behaving like a zymogen. 
Based on their homology with well characterized proteases 
from lower organisms (10, 11, 15) and plants (12-14), the two 
protective proteins can be included in a newly delineated 
family of serine carboxypeptidases (15, 16, 32). For co.rboxy-
peptidase Y and the KEX1 gene product, the active site serine 
has been determined {11, 31). This residue resides in a stretch 
of6 amino acids (Gly-Glu-Ser-Tyr-Ala-Gly) that are identical 
in all proteins of this family (7 in total) but differ from the 
amino aci.ds surrounding the active site serine in serine en-
dopeptidases (Gly·Asp-Ser-Gly-Gly-(Pro)) (33). It seems, 
therefore, that the Gly~Glu-Ser· Tyr-Ala-Gly domain is a pre· 
requisite for serine cn.rboxypeptidnse activity. Moreover, it 
has been suggested that, like in endopeptidases. the essential 
serine residue in carboxypeptidases is activated by the con~ 
certed action of 2 other residues: a histidine and an :J.Spartic 
acid (16). These 3 amino acids form the so-called "catalytic 
triad" Comparison of the 7 serine carboxypeptidases at the 
amino acid level shows that His'28• Asp:t{;l'', and Aspm in the 
mouse protective protein are the only histidine and aspartic 
acid residues conserved throughout the family. The involve-
ment of any of these amino acids in the formation of the 
catalytic triad is currently investigated by site-directed mu· 
tagenesis. Finally, it is remarkable that the protective proteins 
show structural similarity with plant serine carboxypepti-
dases, which are also heterodimeric proteins, with subunits of 
size similar to the 32- and 20~kDa components {16). 
The uptake studies described here have shown that mouse 
protective protein can replace its human homologue in early 
infantile galactosialidosis cells as far as the correction of fJ~ 
galactosidase and neuraminidase activities is concerned Our 
results support the data of Mueller et aL (34), who constructed 
4684 Mouse Protectiue Protein 
mouse-human somatic cell hybrids to locali?.e the genes en-
coding human neuraminidase and protective protein to chro-
mosomes 10 and 20, respectively. These authors observed in 
hybrids retaining chromosome 10 but lacking chromosome 20 
an increase in human neuraminidase activity over the mouse 
background. This is very likely due to the presence of endog-
enous mouse protective protein. It is important to notice that 
the increase of 13-galactosidase activity is apparently not in-
fluenced by the type of protective protein added, indicating 
that mouse and human precursors are as efficiently endocy-
tosed by the human cells. The correction of neuraminidase 
activity instead seems to be species dependent.. This might 
reflect a differential interaction between the latter enzyme 
and either of the two protective proteins, due to changes in 
th~ir tertiary structures. From these datil we have a further 
indication that the determinants responsible for the interac-
tion of protective protein with .8-galactosidase and neuramin-
idase are clearly distinct (9). 
A surprising finding in the nucleotide sequence comparison 
is the high degree of similarity throughout the 350-base pair 
3' -untranslated regions of protective protein cDNAs. There 
are examples of mRNAs that contain sequences in their 3'-
noncoding regions which regulate mRNA turnover (35-37). 
No obvious homology to the consensus sequence is found in 
the 3' -noncoding regions of the protective protein transcripts, 
yet their similarity suggests a possible involvement of these 
sequences in the folding and stability of the mRNA. Whether 
this feature relates to the observed tissue-specific expression 
of mouse protective protein mRNA remains to be investigated. 
In addition, we need to clarify the nature of a transcript 
slightly bigger than the major 2.0-kb mRNA present in con-
siderable amounts in spleen. brain, heart, and ovarium. This 
species might arise from alternative splicing of the precursor 
mRNA. A number of genes encoding lysosomal proteins, 
including .8-galactosidase, have recently been shown to gen-
erate diversity through such a mechanism (38-40). It will also 
be relevant to examine whether the expression of the protec-
tive protein transcript in different tissues correlates with the 
expression of 13-galactosidase and neuraminidnse mRNAs. 
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Human Lysosomal Protective Protein Has Cathepsin A-like Activity 
Distinct from Its Protective Function* 
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Niels J. Galjart, Hans Morreau, Rob Willemsen. Nynkc Gillcmans, Erik J. Bon ten, and 
Alessandra d' Azzo:j: 
From the Department of Cell Biology and Genetics. Erru;mus University, Rotterdam, The Netherlands 
The proteetive protein w-as iU"St discovered because 
of its deficiency in the metabolic storage disorder gal~ 
actosialidosis. It associates with lysosomal .B~galacto­
sidase and neuraminidase, toward w-hich it exerts a 
protective function necessary for their stability and 
activity. Human and mouse protective proteins are 
homologous to yeast and plant serine carboxypepti-
dases. Here, we provide evidence that this protein has 
enzymatic activity similar to that of lysosomal cathep-
sin A: 1) overexpression of human and mouse protec-
tive proteins in COS-I cells induces a 3-4-fold increase 
of cathepsin A-like activity; 2) this activity is reduced 
to -1% in three galactosialidosis patients with differ-
ent clinical phenotypes; 3) monospecific antibodies 
raised against human protective protein precipitate 
virtually all cathepsin A-like activity in normal human 
fibroblast extracts. Mutagenesis of the serine and his-
tidine active site residues abolishes the enzymatic ac-
tivity of the respective mutant protective proteins. 
These mutants, however. behave as the wild-type pro-
tein with regard to intracellular routing, processing, 
and secretion. In contrast. modification of the very 
conserved Cys60 residue interferes with the correct 
folding of the precursor }Xllypeptide and, hence, its 
intracellular transport and processing. The seereted 
active site mutant precursors. endocytosed by galac-
tosialidosis fibroblasts, restore ,8-galactosidase and 
neuraminidase activities as effectively as wild-type 
protective protein. These findings indicate that the 
catalytic activity and proteetive function of the protec-
tive protein are distinct. 
lntralysosomal degradation is a composite process that is 
largely controlled by a battery of acidic hydrolases. The ma-
jority of these glycoproteins are synthesized on membrane-
bound polysomes as high molecular weight precursors and 
routed to the lysosomes via a series of compartment-depend-
ent posttranslational modifications. For the stepwise catabo-
lism of different macromolecules to occur efficiently, anum-
ber of these hydrolases must work in concert and might, 
therefore, reside in a multienzymic complex. An example of 
such a complex could be the one consisting of lysosomal ;3-
galactosidase (EC 3.2.1.23}, N-acetyl-a-neuraminidase (siali-
dase, EC 3.2.1.18}, and the protective protein (1-3}. In human 
• The costs of publication of this nrticle were defrayed in part by 
the payment of par:e char!:"eS. This article must therefore be hereby 
marked "advertisement,. in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. 
t To whom correspondence >'hould be addres.<;<'d: Dept. of Cell 
Biology and Genet!<:,, Erasmu" University. P. 0. Box 1738. 3000 DR 
Rotterdam, The :-letherlands. Tel.: 31-10·4087173-SHO: Fax: 31-10· 
-1087212. 
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placenta (3), bovine testis (2), and porcine spleen and testis 
(4, 5) these three glycoproteins copurify through an affinity 
matrix for 13-gnla.ctosidase. 
The D.SSociation of the protective protein with iS-galactosid-
ase and neuraminidase is essential for the stability and nctiv-
ity of these two glycosidascs within the lysosomes (3, 6, 7). 
This is reflected by the existence of the metnbolic storage 
disorder galactosialidosls.(S), in which a primary defect of the 
protective protein results in a combined iS-galactosidase/neur-
aminidase deficiency (1, 9). Among galactosialidosis patients 
distinct clinical phenotypes exist. ranging from severe early 
infantile forms in which visceromegaly with nephrotic syn-
drome, heart failure, and other abnormalities lead to early 
death or fetal hydrops, to milder late infantile and juvenile/ 
adult variants (8, 10). Bioche::nical heterogeneity within these 
recognized phenotypes has also been observed (11, 12). 
In human cultured fibroblasts the protective protein is 
synthesized as a precursor of 54 kDa which is proteolytically 
processed into a mature two-chain form of 32- and 20-kDa 
polypeptides linked together by disulfide bridges (1, 12). The 
predicted amino ncid sequences of humnn as well as mouse 
protective proteins are homologous to yeast and plant serine 
carboxypeptidases (12. 13). Both protective proteins react 
with the serine protease inhibitor DFP.' but only in their 
mature state (13). Together these findings allowed us to 
predict a serine carboxypeptidase nctivity for the protective 
protein that is apparently synthesized and transported to the 
lysosomes as a zymogen. Some of its characteristics correlate 
well with those of a previously identified carboxypeptidase, 
cathepsin A (EC 3.4.16.1). This enzyme has been partially 
purified from different sources (14) and was shown to exist in 
small and large aggregate forms (15}. In the native small 
aggregate, subunits with molecular masses of 20, 25 nnd 55 
kDa are present, of which the 25-kDa polypeptide reacts with 
DFP (16}. Besides its carboxypeptidase activity. optimal at 
acidic pH, cathepsin A can also function as a peptidyl ami· 
noacylamidase (14, 17). Recently, a deamidasejcarboxypepti-
dase purified from human platelets was shown to have se-
quence identity to the NH~ termini of the protective protein 
chains (18). Enzymatic characterization of this deamidase 
with a variety of substrates and inhibitors also suggested a 
similarity to cathepsin A. 
Here we provide direct evidence that the protective protein 
maintains cathepsin A-like activity. Galactosialidosis is there-
fore the first example of n lysosomal storage disorder associ-
o.ted with a protease deficiency. We also demonstrate by site-
1 The abbreviations u~ed arc: DFP, diisopropylfluorophosphnte; 
)..1ES, ~-{}l-morpholinolethane,.ulfonic acid; Z. benzyloxycmbonyl; 
bp. bnsepnir{;;); G~11 • II'NeuAc-G~se'Cer; nnti-54. antibodie~ rai5ed 
ar:airist recombinant human protective protein: nnti-32. antibodie>< 
rnised a.:ainst the mature denatured human 32-kDn protective protein 
"ubunit; ER, endoplasmic reticulum. 
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directed mutagenesis of the human protective protein that its 
cathepsin A-like activity can be separated from its protective 
function toward ,8-galactosidase and neurnminidase. 
EXPERIMENTAL PROCEDURES 
Cell Cttlt(lrc-Human skin Gbroblnsts from normnl individunl.s. 
patients with the early infantile (19) and juvenile/adult (20) forms of 
gulactosialidosis, and a G~,-ga.ngliosidosis patient we:re obtained from 
the European Ce\1 Bank, Rotterdam (Dr. W. ,J_ Kleijer). Cells from 
the late infantile galactosialidosis pa:ient (21) and both parents were 
provided by Dr. G. Andria, Dept. of Pediatrics, Univeroity of Napels, 
Italy. Fibroblasts were maintnined in Dulbe<:co's modified Eagle's 
medium, Ham"s FlO medium {1:1 vjv) supplemented with antibiotics 
and 10% fetal bovine serum. COS-1 cells {22) were grown in the same 
medium, supplemented with 5% fetal bovine serum. 
Enzyme Assays-For enzyme activity assays and immunotitration 
experiments cells we:re harvested by trypsin treatment and homoge-
nized in double-distilled water. When necessazy, cell lysates were 
subsequently diluted in 20 mM sodium pho~phate, pH 6.9. containing 
1 m!:fml bovine serum albumin. Cathepsin A activity waa measured 
in cell homogenates using a modi!kacion oithe method of Taylor and 
Tappe! (23). Briefly, 5 p.l (2-10 1-'g of protein) of cell homogcnates 
were incubated for 30 min at 37 ·c in 100 1'1 of 50 mM MES, pH 5.5, 
1 mM EDTA, in the absence or presence of 1.5 mM N-blocked 
dipeptides Z-Phe-AW., Z-Phe-Leu, or Z-Glu-Tyr (Bochem). Reactions 
were stopped by addition of on equo.l volume of 10% (v/v) trichloro-
acetic acid. Precipitates were removed by centrifugation. and a frae· 
tion (5%) of the supomnto.nts Wll>l taken to measure the concentration 
of released amino acid by the fluorimetrie method outlined by Roth 
(24). The activities of P-galactosido.se, neuraminidase, and P-hexosa-
minida_~e wuc measured with artificial 4-methylumbellifervl sub-
:;trates (25). Total protein concentrations were determined. ns de-
,;cribed previously (26). 
Antibodies and lmnw.notit.rc.ti.on of Cathepsin A-like Actiuitv-We 
have previously described the prepOI:ltion of antibodies raised ;gain~.t 
n denatured form of the 32-kDa &ubunit of human protective protein 
(12). These uontJ·32H ant1bodies recognize under rt>ducing and dena-
turin::; conditions the 54-kDa precursor form us well ns the 32-kDa 
mature component of the protective protein. To obtain a monospecific 
antiserum that immunoprecipitate~ human protective protein under 
native conditions, the W.tter was overexpressed in Spodoptera fru.gi-
perda (S£9) in._~ect cells, that had been infected with recombinant 
baculovirus containing human protective protein eDNA." Protective 
protein waa purified from the culture medium of infected cells usin~; 
n concanavalin A-Sepharose column (Pharmacia). o.s described earlier 
(2). ":o\nti-54H an?bodies were raised in rabbits against thi~ purified 
prOthn preparatlon. An IgG fraction (2.2 mg of protein/mil was 
pn•pared from anti-54 antiserum using a protein A·Sepharose column 
(Pharmacia). 
Immunotitration of cathepsin A with anti-54 antibodies wus per· 
formed essentially aa described befort> (3). Formalin-fixed Staphylo-
coccus a.urcus cells rimmunoprt>eipitin, Bethesda Research Lo.bora-
torics) were added to the srunples to remove anti"en-antibody com-
plexes. "' 
Isolation of eDNA Clones and DNA Sequence Anai.ysis-A chicken 
embzyo Agtll eDNA library (Clonte<:h, Pule Alto, CA} (27). consisting 
of 1 X 10" independent clones, was plated out ss described before (13) 
and screened llsin~; the heterologous human protective prot<> in eDNA, 
Hu54, as a probe (1:?:. 281. The lon~est eDNA insert was subcloned 
into pTZlS and 19 (Pharmocia) (29) and scqllenced on both strands 
(30. 31). Compurison to the hllmun sequence showed that the chicken 
:,DNA lacks the ATG stun codon and part of the signal peptide. 
:Se_q.uence data w~re analyzed w1th the programs of tho Univeroity of 
\VJsconsm GenetiCS Computer Group (321. Protein alignments were 
al~o done with the latter software package. 
Pfusmid Con.~tructs-In vitro mutagenesis of human protective 
protem eDNA was carried out using the method described by Higuchi 
et aL (33). Polymerase chain reaction-amplified DNA fragments, 
containing the desired mutations givin~ rise to single amino acid 
"ubstitutions. we:re introduced in the normal humnn eDNA bv suitable 
ro:-::;triction enzyme sites. Using the same procedure tho. deletion 
construct 32(..::.20) was generuted by introducinr; a stop codon in one 
oft~! amplificotJon primel'S. The stop codon follows immediately the 
Arl:"" residue. A 365-bp BamHI fragment. with the point mutation 
'E .. J. Bonten and A. d'Azzo. manuscript in preparation. 
that gives rise to the Ser'·"' to Alo100 amino acid change, was subse-
quently subs~ituted for the wild-type fragment into the 32(.:l20) 
construct, usmg standard cloning procedures (29). This resulted in 
the 32SA(..l.20). The 20(..l.32) construct encodes the human 20-kDa 
subunit tagged with the signal sequence (residues 299 to 452 and -28 
to + 1 in the human protein, respectively). The eDNA stretches 
enco~ng these two ports of the protective protein preproform were 
amphficd_ by polymeruse chain reaction and afterwards ligated to-
gether usmg nn Nco I restriction enzyme site introduced in two of the 
amplification primers. This site does not alter the amino acid se-
quenc:s of the 20-kDa subunit or signal peptide. All DNA fragments 
resulting from polymerase chain reuction amplification were verified 
b.Y s~uencing as described above. The oligonucleotides needed for 
SJte-dix:cted mutagenesis WC'te synthesized on an Applied Biosystems 
381A oligonucleotide synthosiz.er. 
_Humo.n(chicken eDNA, HCh1, was mode by exchange of 5'-end 
chicken w1th human eDNA sequences at a conserved Psti restriction 
enzyme site. All constructs were cloned into a derivative of the 
mammalian expression vector pCD-X (34) as described previously 
(12). 
Tro.nsfcction in COS-I Cells-COS-1 cells were see<l.ed out in 30-
mm dishes 1-2 days prior to transfection and grown to 30% con-
fluency. Transfection in COS-1 cells, metabolic labeling oftransfccted 
cells, and preparation of cell extracts and media were carried out as 
described "before (12, 35). C<.>lls were labeled with [3H]leueine (143 Ci/ 
m:nol, Amersham Corp.). Immunoprecipitotion of radiola~led pro-
tems fr_om ~elllysates and media waa performed using anti-32 or anti-
54 o.ntlbodies, aa reported eurlier {35). Radioactive proteins were 
resol:o:<f on 12.5% pol~acrylamide gels under reducing and denaturing 
eondiuons and VlSuulized by fluorogrophy of gels impregnated with 
Amplify {Amersham Corp.). For the DFP-binding US~;Uy and direct 
measuremont of cathepsin A activity, COS-1 cells were ~ansfected 
with vanous pCD constructs and maintained afterwards for 72 h in 
normul _culture J:?edium. SLJbsequently, cells were harvested by treat-
ment Wlth trypsm. Cell lyrotes were either incubated with [~H]DFP 
(DuPont-New England Nuclear, 3.0 Ci/mmol) (13) or used as such 
for detection of cathepsin A activity as described above. 
. Up taW:!_ Studies in Human Fibroblasts-COS-1 cell-derived protec-
tiVe protem precursors were obtained from the medium of unlabeled 
COS-1 cells, transfeeted in 100-mm Petri dishes. Media were concen-
trated as described prt>viously (35) and· half of the concentrated 
material wns added to the medium of recipient early L:Uantile galac-
tosJalidoais fibroblasts (12). After 5 days of uptake the medium wo.s 
replaced with frt>sh medium containing the other half of concentrated 
muterial. 2 days later cells were harvested by trypsin treatment, and 
celll~tes were purtly used for enzyme activity a..-<says. The remain-
der ot these homogenutes wns diluted 7-fold in 10 mM sodium phos· 
phate buffer, pH 6.0, contoming 100 mM NuCl and 1 mg/ml bovine 
serum albumin. After centrifugation to remove insoluble material the 
eelllysates were divided into three aliquots of 25 1'1 each and incubated 
for 1.5 h with 1..5 1-'1 ofpreimmune serum, anti-54 antibodies, or anti· 
n_ative human .!3-galoctosidase antibodies. Immunoprecipitin, exten-
Sively waahed Jn the afort>mentioned buffer, wns subsequently added 
to the samples, and after 30 min antibody-antigen complexes W1lre 
removed by centrifugation. All steps we:re performed on ice or at 4 ·c. 
The supemato.nts were assayed for $-galactosidase activity. 
Indirect lmmunofluorcsceru:e-COS-1 cells, transfected with se-
lected pCD constructs, were treated mildly with trypsin 48 h after 
transfection and subsequently reseeded at low density on coverslips. 
16 h later cells were fi."':ed and incubated with anti-32 antibodies and 
in o se<:ond step with goat anti-(rabbit lgG) conjugated with fluores-
cein (36). 
lmmu.noelectron Microscopy-Transfected COS-1 cells were fu:ed 
in 0.1 M phosphate buffer, pH 7.3, containing 1% acrolein and 0.4% 
glutaraldehyde. Further embedding in gelatin, preparation for ultra-
czyotomy. and the methods for immunoelectron microscopv were aa 
reported earlier (37). -
RESULTS 
Euidence That the Protectiue Protein Is Similar to Cathepsin. 
A-We first ascertained whether the protective protein main-
tains carboxypeptidase activity aside from its protective func-
tion. The choice of the synthetic substrate to use in the as..<;ay 
was dictated by the similarity of the protein to cathepsin A 
(14-18). The latter hydrolyzes preferentially at acidic pH 
acylated dipeptides having a hydrophobic residue in the pe-
106 
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nultimate (Pl) position (38). Of these N-blocked dipeptides 
Z-Phe-Ala was reported to be the most specific substrate for 
cathepsin A (38). 
In total cell homogenates from human cultured fibroblasts 
we have measured the hydrolysis of Z-Phe-Ala as well as Z-
Glu-Tyr and Z-Phe-Leu. The rate of hydrolysis is maximal 
for Z-Phe-Ala {Table I). 3-fold lower for Z-Phe-Leu (normal 
fibroblasts: l, 163 milliunits/mg protein; 2, 93 milliunits/mg 
protein) and barely detectable for Z-Glu-Tyr (not shown). In 
order to prove that the protective protein is the enzyme 
responsible for the cleavage of Z-Phe-Ala, we raised mono-
specific polyclonal antibodies in rabbits against a human 
native protective protein preparation (anti-54 antibodies). As 
shown in Fig. 1, virtually all carboxypeptidase activity toward 
this substrate is precipitated at increasing antibody concen~ 
trations. Since the purified preparation used for immunization 
of the rabbits was obtained from the culture medium of Sf9 
insect cells infected with a recombinant baculovirus expres~ 
sion vector (39).2 it is unlikely that proteins of human origin, 
other than the protective protein, are directly precipitated by 
the antibodies. From these results we conclude that lysosomal 
protective protein has a substrate specificity overlapping with 
that of cathepsin A. We have also tested whether .B·galacto· 
sidase activity is coprecipitated with cathepsin A by virtue of 
the association of these two proteins. Indeed, about one-third 
of total .B~galactosidase activity is brought down at ma.-ci.mal 
antibody concentrntion. The vulues for .B-hexosaminidase, 
measured in the fibroblast homogenates as a reference en-
zyme, remained unchanged throughout the experiment. 
TABU: I 
Cathepsin A-like activity in normal and mw:ant human fibroblasts 
Lysates of different humllil cultur<.-d fibroblasts wore incubated for 
30 min at 37 ·c in SO mM MES, pH 5.5. containing 1.5 mM Z-Phc-
Ala. Cathepsin A-like activity was determined by indirect fluorimetric 
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• One milliunit is defme<l as the enzvme activity that releases 1 
nmol of alanine per min. • 
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Fie. 1. Immunotitration of cathepsin A·likc activity. In-
creasing amounts of an IgG antibody fraction. raised against human 
native protective protein precul"Sor. wer~:: added to a cell extract of 
normal human fibroblasts. Antibody-antigen complexes were rc· 
moved bv addition of S. aureus cells and the remaining carboxypep-
tidase {CPJ activity toward the acylate<l dipeptide Z-Phe·Ala wo.s 
measured in the supernatant. 
Carbox:ypeptidcu.e Deficiency in Galactosialidosis Fibro-
blasts-The same dipeptide, Z-Phe-Ala, was used as substrate 
to measure cathepsin A-like activity in fibroblast homage-
nates from nonnnl individuals, a GMt· gangliosidosis patient 
with an isolated P-galactosidase deficiency. different galacto-
sialidosis patients, and carriers (Table I). In contrast to nor-
mal as well as c~~-gangliosidosis fibroblasts the galactosiali-
dosis cell strains tested have minute activities toward the 
substrate. Clear heterozygote values are measured in the 
carrier samples. The normal hydrolysis of Z-Phe~Ala meas-
ured in GM 1-gnngliosidosis cell extract indicates that an iso-
lated .B·galactosidase deficiency does not influence the car-
boxypeptidase activity of the protective protein. 
Analysis of Conserved Domains in Protective Proteins of 
Different Species-Amino acid sequence comparison with 
other well defmed serine carboxypeptidases (40-42) revealed 
that the protective protein/cathepsin A is a member of this 
family of enzymes (12, 13). Similarly, comparison of the 
primary structures of protective proteins from different spe-
cies could disclose domains in the human protein important 
for its association with P·galactosidasejneuraminidase and, 
hence, for its protective function. However, the previously 
charucterized mouse protective protein appeared to be almost 
identical to its human counterpart (13). We therefore isolated 
the eDNA encoding chicken protective protein. Its predicted 
amino acid sequence is shown in Fig. 2, aligned with those of 
the humnn and mouse proteins. The chicken sequence lacks 
the first methionine residue and part of the signal peptide. 
Identity between the different proteins is 67% (chicken/ 
human), 66% (chicken/mouse), and 87% (mouse/human). 
The serine, histidine, and aspartic acid residues that are 
known to form the catalytic triad of serine carboxypeptidases 
(43) are found in the chicken protective protein/cathepsin A 
at positions 150, 431, and 375, respectively. Ser100 and Hism 
are included in two of the three highly conserved regions 
(boxed in Fig. 2) in this family of enzymes. Remarkably, 
however, the chicken enzyme has a glycine for alanine sub· 
stitution at position 152 that occurs within the Gly-Glu-Ser-
Tyr-Ala-Gly domain. containing the active site serine. All 
three protective proteins have 9 conserved cysteine residues, 
probably crucial for their teniary structure as well ns function. 
Both chicken and mouse homologues have two additional 
cysteines, one on each subunit of their respective two~chain 
forms. but at different positions. 
Additional essential residues and domains emerge from the 
sequence alignment. Amino acids surrounding the two prote-
olytic cleavage sites (Fig. 2, vertical arrows) are largely iden-
tical. An internal repeating motif (underlined in Fig. 2), 
characterized by 2 recurring Trp residues 16 amino acids 
apart. is present in each subunit of all three protective pro-
teins, suggesting an ancient intragenic duplication. Notably, 
this "'repeat" within the 32-kDa polypeptide includes the 10-
amino acid domain (residues 53-62, boxed in Fig. 2). conserved 
in all serine carboxypeptidases. Four potential N-linked gly~ 
cosylation sites are found in the chicken protective protein 
(Fig. 2, hatched boxes), two of which are in identical positions 
in the three sequences. 
Mutagenesis of Human and Chicken Protective Proteins-
To investigate whether the cathepsin A-like nctivity of the 
protective protein is essential for the activation and stabili-
zation of ~-galactosidase and neuraminidase we used a genetic 
approach. As summarized in Fig. 3, mutant nnd hybrid pro-
tective proteins were obtained by site-directed mutagenesis of 
wild-type cDNAs, encoding either the human or chicken 
forms. The first series of mutants (Fig. 3. upper bar) carried 
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FIG. 2. Alignment of predicted amino acid sequences of human. mouse. and chicken protective 
proteins. Amino acid sequenc~ of previously characterized humun (HU) and mouse (MOl protective proteins 
are shown aligned with tbe chicken (CH} homologue. Residues on thf.' [ou.rth line (consensus sequence) denote 
identity at those positions in the three protective proteins. The three domains, dwracteristie of S('rine eru-boxypcp-
tidascs, and the aspartic acid residue, con'*'rved throughout this family of enzymes. are boxed. Potential N-linked 
glycosylation sit~ are indicated with Jwtched boxes. Vertical arrows denote proteolytic cleavage sites. The internal 
reJ){!ating motif in 32- und 20-kDa subunits is underlined. Numbers on thf.' left refer to pooitions of tbe amino a.:::idB 








32-kDa protein carrying the Ser160 to Ala1:.o amino acid sub-
stitution (Fig. 3, middle bars). 
The human-chicken hybrid construct. HChl (Fig. 3, lower 
bar). was made to identify determinants on the human pro-
tective protein, important for its association to ~·galactosid­
ase/neuraminidase. Furthermore, the replacement of chicken 
with human 5' end eDNA sequences provided HChl with the 
correct translation initiation codon. As a result, the NH2 
terminus of the HChl hybrid precursor contains 60 amino 
acids of human origin. 
FIG. 3. In vitro mutagenized and hybrid protective pro-
teins. The prcprofrom of human prot~ctive protein is repr~ntcd by 
the upper bar. Hatched part, signal sequence; stippled part, 32-kDa 
subunit; cross-Mtchcd part, 20-kDa subunit. Single amino aeid sub· 
stitutions art:' indicate<i. The three middle bars represent the deletion 
mutant..~. In the 328A(J.20) mutant the Ser'·.o to Ala'"" substitution is 
nlso present. The 20(t.32) mutant is to.r;gOO with the human signal 
sequence (hatchcdpart). The lower bar represents the human/chicken 
hybrid protein, having the signal seq_uence (hatched part) and the 
most N"H2·terminal 60 amino acids (stippled part) of the human 
protective protein. 
Transient Expression of Mutant and Hybrid Protective Pro· 
teins in COS·l Cells-To follow the intracellular transport 
and processing of mutant and hybrid protective proteins, their 
corresponding cDNAs were subcloned into a derivative of the 
expression vector pCD-X and transfected into COS-1 cells. 
Human and mouse protective protein constructs (pCDHu54 
and pCDMo54) were included in the experiments as controls. 
Transiently expressed proteins were detected 2 days after 
transfection by metabolic labeling with [0H]leucine followed 
by immunoprecipitation from celllysates and media (Fig. 4). 
Immunoprecipitations were carried out using two different 
Mtibodies: those raised against the human denatured 32-kDa 
polypeptide (anti-3'2. antibodies), that recognize under reduc-
ing conditions the 54-kDa precursor as well as the mature 32-
kDa component, or the anti-54 antibodies. catalytic triad, Ser1:.o was replaced by alanine and His429 was 
mutated into glutamine, in order to abolish cathepsin A·like 
activity. The third point mutation was introduced nt residue 
Cys00 to study the effect of this nlteration on the correct 
folding, transport, and processing of the protective protein. 
The mutants 32(il.20) and 20(;:."1.32) were deleted of either of 
the two subunits in order to check their reciprocal influence 
v:ithin the two-chain form on the cathepsin A and/or protec· 
tive activities. They encode truncated 32- and 20-kDa poly· 
peptides, respectively. The la.tter was tagged with the human 
signal sequence to allow its translocation into the endoplasmic 
·eticulum (ER). The 32SA(.:.\.20) mutant encodes a truncated 
Fig. 4 shows that singly transfected pCD constructs direct 
the synthesis of mutated or hybrid protective proteins that 
are stable under the conditions used. The SA 160 and HQ"29 
mutant precursors behave as wild-type protective protein in 
that they undergo norma.l proteolytic processing and the 
unprocessed precursors are secreted into the medium (Fig. 4. 
lanes 1, 3, and 4). In contrast. the cysteine to threonine 
substitution apparently interferes with the maturation and 
secretion of the precursor molecule (Fig. 4, lane 2). However, 
it is also possible that an aberrantly folded mature mutant 
protein evades recognition by the anti-32 antibodies. 
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Fie. 4. TJ:"nnsientcxpressionofnonnal human, mutant. and 
hybi:"id protective proteins in COS-1 cells. COS-1 cells were 
transfected with Vnl'ious pCD constructs: v.;t(sc) and (a) represent 
human protective protein eDNA in the sense and antisense orienta-
tion, respe<:tively; CT. SA, o.nd HQ o.re th" single amino acid substi-
tutions; 32 and 20 reprCGI.lnt the 32(~0) and 20(~32) ddetion mu-
Ulnts, and HCh is the human-chicken hybrid protective protein. All 
abbreviations are explained in Fig. 3. 2 days after transfection newly 
synthesized proteins were labeled with [3H]leucine for nn additional 
10 h. Labeled proteins were irnmunoprecipitated from cells and media 
using anti-32 antibodies (/an.::sl-4 and J0-12) or anti-54 antibodies 
(lanes S-9). Proteins were separated by geldectrophoresis under 
reducing and denaturing conditions and visualiz~d by fluorography. 
Molecular sizes of precursors, mature subunits, and truncated poly· 
pcptides are indicated at le/L For the medium samples only the 54-
kDa pan of the gel is shown since the uncleaved 54-kDa precursor is 
the only form of the prote<:ti.vc protein detecred in th~ medi.um of 
trnnsfected COS-1 cells. Exposure time for lanes J-4 and 10-12 wa$ 
2 days; for lanes 5-9, 3 days. 
The 32(.:l20) deletion mutant construct encodes a 34-kDa 
polypeptide that is -2 kDa larijer than the corresponding 
wild-type subunit (Fig. 4, lD.ne 5). A possible explanation for 
this size difference is that additional carboxyl-terminal proc-
essing of the latter takes place, an event that is impaired in 
the mutant 32(A20). This processing step may normally occur 
after endoproteolytic cleavage of the 54-kDa precursor either 
in an endosomal or lysosomal compartment. In addition, 
altered glycosylation of the 32(ll.20) mutant in comparison 
with the wild-type subunit may also contribute to this ob-
served difference. The 20(ll.32) mutant is very similar in size 
to the 20-kDa component of the mature protective protein 
(Fig. 4, lane 6). Neither of the two independently synthesized 
polypeptides are secreted into the medium. To test their 
capacity to associate and to analyze the influence of this event 
on their intracellular transport and secretion, COS-1 cells 
were cotransfected with both pCD32(ll.20) and pCD20(ll.32). 
Binding of the two truncated proteins was proven by their 
coprecipitation with monospecific antibodies against either 
the 32- or the 20-kDa denatured subunit (not shown). Sur-
prisingly, however, their interaction seems to cause a severe 
reduction in the amount of immunoprecipitable 34-kDa poly~ 
peptide, as compared to the single transfections (Fig. 4. lanes 
5-7). We envisaged that formation of an "active" two-chain 
cathepsin A soon after synthesis could underly this effect. 
This hypothesis was supported by the observation that assem-
bly of a truncated 34-kDa polypeptide, carrying the Ser'.•'' to 
Ala1'"' active site mutation, with the 20·kDa polypeptide does 
not lead to reduced immunoprecipitable material {Fig. 4. lanes 
8 and 9). The results further indicate that association of the 
different subunits does not induce their secretion. 
The HCh1 hybrid precursor is about 4 kD:J. larger than the 
human preform {Fig. 4., lanes 1 and 10). This is due to the 
presence of two extra sugar chains in the chicken protective 
protein, since tunicamycin ueatment prior to and during 
labeling leads to the synthesis of precursor molecules of 
identical size (not shown). The hybrid precursor is secreted 
into the culture medium, but no mature form can be precipi-
tated intracellulary (Fig. 4. lane 10). A likely explanation is 
that proteolytic processing to the mature hybrid two-chain 
protein does occur but this form is not brought down by the 
antibodies under the experimental conditions used. 
Localization of Mutant and Hybrid Protective Proteins-
Given the differential behavior of mutant and hybrid protec-
tive proteins in transfected COS-1 cells, we analyzed their 
subcellular distribution by indirect immunofluorescence and 
immunogold labeling techniques. At)ight microscopy a typical 
lysosomal labeling pattern and a diffuse staining of the per-
inuclear region are observed in cells expressing the wild-type 
human, the HCh1 hybrid. and the SA100 mutant protective 
proteins (Fig. 5, A-C). The HQ4 ::t> mutant protein behaves 
similarly (not shown). In contrast. the CT"0 precursor as well 
as the deletion mutants all seem to accumulate in the perin-
uclear region (Fig. 5, D-F). 
For a more refined localization. ultrathin sections of trans 
fected cells were probed with anti-32 antibodies followed b~ 
Fie. 5. Immunocytochemical locnlization of normal, mu-
tant, and hybrid protective proteins in transfected COS-1 
cells. COS-1 cell& were treated with trypsin 48 h after transfection 
and reseeded on coverslips. 16 b later. cells were fJXcd and incubated 
with anti-32 antibodies. The introcellular distribution of normal 
human protective protein (A). HChl hybrid (B). and muu:nr~ SA""' 
(C), C'I"'"' {D), 32(~20) (£). and 32(~20)/20(..0.32) (FJ 1S 5ho,~·n. 
Abbreviations used to define mutant and hvbrid prote<:tive proteins 
are cxl_"llained in Fig. 3. :M<..gnification: A. -B. C. w;;oox: D. E. F, 
2000X. 
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goat anti-(rabbit IgG)-gold and analyzed by electron micros-
copy. As shown in Fig. 6. overexpressed wild-type prctective 
protein is compartmentalized in lysosomes and is detected in 
large amounts in the Golgi complex and rough ER (Fig. 6, .4. 
and B). A similar pattern is seen in cells transfected with the 
HCh1 hybrid protein, the SA'M mutant (Fig. 6, C and D) and 
the HQ"~~ protein (not shown). Immunogold labeling is re-
stricted exclusively to the roughER in cells expressing either 
the C'f"'l mutant or the tronca~d subunits (not shown). COS-
1 cells transfected with an antisense eDNA were used to 
estimate background labeling due to endogenous protective 
protein. The number of gold particles in lysosomes, Golgi 
complex, and rough ER was on average one or two. All 
together these results identify two types of modified protective 
proteins: those whose intracellular transport and processing 
overlap with wild-type protective protein (SA11..o, HQ"~"-'. 
HCh1) and tho:;e that accumulate in the ER and are neither 
processed nor secreted (C~, deletion mutants). 
Protective Protein Active Site Mutants Lack Cathepsin A-
like .4.ctiuity-The similar churncteristics observed thus far 
for the active site mutants with respect to wild-type protective 
PIC. 6. Cryoscctions of COS-1 
cells, transfcctcd with normal hu-
man {A and B). HChl hybrid {C) or 
SA'M mutant (D) protective pro-
teins and labeled with anti-32 anti-
bodies and goat anti-(rabbit lg-G)· 
gold. A, shows extensive labeling of the 
Gol¢ complex (G) nnd lysosomes (L). in 
cells e:<pn'$sing: the normal human pro· 
tein. A low magnification of the perinu-
clear reg: on is shown in B with extem;ive 
lnbelinr: of rou>:h endopla._~mic reticulum 
structures (Rl, but not of a mitochon-
drion (ML An identical labeling pattern 
is observed in cells e:<p!X'ssing the HChl 
hybrid or SA''.u mutant protective pro-
teins. Correct lysosomal targeting of 
these modified proteins is ~hown in (C) 
and (D). Bars. 0.1 ilffi-
protein imply that their tertiary structures are not grossly 
modified by the amino acid substitutions. We next ascertained 
whether cathepsin A-like activity wns measurable in cells 
expressing these two mutant proteins compared to cells trans· 
fected with Hu54. Mo54. HChl, and 32(~20) constructS. Two 
independent nssays were used. First, COS-1 cell extracts were 
incubated with {"HJDFP, followed by immunoprecipitation 
with nnti-54 antibodies (Fig. 7. upper panel). As we have 
shown before, human and mouse protective proteins are able 
to react with the inhibitor after proteolytic cleavage cf their 
zymogens (Fig. 7. lanes 1 und 2). Only the large subunit, 
carrying the serine active site, is detectable. The mouse form 
is slightly bi~;ger in size and reactS poorly with the antibodies. 
In contrast, neither the SA u.o, containing a modified active 
site serine, nor the HQ"'~ mutants show any binding capacity 
(Fig. 7, lanes4 and 5). Likewise, the 32(A20) deletion mutant, 
missing the 20-kDa subunit, does not renct with the inhibitor 
(Fig. 7, lane 6). Mnture HChl hybrid molecules, if present, 
again are not immunoprecipitable (Fig. 7, lane 3). Cells trn.ns-
fectcd with an antisense wild-type construct were included in 
the experiment as estimate of the level of endogenous COS-1 
, , 0 





FIC:. i. ['HJDFP labeling and cathepsin A acth':ity of nor-
mal. mutant, and hybrid protective proteins. Cell extracts of 
COS-1 cells, transfectcd with selected constructs, were incubated 
wi.th ['H)DFP, followed by irnmunopreeipitation using anti-54 anti-
bodies (upper pand). Molecular ~iw is indicated at left. Exposure 
time was 6 days. The pCD constructs used nrc abbreviated O-" before 
with the nddltion ofpCD~1o54 sense <Mo). The same set of constructs 
was trnns!ected scparntely into COS-1 cells to directly test cathepsin 
A activity in the different cell extr-uctF.. using Z-Phe-Ala as substrate 
(/f;wer panel). Hatckd vertical bars represent rntes ofhydl'olysis. One 
unit is defined as the enzyme activity that rele1ll:JCS 1 l"mol of nlanine 
per min. 
protective protein (Fig. i.lane 7). Since the SA'w and HQ•::.-r· 
mutants resemble most the wild-type protective protein, it is 
conceivable that nl.l antibodies are efficiently competed out 
by unlo.beled molecules only in these cell extracts. This ex-
plains the lack of signal in lanes 4 nnd 5 compared to lane 7. 
The results obtained with DFP inhibitor are well supported 
by direct measurements ofZ-Phe-Ala hydrolysis in lysaws of 
cells transfected independently with the same set of con-
structs (Fig. 7, I.Dwer panel). Equnl increase in cathepsin A-
like activity above endogenous COS-I levels is measured in 
cells expressing the wild-type human and mouse protective 
proteins. These results demonstrate directly that both pro-
teins have cathepsin A-like activity and that only a small 
proportion of the mouse protective protein is immunoprecip-
itated. The SA '~0 nnd HQ421l mutants are completely inactive, 
.o.s is the case for the deletion mutant (Fig. 7) and the CT'"l 
mutant (not shown). The -2.5-fold increase in activity, de-
tected in HCh1-expressing cells, confmns that this hybrid 
protein must be present in its mature two-chain form. Sur-
prisingly, however, it has nn altered substrnte specificity, as 
compared to human and mouse wild-type proteins, since it 
preferentially cleaves Z-Phe-Leu over Z-Phe-Ala (not shown). 
This effect could be due to the glycine for alanine substitution 
at position 152 in the chicken protective protein. 
Dual Function of the Protective Protein-The two active 
site mutations have been shown by different criteria to abolish 
the carboxypeptidase activity of the protective protein with-
out disturbing its tertiary structure. Therefore. these mutllnts 
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are excellent candidates to test. in uptake studies, whether 
loss of cathepsin A-like activity influences the protective 
function. For this purpose secreted modified precursors from 
transfected COS-1 cells were added to the medium of early 
infantile galactosinlidosis fibroblasts deficient in protective 
protein mRNA. Similarly. the s&:reted HCh1 hybrid as well 
as mouse precursor proteins were also tested. After uptake, 
cells were harvested and P-galactosidnse and neuraminidase 
activities measured. As shown in Table II. the SA'(,{> and HQ420 
mutant precursors, endocytosed and processed by the defi-
cient cells. restore 1)-galactosida_-;e and neuraminidase activi-
ties as efficiently as the wild-type protein. Thus, the protective 
protein has catalytic activity clearly distinct from its protec-
tive function. Surprisingly, the HChl hybrid molecule has 
maintained the capacity to bind and activate {3-gnlactosidase 
and neuraminidase. nlthough the overall identity between 
chicken and human sequences is only 6i%. It seems that the 
modified active site domain (Gly-Glu-Ser·Tyr-~-Gly) and 
altered substrate specificity have no influence on the protec-
tive function of HChL As observed earlier (13), the mouse 
homologue, 87% similar tO human protective protein. adopts 
a configuration not entirely suitable for the activation of 
human neuraminidase. 
Confirmation that the SA'w and HQ4~ mutants exert their 
protective function via physical association with ,6-galactosid-
ase was obtained by examining the coprecipitation of this 
enzyme with different endocytosed protective proteins. Gal-
actosialidosis cell lvsates used to measure correction of {3-
;;alactosidasejneura'minidase activities were incubated with 
anti-54 antibodies and, as control, with preimmune serum or 
anti-native human /)·galactosidase nntibodies. Fig. 8 shows 
that 22, 25, and 34% of .8-galactosidase activity is coprecipi-
tated with anti-54 antibodies in cells that have taken up the 
wild-type human, the SA1:.o, and the HQ.:" mutant protective 
proteins, respectively. A comparable percentage of-activity is 
coprecipitated in a normal human fibroblast homogenate. 
These results demonstrate that a proportion of active (3-
galactosidase is indeed associated v.-ith the SA1:.o and HQ'~ 
mutant proteins, and that the enzyme bas equal affinity for 
the active site mutants and wild-type protective protein. Fur-
thermore, the values are specific since $-galactosidase activity 
is either not at all or to a lesser extent coprecipitated in cells 
treated with the HCh1 hybrid or mouse protective proteins, 
TABLE II 
Restoration of (3-galactosidase and neuraminidase acti.uitks in 
galactosialidosi..o fibroblost.~ aftl!r uptake of oariou.s COS-I cell-derived 
protl!ctit'e protein precursors 
Equivalent amounts of secreted precursor proteins from the me-
dium oftro.nsfectcd COS-1 cells were added to the culture medium of 
curly infantile ~actosio.lidosis fibroblo.sts. After 7 days of uptake, 
cells were harvested o.nd cnz;.•me activities meo.sured using 4-mcth-
ylumbelliieryl substrates. The results are reprcsento.tive of e:xperi· 
ments carried out several times. 
Addition of Activity 
Cell :<tl'ain prot<-ctive 
protein• #-Golncto..ida"e ~eurnminidase 
milliwU.t..<" /rnt microunit:;/mg 
protem pro!cin 
Early infantile galac- v.'t (se) 5.18 550 
tosialidosis SA 5.18 533 
HQ 4.83 700 
MoM 4.17 80 
HChl 5.:.?:7 500 
wt (a) 0.58 lZ 
O.i:.?: 5.1 
Ncrrnal fibroblasts 7.33 900 
Q One milliunit i" defined o.s the enzyme activity tho.t releMcs 1 
nmol of 4-mcthylumbellifcronc per min. 





' I ~ !:! Anti-54 DAnll-l)gal 
E ~ :~ ro ? 
" I 1 ' ) 
• D m ' ~ 
Norm~l G., EJ. GS - wt (w) SA i-IQ Mo54 HCh1 wt (a) 
'he. ::1. Precipitation of P·s:nlactosidase activity in g:alacto-
sialidosis fibroblo...:;ts after upta.ke of various COS-1 cell-de-
dvcd protective protein precursors. Early infantile gnluctosiali-
dosis (E.I.GS) cell homogenates from the uptake experiment de-
scribed in Tabk II were each divided in three aliquots and incubated 
with either preimmune serum, the anti-54 .o.ntibodies. or anti-native 
human )3-galnctosiduse antibodies. k< controls, normal human fibro-
blnsts and cells from a G:>wgnng!iosidosis patient were treated in the 
game manner. After precipitation of antibody-antigen complexes. the 
remainin~; P'·I:"Cllncwsiduse activity was measured in the aupern::~tunts 
(vertical bars). The vulu~ obtained in prdmmune serum treated cells 
after endocytosis of wild-type human protective protein is taken us 
100% activity. Except for normal and G~u-r:o.ng-liosidosis fibroblasts, 
all P-:::o.lactosidusc activities are expressed as a percenta:::e of this 
vnlue. Cell homol:"enates tO the right of the arrow represent E.I.GS 
fibrobl...'\Sts that have t.:lken up the different COS-1 Cl'll-dcrived pro-
tective protein precursors (nbbrcvi::ttcd us in Fig. 4). 
respectively. This, in tum, is not surprising if we take into 
account the lower affinity of anti-54 untibodies for chicken 
and mouse mature protective proteins. On the other hund, u 
complc:x formed by human .6'-galactosidase and protective 
proteins from other species may be more susceptible to dis-
sociation. In human fibroblasts neuraminidase is inactivated 
upon dilution or freeze/thawing, therefore its coprecipitation 
with the protective protein cocld not be examined. 
DISCUSSION 
The primary structure of human protective protein has 
suggested a putative carboxypeptidase activity by virtue of its 
homology with yeast carboxypeptidase Y and the KEX1 gene 
product. We now directly demonstrate that the protective 
protein at acid pH cleaves the acylated dipeptidcs Z-Phe-Ala, 
Z-Phe-Phe. and Z-Phc-Leu wi~h clear preference for the first 
named substrate. This chymotrypsin-like activity closely re-
sembles that of lysosomal cathepsin A {14). Several lines of 
evidence confinn this similarity: 1) monospecific antibodies 
against native human protective protein precursor precipitate 
virtually all carboxypeptidase activity toward Z-Phe-Ala; 2) 
overexpression of protective protein in COS-1 cells leads to 
increased cathepsin A-like activity; 3) cells from a galactosi-
alidosis putient deficient in protective protein mRNA have 
less than 1% residual cathepsin A-like activity. 
Considering the highly specific binding of the protein to 
lysosomal .6'-galactosid.ase and neuraminidase, it was reason-
able to assume that terminal processing of these two enzymes 
would be the principal role of the carboxypeptiduse. Our 
genetic analysis. however, provides evidence that the catalytic 
and protective functions of the protective protein are distinct, 
since loss of its cathepsin A activitv does not influence its 
ability to stabilize and activute the o~her two enzymes. These 
separable functions could relate to the existence of free and 
associated pooh; of protective protein and $-galactoQdase in 
human tissues. A number of indications support this notion. 
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Preliminary studies by gel filtration suggest that precursor 
and mature protective protein/cathepsin A can form homo-
dimers of -95 kDa free of $-galactosidase/neuraminidase. 
Conversely, the immunotitration experiments presented here 
have shown that not all $-galactosidase activity is coprecipi-
tated with cathepsin A using anti-54 antibodies. Earlier data 
agree with these results since a fraction of ,6-galactosidase was 
found unassociated in crude glycoprotein preparations of hu-
man plact:nta {3). 
The reason for maintenance of these different pools of 
enzymes could be the need to catabolize a broad spectrum of 
substrates in different metabolic pathways. A recent report 
by Jackman et aL (18) emphasizes this hypothesis. These 
authors, in an effort to characterize a deamidase released from 
human platelets, came to the unexpected finding that their 
purified enzyme is probably identical to the protective protein. 
They further demonstrate that in vitro this platelet enzyme 
has deamidase as well as carboxypeptidase activity on biolog-
ically important peptides, like substance P. bradykinin, an-
giotensin I, and oxytocin. The deamidase activity is optimal 
at neutral pH, whereas the carboxypeptidase works best at 
pH 5.5. The purified two-chain enzyme forms homodimers of 
95 kDa at this pH (18). In view of the characteristics of the 
enzyme, they also came to the conclusion that it is similar to 
cathepsin A. We can deduce from our mutagenesis studies 
that the deamidase activity of the protective protein is also 
separable from its protective function. This d00.> not exclude, 
however, that in lysosomes the cathepsin A/deamidase works 
in cooperation v:ith $-galuctosidasc and neuraminidase. For 
example, an exopeptidase might be required after endoproteo-
lytic cleavage of glycoprotein substrates, to trigger the effi. 
cient hydrolysis of their sugar side chains by the associated 
glycosidases. On the other hand, complex formation may 
modulate cathepsin A/deamidase activity. A better under-
standing of the functions of the protective protein requires 
the identification of substrates that are targets of the enzyme 
in vivo. It is noteworthy that protective protein mRNA expres-
sion is high in mouse kidney, brain. and placenta (13), sug· 
gesting the need of a cathepsin Afdeamidase activity in these 
tissues, e.g. for the inactivation of bioactive peptides such as 
oxytocin and kinins. 
Extended knowledge of the protective protein could arise 
from the analysis of individual galactosialidosis patients, done 
in light of the results reported here. These patients have so 
far been identified and diagnosed on the basis of their reduced 
P-galactosidase/neuraminidase activities. Only recently. a 
carboxypeptidase deficiency was reported for the first time in 
three late infantile/juvenile patients (44), although the less 
specific 2-Phe-Leu substrate was used in these studies. The 
ability to directly detect residual cathepsin A activity in 
patients will allow the identification of individuals having an 
isolated cathepsin A/deamidase deficiency but normal protec-
tive protein function. The creation of animal models having 
targeted cathepsin A/deamidase active site mutations could 
prove instructive in this context. 
Except for the active site mutants the other modified hu-
man protective proteins are all retained in the ER. In the case 
of the mutant precursor with a cysteine to threonine substi-
tution at position 60 this is likely due to improper folding of 
the precursor polypeptide (45). This cysteine residue is em-
bedded within the 10-residue region thnt is most conserved 
among all carOOxypeptidases and must be important for their 
three-dimensional structures (46). Moreover, this domain in 
the protective proteins is part of an internal repeat occurring 
once in the 32- and 20-kDa chains. Since this motif is char-
acterized by tryptophan residues it could be engaged in intra-
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or intermolecular hydrophobic interactions. As deduced from 
the cotransfection experiments. the truncated 32/20 and 
32SA/20 polypeptides can spontaneously associate in the ER 
but are subsequently retained. This could imply that a single 
chain precursor is essential for correct transfer of the protec-
tive protein to the Golg:i complex. Alternatively. aberrant 
assembly of the two chains could also cause retention, al-
though we have indications that coexpr~sion of the separate 
subunits in insect cells leads to a 3-4-fold increase in cathep-
sin A activity. The possibility that formation of an active 
dimer in the ER has a deleterious effect on de novo synthesized 
proteins awaits further investigations. 
The crystallization of wheat serine carbo,,:ypeptidase II has 
recently revealed remarkable structural homology of this en-
zyme to zinc carboxypeptidase A (43). It was spe<:ulated that 
these two proteases share a common ancestor, perhaps a 
binding protein that had divergently acquired greater catalytic 
activity by two different mechanisms. In this scenario binding 
to other proteins comes before catalytic activity. The protec-
tive protein is about 30% identical to wheat. serine carboxy-
peptidase II. Interesting: questions that arise are those of how 
the catalytic/protective activities of this pleiotropic member 
of the serine carboxypeptidase family have evolved and what 
came first. 
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Summary 
In lysosomes the acid hydrolases b-galactosidase and neuraminidase acquire a stable and 
active conformation through their association with a third glycoprotein, the protective 
protein. The latter Is synthesized as a 54 kDa precursor that Is processed in endosomes or 
lysosomes into a 32/20 kDa two-chain product. The protein has amino acid sequence 
homology to serine carboxypeptldases and Is Identical In the N·termlnl of the two chains to 
a deamldase/carboxypeptldase Isolated from human platelets. It actually resembles closely 
a previously characterized lysosomal enzyme, cathepsin A. Site-directed mutagenesis 
experiments have demonstrated that Its catalytic activity and protective function are 
distinct. In order to delineate domains and signals on the human protective protein that 
govern Its Intracellular transport, processing and quaternary structure we overexpressed 
normal as well as In vitro mutagenized protective proteins In COS-1 cells. The results 
indicate that all mutated precursors are withheld, either partially or completely, In the ER. 
Complete retention leads to the degradation of the mutant proteins. Of the two 
oligosaccharide chains present on human protective protein the one on the 32 kDa subunit 
acquires the rnannose-6-phosphate (M6P) recognition marker, whereas the one on the 20 
kDa subunit appears to be essential for the stability of the mature two-chain protein. 
Wildtype human protective protein precursors predominantly form homodlmers of 85 kDa 
at neutral pH, Indicating that dlmerization could occur at the level of the ER. 
Lysosomal protective protein has two thus far identified modes of action: a catalytic 
activity overlapping with the one of a previously isolated lysosomal enzyme 
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cathepsin A and a protective function towards lysosomal !3-D-galactosidase (EC 
3.2.1.23) and N-acetyl-a-neuraminidase (EC 3.2.1.18). It copurifies from different 
tissues of various species in a high molecular weight complex with the two 
glycosidases (Verheijen et al, 1982; 1985; Yamamoto et al, 1982; Yamamoto and 
Nishimura, 1987) and its presence in lysosomes is essential lor their stabilisaton 
and activation (d'Azzo et at, 1982; Hoogeveen et at, 1983; van der Horst et al, 
1989). Mutations that interfere with the protective function of the protein result in a 
severe combined 13-galactosidase and neuraminidase deficiency (d'Azzo et at, 
1982; Wenger eta/, 1978), the hallmark oi the rare metabolic storage disorder 
galactosiali dosis (Andria et at, 1981 ). 
The primary structures of human, mouse and chicken protective proteins, as 
determined from their cloned cDNAs, are homologous to the yeast and plant serine 
carboxypeptidase family of enzymes (Breddam, 1986; Galjart eta/, 1988; 1990; 
1991). In addition, it has also been shown that human platelets, upon thrombin 
stimulation, release a deamidase/carboxypeptidase that is likely identical to the 
protective protein (Jackman et al, 1990) and may function in the local (in)activation 
of bioactive peptides. The carboxypeptidase activity, optimal at acid pH, has been 
compared with that of cathepsin A (Jackman et at, 1990; McDonald and Barrett, 
1986). In accordance with these results we have given direct evidence that the 
protective protein maintains cathepsin A-like activity (Galjart et at, 1991 ). Moreover, 
it was shown that in vitro mutagenized protective proteins, deficient in their 
cathepsin A-like activity, retain completely their protective function, indicating that 
these two roles are distinct (Galjart et al, 1991 ). 
In biosynthetic labeling studies the first immunoprecipitable form of human 
protective protein is a glycosylated 54 kDa precursor (d'Azzo et at, 1982), that is 
proteoly1ically converted within one hour after synthesis to a mature two-chain 
product of disulfide linked 32 and 20 kDa subunits (d'Azzo et at, 1982; Galjart eta/, 
1988). The two-chain form binds the serine protease inhibitor diisopropylfluo-
rophosphate1 demonstrating that maturation serves primarily to release the 
carboxypeptidase activity (Galjart et al, 1990). Whether the protective function is 
also inhibited in the 54 kDa zymogen remains to be investigated. After the initial 
endoproteolytic cleavage of the precursor, the 32 kDa subunit appears to undergo 
additional carboxyterminal processing of about 1-2 kDa (Galjart et al, 1988; 1991 ). 
Complexes of the protective protein/i)-galactosidase/neuraminidase have 
been analyzed mainly by determining the distribution of the two glycosidase 
activities over high and low molecular weight forms (Hoogeveen et al, 1983; Potier 
et al, 1990; Scheibe et at, 1990; Verheijen et at, 1982; 1985; Yamamoto et at, 1982; 
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Yamamoto and Nishimura, 1987). lmmunochemical detection of the protective 
protein in one of these studies revealed that the majority of the two-chain form is 
not resolved in the complex (Hoogeveen et at, 1983). The quaternary structure of 
cathepsin A has also been probed by detection of its enzymatic activity in different 
aggregation states (Kawamura et at, 1974; 1975). The purified two-chain 
deamidase/carboxypeptidase is a homodimer of 94 kDa (Jackman et at, 1990), 
whereas, using different experimental conditions, its toad skin homologue can be 
resolved both as a homodimer and as a multimeric aggregate (Simmons and 
Walter, 1980). Together, structural and functional analyses indicate that pools of 
free and complexed protective protein/cathepsin A exist, that may have different 
functions in intra-or extracellular compartments (Galjart et at, 1991 ). Interestingly, 
the two-chain plant serine carboxypeptidases which have subunits of a size similar 
to the ones of the protective protein/cathepsin A, are also found as homodimers, 
but never in multi me ric forms (Breddam,1986). 
In this report we have analyzed the intracellular transport and processing in 
transfected COS-1 cells of normal and in vitro mutagenized protective proteins, in-
dependently of ~-galactosidase or neuraminidase. The purpose of this work was to 
get insight in the domains and signals present in the protective protein that govern 
these aforementioned events. 
Experimental Procedures 
Plasmid constructs 
In vitro mutagenesis of human protective protein eDNA was carried out using the method of 
Higuchi eta! (1988}. DNA fragments with the desired point mutations were amplified by PCR and 
exchanged for wildtype eDNA segments using suitable restriction enzyme sites. In the final 
construct the DNA derived from PCR amplification was verified by double strand plasmid 
sequencing (Murphy and Kavanagh, 1988). Oligonucleotides for site-directed mutagenesis were 
synthesized on an Applied Biosystems 381 A oligonucleotide synthesizer. All constructs were 
cloned into a derivative of the mammalian expression vector pCD-X (Galjart et at, 1988; 
Okayama and Berg, 1982), using standard procedures (Sambrook et al, 1989). 
Transtections in COS-1 cells 
COS~1 cells (Giuzman 1981) were maintained in Du!becco·s modified Eagle's medium- Ham's 
F1 0 medium (1 :1, vlv), supplemented with antibiotics and 5% (vlv} fetal bovine serum. 
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For biosynthetic labeling studies cells were seeded out in 30 mm dishes and grown to 
30% confluency. Transfection of COS-1 cells, metabolic labeling and preparation of cell extracts 
and media have been described previously (Galjart eta!, 1988; Proia eta!, 1984). Labeling was 
carried out with 60 J.A.Ci [3H]leucine per ml labeling medium (143 Ci/mmol, Amersham Corp.) or 
100 J.LCi [32p]phosphate per ml labeling medium {carrier free, Amersham Corp.), for the time 
periods indicated in the legends to the figures. In pulse-chase experiments 0.3 mg of unlabeled 
leucine per ml labeling medium was added to the dishes after the 30 min pulse . 
lmmunoprecipitation methods using fixed Staphylococcus aureus cells (lmmunoprecipitin, BRL) 
have been described (Proia eta!, 1984), as have the antibodies that recognize all forms (54, 32, 
20 kDa) of the protective protein and are designated anti-54 antibodies (Galjart et at, 1991). 
Normally we pretreat lmmunoprecipitin as suggested by the supplier, a step that introduces 
reducing and denaturing_agents into the cell extracts at an early stage. In the 16 hr pulse 
experiment, however, the lmmunoprecipitin used was extensively washed with 
immunoprecipitation buffer after pretreatment, such that reducing agent was removed. 
Radioactive proteins were resolved on 12.5% polyacrylamide gels under reducing and denaturing 
conditions (Hasilik and Neufeld, 1980), fixed and visualized by autoradiography ([32p]Jabeled 
samples) or lluorography ([3H]Ieucine labeled material). In the latter case Amplify (Amersham 
Corp.) was used to enhance the signals. 
Limited proteolysis with trypsin 
In order to obtain larger quantities of secreted proteins COS-1 cells were transfected in 100 mm 
dishes. Cells were labeled with [3H]Ieucine 48 hr after transfection in medium without fetal bovine 
serum. 16 hr later media were collected, centrifuged for 5 min at roomtemperature and 1 000 
rpm, to remove detached cells, after which bovine serum albumin (BSA, Boehringer Mannheim) 
was added to the supernatant in a final concentration of 1 mg/ml. Media were concentrated and 
desalted as described previously (Proia eta/, 1984). Aliquots of 60 J.tl, corresponding to about 
12.5% of the original volume, were taken and brought to 200 J.LI with 20 mM sodium phosphate 
pH 6.8. One sample was left as such on ice, the remainder was incubated with 1.5 J.L9 trypsin 
(Sigma) for 0, 2. 5, 10, 30 min at 37 Oc. Trypsin was inactivated by the addition of 3 Jl9 bovine 
pancreas trypsin inhibitor (Sigma). In the 0 min time point the inhibitor was actually added before 
the trypsin. The procedure used here is a modification of the one described by Frisch and 
Neufeld (1981 ). After proteolysis 10 J..L.I samples were taken for detection of cathepsin A-like 
activity using the N-blocked dipeptide benzyloxycarbonyl-phenylalanyl-alanine (Z-Phe-Aia) and a 
modified procedure (Galjart eta!, 1991) that is based on the method of Taylor and Tappe! 
(1973). Liberated alanine was measured by the fluorimetric method outlined by Roth (1971). 
From the remainder of the aliquots (about 150 J.LI) radiolabeled proteins were immunoprecipitated 
using anti-54 antibodies. Proteins were resolved and visualized as described above. 
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Gelfiltration 
COS-1 cell-derived protein precursors were obtained from the medium of [3H]Ieucine labeled 
C0$-1 cells, transfected in 100 mm dishes and labeled in the presence of 2.5% dialyzed fetal 
bovine serum. Media were concentrated and desalted (Proia eta!, 1984) .and 20% of this 
material was diluted fivefold in 50 mM 2-[N-morphonno]ethanesulfonic acid (MES) pH 6.95, 
containing 100 mM NaCI . This samp!e was applied to a column (85 x 1.53 em, Pharmacia). 
containing Sephacryl 8200 HR (Pharmacia), preequilibrated in the same buffer. Elution was 
carried out at a flow rate of 5.4 ml/hr and fractions of 0.9-0.95 ml were colfected. All steps were 
performed at 4 Oc. After gelfiftration fractions were prepared for immunoprecipitation by 
preclearing each fraction once with 100 J..LI pretreated lmmunoprecipitin. Radiolabeled proteins 
were immunoprecipitated using anti-54 antibodies only, or a mixture of these and a monospeciflc 
antiserum against denatured human 64 kDa ~-galactosidase (Morreau eta/, 1989). Radiolabeled 
proteins w!fre separated and visualized as described above. The column was calibrated with the 
fo!lowing set of globular protein markers (Pharmacia): ferritin (440 kDa), aldolase (158 kDa), 
albumin (67 ~Da), ovalbumin (43 kDa) and chymotrypsinogen (25 kDa). 
lmmunoelectron microscopy 
Transfected COS-1 cells in 100 mm dishes were fixed in 0.1 M phosphate buffer pH 7.3. 
containing 1% acrolein and 0.4% glutaraldehyde. Further embedding in gelatin, preparation for 
ultracryotomy and other methods for immunoelectron microscopy were as reported (Willemsen et 
a!, 1986). The antibodies against the 32 kOa denatured chain of human protective protein (anti-
32 antibodies) have been described (Ga!jart et at, 1988). This monospeclfic antiserum recognizes 
under reducing and denaturing conditions the 54 kDa precursor as wei! as the 32 kDa mature 
subunit of the protective protein. 
Results 
Mutagenesis of human protective protein 
We have recently described point mutations in the human protective protein eDNA, 
that alter key amino acid residues within the three domains highly conserved 
among the members of the serine carboxypeptidase family (Galjart et at, 1991 ). 
Two of these amino acid substitutions, Ser150 to Ala and HiS429 to Gin (henceforth 
called SA150 and H0429), abolish cathepsin A-like activity without affecting the 
protective function. The third, Cys6o to Thr (CT6Q), impairs the transport of human 
protective protein out of the ER. To investigate the role of other residues, crucial for 
structure and function of the protein, additional amino acid substitutions were intra-
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duced in vitro. As summarized in Fig. 1 (lower part) the acquisition of either one or 
both oligosaccharide chains present on the human protein (Galjart eta/, 1988) was 
prevented by modification of Asn117 to Gin (N0117 or NQ1) and/or Asn305 to Gin 
(N0305 or NQ2). Furthermore the active site serine residue at position 150 was 
changed into leucine (SL 150) to determine the influence of a bulky amino acid in 
that position on the transport and activity of the protective protein. 
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Fig. 1 Transient expression of normal and in vitro mutagenized human protective 
proteins in COS-1 cells. The preproform of human protective protein is represented 
by the bar in the lower half of the figure, the hatched part being the signal sequence. The 
start of the 20 kDa subunit is indicated by a vertical line in the bar. The position and 
sequence of three domains, highly conserved in serine carboxypeptidases, is drawn 
above the bar, as are the two potential glycosylation sites found in the protective protein. 
Single amino acid substitutions are depicted, numbers refer to the position of the 
residues within the protective protein. The CT5o mutant has been described previously 
(Ga!jart et al. 1991). C0$-1 cells were transfected with pCD-constructs containing the 
various cDNAs: wt (se) and (a) represent human protective protein eDNA cloned in the 
sense and antisense orientation respectively; NQ1 is N0117, N02 is N0305, N01&2 is 
the double glycosylation mutant N0(117 & 305): CT and SL are the CT5o and SL150 
mutants respectively. Newly synthesized proteins were labeled 2 days after transfection 
for an additional 16 hr with [SH]Ieucine. lmmunoprecipitations from cell extracts and 
media were carried out using anti-54 antibodies. Radiolabeled proteins were resolved by 
SDS-PAGE under reducing conditions and visualized by fluorography. Exposure times for 
cell samples. 4 days {lanes 1-5) or 2 days (lanes 6 and 7). for all media samples. 2 days. 
The molecular sizes of wildtype human precursor and mature polypeptides are shown at 
left. The arrowhead indicates the position of the 18 kDa subunit generated after 
proteolytic cleavage of the NOsos mutant protein. 
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Transient expression of normal and mutant protective proteins in COS-1 cells. 
The various newly synthesized mutant cDNAs were cloned into the eukaryotic 
expression vector pCD-X, transfected into COS-1 cells and transiently expressed. 
Intracellular transport and processing of the mutant proteins were followed 48 hr 
after transfection and compared to wildtype human protective protein by labeling 
COS-1 cells with [3H]Ieucine for an additional 16 hr. Radiolabeled proteins from 
cell lysates and media were immunoprecipitated with anti-54 antibodies. The 
immunoprecipitated material was resolved on a 12.5 % 80S-polyacrylamide gel, 
under reducing conditions (Fig. 1, upper part). Wildtype 54 kDa protective protein 
precursor is detected both intra- and extracellularly, whereas the mature subunits 
of 32 and 20 kDa are visualized in substantial amounts within the cells only (Fig. 1, 
lane 1 ). The two single glycosylation mutants, N0117 and N0305. are synthesized 
as precursors of slightly reduced sizes, that are secreted but to a lesser extent than 
the wildtype protein (Fig. 1, lanes 1-3). Deletion of both oligosaccharide chains in 
the N0(117 & 305) mutant precursor results in the synthesis of a polypeptide of 
even smaller size (Fig. 1, lanes 2-4), that is not secreted at all (Fig. 4, lane 4). Tuni-
camycin treatment of transfected COS-1 cells prior to and during labeling revealed 
that the protein moieties of wildtype, N0117. N03o5 and N0(117 & 305) have an 
identical electrophoretic mobility (not shown). Of the three glycosylation mutants 
only N0305 can be detected in a processed form, consisting of 32 and 18 kDa 
subunits (Fig. 1, lane 3). This indicates that endoproteolytic processing of this 
mutant precursor takes place at the correct site but, as expected, lack of the 
oligosaccharide chain gives rise to a small subunit of 18 kDa. 
Both CT6o- and SL150- precursors are not detected in a processed form 
and only the SL150 mutant can be immunoprecipitated from the culture medium, 
albeit in minute amounts (Fig. 1, lanes 6 and 7). Endogenous COS-1 protective 
protein is visible throughout the fluorograph (Fig. 1 ). Together the data demonstrate 
that each targeted amino acid substitution has a profound effect on the processing 
and secretion of the protective protein. 
To determine which of the two oligosaccharide chains on human protective 
protein acquires the mannose-6-phosphate (M6P) recognition marker transfected 
COS-1 cells were labeled with [32P]phosphate. Radiolabeled proteins from cell 
homogenates and media were immunoprecipitated using anti-54 antibodies. For 
comparison cDNAs encoding mouse protective protein (Galjart et at, 1990) and a 
human-chicken hybrid protective protein (Galjart eta!, 1991) were also transfected. 
As shown in Fig. 2, both the precursor polypeptide as well as the 32 kDa chain of 
human and mouse protective proteins incorporate the label (Fig. 2, lanes 1 and 2), 
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demonstrating that it is the sugar moiety on the 32 kDa subunit that carries the M6P 
recognition marker. The anti-54 antibodies immunoprecipitate mouse protective 
protein less efficiently. The same holds true for the human-chicken hybrid, of which 
only the 58 kDa precursor form is brought down by the antibodies under the 
experimental conditions used (Fig. 2, lane 3). Of the three glycosylation mutants 
only N0305 is phosphorylated and in part processed (Fig. 2, lanes 7-9), indicating 
that loss of the sugar moiety on the 20 kDa polypeptide does not influence the 
phosphorylation process. A notable difference is now detected between CTso- and 
SLt5o-mutant precursors: the latter is phosphorylated and secreted in tiny 
quantities into the culture medium (Fig. 2, lanes 4 and 5). The faint 54 and 32 kDa 














Fig. 2 Phosphorylation of transiently 
expressed protective proteins. 
C0$-1 cells were transfected with the 
pCD-constructs descnDed in Ag.1 and 
with two other expression plasmids con-
taining the cDNAs encoding mouse pro-
tective protein (Mo) and a human-
chicken hybrid protective protein (HCh). 
Two days after transfection cells were 
labeled with [32 P] phosphate and ra-
dio labeled proteins were immunopre-
cipitated from cell lysates and media 
using anti-54 antibodies. Molecular 
sizes of precursor and mature polypep-
tides are indicated at left. Exposure 
time of the autoradiograph was one 
day. 
Turnover of normal and mutant protective proteins in transfected COS-1 cells. 
To further investigate the fate of the normal and mutant protective proteins pulse-
chase experiments were carried out. Transfected COS-1 cells were labeled with 
[3H]Ieucine for 30 min, and chased for a maximal period of 6 hr. As shown in Fig. 3, 
processing of the 54 kDa wildtype precursor to its 32/20 kDa two-chain form is 
detected after 30-60 min chase (Fig. 3, wt(se), lanes 1-5). The majority of the 
124 
overexpressed precursor, however, is secreted into the culture medium. Secreted 
molecules are visible after 30 min chase. Accumulation of radioactive material in 
the medium reaches a maximum level at 3 hr and declines after 6 hr, indicating that 
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Fig. 3. Pulse-chase analysis of wildtype and mutant protective proteins. 
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C0$~1 cells, transfected with the pCD~constructs explained in Ag. 1, were labeled for 30 
min with [SH]Ieucine and chased for the periods of time indicated above the lanes. La-
beled proteins were immunoprecipitated from cell extracts and media with anti-54 
antibodies, separated by $0$-PAGE under reducing conditions and visualized by 
fluorography. Molecular sizes of precursor and mature polypeptides are at left. The 
arrowhead indicates the position of the 18 kDa subunit of the NOsos mutant protective 
protein. Exposure times of the fluorographs. cell samples: wt(se), B days: NQt. NQ1&2, 
CT, SL, 4 days; NQ2. wt(a). 20 days; all media samples: 2 days. 
Deletion of the oligosaccharide chain on the 32 kDa subunit results in the 
synthesis of a mutant precursor, which is not proteolytically processed, but is 
secreted (Fig. 3, NQ1, Janes 1·5). However, release of this precursor from 
transfected cells is more gradual compared to wildtype protein and no decline is 
visible after 6 hr chase, suggesting that once the NOtt7 precursor arrives in the 
medium it is stably stored and not endocytosed. The N0305 mutant protein instead 
behaves differently. lntracellularly, the processing to a 32i18 kDa two-chain form is 
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followed by degradation of this aberrant mature protein (Fig. 3, NQ2, lanes 1-5). 
Thus, either the deletion of the oligosaccharide chain on the 20 kDa subunit is 
deleterious for the stability of the mature form or it is the amino acid substitution per 
se that causes this instability. Secretion of the N0305 precursor appears to be de-
layed in comparison to wildtype and N0117 precursors and the amount of 
immunoprecipitable material is reduced. The kinetics and degree of secretion of 
N0117- and N0305 mutants suggest that both precursors are in part withheld 
intracellularly. This effect is apparently additive since the double glycosylation 
mutant is not detected in the culture medium. Instead it is slowly degraded after 
synthesis without undergoing any processing (Fig. 3, N01 &2, lanes 1-5). The same 
happens to the CTso- and Sltso-proteins, yet in the latter case small quantities of 
the mutant precursor polypeptide escape to the culture medium after 3-6 hr chase 
(Fig. 3, CT and SL, lanes 1-5). Processing of endogenous COS-1 protective protein 
can be visualized after a prolonged exposure of the fluorograph (Fig. 3, wt(a), lanes 
1-5). lntracellularly, its maturation pattern is similar to that observed for wildtype 
protective protein, but no immunoprecipitable form is recovered from the culture 
medium. In the wt(se) and N0305 fluorographs, that were exposed for longer 
periods (8 and 20 days, respectively), the presence of an additional proteolytic 
fragment of 35 kDa is detected. This protein is likely the result of aspecific 
proteolysis. 
Limited proteolysis of secreted wildtype and selected mutant protective proteins 
with trypsin. 
Amino terminal sequencing of the 20 kDa chain derived from purified placental 
protective protein revealed that its first amino acid is preceded in the precursor 
molecule by an arginine at position 298, a residue conserved in mouse and 
chicken protective proteins (Galjart et at, 1988; 1990; 1991 ). Therefore, we 
assessed whether the normal endoproteolytic processing of precursor protective 
protein could be mimicked by trypsin and yield a mature and active two-chain 
enzyme. Initial experiments demonstrated that limited proteolysis of COS-1 cell-
derived 54 kDa precusor with trypsin gives rise to a two-chain molecule whose big 
subunit binds radiolabeled DFP (not shown). On SDS-PAGE this subunit is slightly 
larger than the normal 32 kDa chain, whereas the trypsin-generated 20 kDa 
subunit is identical in size to the wildtype (Zhou et at, 1991 ). We extended these 
experiments to determine the influence of the deletion of either of the two 
oligosaccharide chains on the stability and/or activity of the protective pro-
tein/cathepsin A. Radiolabeled COS-1 cell-derived precursors were aliquotted and 
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each sample incubated with a fixed amount of trypsin for increasing periods of time. 
Reactions were stopped by the addition of trypsin inhibitor. Afterwards cathepsin A 
activity was measured in each aliquot followed by immunoprecipitation with anti-54 
antibodies. As shown in Fig. 4, trypsin digestion of wildtype human protective 
protein precursor gives rise to a two-chain product with constituent polypeptides of 
about 32 and 20 kDa. This protein is resistant to further trypsin digestion up to 30 
min at 37 oc (Fig. 4, lanes 1-6). Concomitant with the appearance of the two-chain 
product(s) there is a sharp increase in cathepsin A-like activity, which declines only 
after 30 min. The first cleaved bond(s) is highly trypsin-sensitive, since even at t=o 
small amounts of precursor protein are converted (Fig. 4, lane 2). The residual 
cathepsin A-like activity in the aliquot that was not treated with trypsin (Fig. 4, lane 
1) is due to the presence of some processed protective protein, inadvertently 
generated while manipulating the culture medium. 
Surprisingly, the secreted and cleaved N0117 mutant is as resistant to 
trypsin digestion as wildtype precursor (Fig. 4, lanes 7-12). The two-chain product 
has a large subunit of about 30 kDa. but a normally sized 20 kDa subunit. The lack 
of an oligosaccharide moiety does not impair cathepsin A-like activity. However, 
deletion of the second oligosaccharide chain has a drastic effect on protease 
resistance (Fig .. 4, lanes 13-18). Cleavage of the N0305 mutant precursor with 
trypsin initially gives rise to a two-chain product with subunits of about 32 and 18 
kDa. Along with the appearance of the two-chain product a low cathepsin A-like 
activity can be detected, but both immunoprecipitable material as well as enzymatic 
activity disappear upon prolonged trypsin treatment These results correlate well 
with the pulse-chase experiments presented earlier. Both types of study indicate 
that once an N0305 mature protein is formed it is unstable. 
From their behaviour on SDS-PAGE it appears as if the three secreted 
precursors are all cleaved after the same residue(s) .. However, we have not 
determined the exact site of hydrolysis by trypsin. nor whether multiple cleavages 
can occur. Thus. even a small and undetected difference in proteolytic cleavage of 
the three precursor proteins could have a profound effect on catalytic activity of the 
corresponding two-chain forms. This would explain why a trypsin-cleaved two-
chain N0305 mutant protein is catalytically less active. In addition. differences in 
amount of secreted protein and/or resistance to trypsin will also account for the 
observed differences in enzymatic activities. 
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Fig. 4. Limited proteolysis with trypsin of wildtype and mutant protective protein 
precursors. 
COS-1 cells were transtected with pCD-constructs encoding wildtype human, NOt- or 
NQ2- mutant protective proteins. Two days later cells were labeled with [3H]Ieucine, 
after which secreted proteins were collected by ammoniumsulphate precipitation,using 
1 mg!mf BSA as carrier, and desalted. Aliquots of the concentrated preparations were 
incubated at 37 oc with 1.5 J..l9 trypsin tor the indicated periods of time. Reactions were 
stopped with 3 lJ.9 trypsin inhibitor. Cathepsin A-like activity towards the acyfated 
dipeptide Z-Phe-Aia was measured in a part of each aliquot. One mi/liunit of activity is 
defined as the enzyme activity that releases one picomole of alanine per min. The 
remainder of the samples was used for immunoprecipitation using anti-54 antibodies. 
Labeled proteins were further treated and visualized as described in Ag. 1. Molecular 
sizes of prestained protein standards are indicated to the left of each panel. 
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Fig. 5. Subcellular localization of overexpressed mutant protective proteins. 
COS-1 cells, transiently transtected with pCD·SLt50 (A), -NOt (B), or -NOz (C. D), were 
fixed 72 hr after transfection, embedded and prepared to immunoefectron microscopy. 
Cryosections were incubated with anti-32 antibodies followed by goat anti-(rabbit lgG)· 
gold labeling. The SLtso- and NOt- mutant proteins are only detected in rough 
endoplasmic reticulum structures {R), whereas the N02-mutant is also detected in low 
amounts in the Golgi complex (G) and lysosomes {L). Bars, 0.1 J.Lm. 
Localisation of mutant human protective proteins 
In order to correlate the turnover of the different mutant protective proteins with a 
subcellular compartment, immunoelectron microscopy was carried out on 
transfected COS-1 cells. Ultrathin sections of these cells were probed with 
antibodies against the denatured 32 kDa subunit of human protective protein (anti-
32 antibodies), followed by an incubation with goat anti-(rabbit lgG)-gold. 
Previously we have shown that in COS-1 cells wildtype human protective protein 
compartimentalizes in structures corresponding to rough ER (RER), Golgi complex 
and lysosomes, whereas the CTso mutant precursor was retained in the RER 
(Galjart et at, 1991 ). Fig. 5 shows that COS-1 cells, transfected with SL 150- or 
N0117-mutant cDNAs, are labeled almost exclusively in RER structures and not in 
the Golgi complex or lysosomes (Fig. 5 A and 8, respectively). The same results 
were obtained with cells overexpressing the double glycosylation mutant (not 
shown). Thus, degradation of CTso-. SL150- and N0(117 & 305)· precursors is 
likely to occur within the ER. In cells overexpressing the N0305 mutant protein 
instead some labeling above background is observed in Golgi complex as well as 
in lysosomes (Fig. 5C, D). This indicates that the N0305 mutant protein reaches 
the lysosome, where it is subsequently processed and degraded. 
Quaternary structure of human protective protein precursor 
The native conformation of wildtype protective protein precursor was investigated 
by gelfiltration. A concentrated COS-1 cell-derived precusor preparation was 
diluted in buffer at neutral pH and applied to a Sephacryl S-200 HR column. To test · 
the influence of ~-galactosidase molecules on the conformation of human 
protective protein precursor, medium of COS-1 cells, cotransfected with human 
protective protein and ~-galactosidase cDNAs, was also applied on the column. 
After elution fractions were immunoprecipitated with anti-54 antibodies and anti-
human denatured ~-galactosidase antibodies (Morreau et at, 1989). As shown in 
Fig. 6, under the conditions used, human protective protein precursor is 
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Fig. 6. Gelfiltration of human proteotive protein precursor. 
COS~ 1 cells were either singly transfected with the pCD-construct encoding wUdtype 
protective protein (Hu54) in the sense (se) orientation, or double transfected with this 
plasmid and a construct containing eDNA encoding human b-galactosidase (HbGat), 
also in the sense orientation. Labeling was as described in Fig. 1. Secreted proteins 
were concentrated and part of the preparation was applied on a Sephacryl S-200 HR 
column. After elution radiotabeted proteins in each fraction were immunoprecipated 
using anti-54 and anti-human b-galactosidase antibodies. About 10 % of the original 
concentrated preparation was taken along in the immunoprecipitation and is shown in 
the left part of the figure. Proteins were further treated as described in the previous 
figures. The elution position of the separately applied globular marker proteins is 
indicated above the fluorograph. PPp, protective protein precursor; bGp, b-
gatactosidase precursor. Exposure times, 3 days for left panel, 14 days for upper panel 
and 7 days for lower panel. 
predominantly recovered from the column in a fraction corresponding to a 
molecular mass of 85 kDa. A small percentage o.i precursor molecules is detected 
in multimeric form (> 440 kDa). This distribution pattern is not influenced by the 
presence of ~-galactosidase precursor. The latter is more equally divided over 
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monomeric (90 kDa) and broad multimeric peaks. The data indicate that the 
protective protein can form homodimers as well as multimeric aggregates at 
precursor level and neutral pH, independent of the presence of ~-galactosidase 
precursor. The estimated size of the homodimeric form is smaller than would be ex-
pected of two precursor molecules of 54 kDa. Actually, peak fractions of ho-
modimeric protective protein and monomeric ~-galactosidase almost coincide. This 
indicates that protective protein dimers do not assume a globular shape, whereas 
~-galactosidase precursor monomers elute with a calculated molecular mass that 
correlates very well with the size estimated by SDS-PAGE (d'Azzo eta/, 1982). 
Total cell extracts of labeled COS-1 cells, transfected with normal protective 
protein eDNA have also been used for gelfiltration analysis, at pH 5.5. This gave 
rise to identical results as shown in Fig. 6 with the addition that also mature 
protective protein forms homodimers (not shown). Both precursor as well as mature 
protein elute in the same fractions. Thus, proteolytic conversion of the protective 
protein does not alter dramatically its hydrodynamic properties. These data agree 
well with the gelfiltration studies of Jackman et al (Jackman eta!, 1990), who 
demonstrated that their purified platelet deamidase elutes as a homodimer of 94 
kDa. 
Discussion 
We have analyzed the intracellular transport, processing and stnucture of protective 
proteins carrying targeted amino acid substitutions in order to get insight in the 
conformational characteristics of normal precursor and mature proteins, 
independently of j3-galactosidase or neuraminidase. Experiments were carried out 
using the COS-1 cell system to transiently express normal and mutated proteins. 
We have found that all aminoacid substitutions interfere with or impair 
completely the exit of the different mutant proteins from the ER. These· results are 
in contrast to the behaviour of two protective protein active site mutants, SA150 and 
H 0429, described earlier (Galjart et a!, 1991 ), whose biosynthesis and 
processsing resemble completely that of the wildtype protein. After synthesis the 
ER-retained mutant proteins are degraded. Their turnover is not as rapid as the 
degradation of the T cell receptor a-chain (Lippincott-Schwartz eta/, 1988), but it 
compares well to the turnover rate of a natural mutant of the a-subunit of lysosomal 
J3-hexosaminidase (Lau and Neufeld, 1989). Although different amino acid 
substitutions could well result in differential folding of the various mutant 
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precursors, the observed degradation rates seem quite similar. The SL 150 mutant 
is even phosphorylated, albeit poorly, indicating that part of the total pool of 
synthesized molecules reach a pre-Golgi site where the first phosphorylation step 
is thought to occur (Lazzarino and Gabel, 1988). Some of the phosphorylated 
molecules are allowed to leave the ER, as judged by the detection of small 
quantities of SL 150 precursor in the culture medium. The other part could be 
specifically retrieved from a post-ER compartment (Pelham, 1989). It is interesting 
to note that an alanine substitution of the active site serine in the protective protein 
is well supported but replacement of the same amino acid with a more bulky 
leucine residue has drastic effects on the conformation of the precursor molecule. 
A large amount of labeled human precursor protein is secreted instead of 
being transported to the lysosomes. This is not uncommon for overexpressed 
lysosomal enzymes, it has for example been found for the a-subunit of human ~­
hexosaminidase in transfected COS-1 cells (Lau and Neufeld, 1989), for human 
cathepsin D in baby-hamster kidney cells (Horst and Hasilik, 1991; Isidore et at, 
1991) and for mouse cathepsin L, which is the major excreted protein (MEP) in 
transformed mouse fibroblasts (Dong et al, 1989). Secretion of the a-subunit of ~­
hexosaminidase (Lau and Neufeld, 1989) and human cathepsin D (Horst and 
Hasilik, 1991; Isidore et af, 1991) by the different cell types is not influenced by the 
addition of the lysosomotropic agent NH4CI, something we noticed as well in the 
case of overexpressed human protective protein (Galjart et af, 1988). It has been 
suggested that different protein sorting systems are present, that target lysosomal 
enzymes to their final destination with variable efficiency (Horst and Hasilik, 1991; 
Isidore et af, 1991 ). 
N0117- and N0305 glycosylation mutants are secreted in reduced amounts 
compared to wildtype protective protein, a fact that is explained by their partial 
intracellular retention. However, we were unable to demonstrate with 
immunoelectron microscopy the presence of N0117 precursor protein in the Golgi 
complex in contrast to the N0305 mutant. Perhaps transport of N0117 molecules 
through this compartment is very rapid, because of the lack of a productive 
interaction with the phosphotransferase system and in turn with M6P-receptors. If 
the possible influence of an Asn to Gin amino acid substitution on the three 
dimensional structure of the protective protein is excluded, we can ascribe the 
following potential functions to the two oligosaccharide chains: 1) both are impor-
tant for the timely exit of protective protein precursors from the ER; 2) the chain on 
the 32 kDa subunit is necessary and sufficient for acquisition of the M6P-
recognition marker, it is however neither essential for the stability nor for the 
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catalytic activity of mature two-chain protective protein; 3) the chain on the 20 kDa 
subunit is crucial for the stability of the mature two-chain form. The latter 
supposition is substantiated both by the pulse-chase experiments as well as by the 
limited proteolysis with trypsin. In addition to what we observe experimentally, the 
position of the oligosaccharide chain on the 20 kDa subunit near the 32120 kDa 
boundary and its location within a conserved stretch of amino acid residues could 
also imply a specific role for this sugar chain. Combined the findings indicate that it 
could actually serve as an age marker for the protective protein (Winkler and 
Segal, 1984a; 1984b). In this model its stepwise trimming by glycosidases in the 
lysosome would render the mature protective protein increasingly unstable. 
Limited proteolysis of the wildtype protective protein precursor with trypsin 
immediately gives rise to a mature two-chain molecule, that is rather resistant to 
further cleavage. From the size of the generated 2Q·koa fragments it seems as if 
both the initial intracellular endoproteolytic processing as well as the trypsin 
cleavage take place within the same domain, perhaps even after the same residue. 
The results indicate that a region is present in the precursor molecule that is very 
sensitive to proteolysis and it will be of interest to determine whether other 
enzymes could cleave within the same domain. If so one could imagine that the 
conversion of protective protein to its mature form could occur in an extracellular 
environment by circulating proteases. 
The gelfiltration experiments suggest that dimerisation of wildtype human 
protective protein precursors takes place at neutral pH. Such an event could occur 
within the ER, althOugh this should be demonstrated experimentally.The finding of 
a natural mutant protective protein that cannot form dimers and is partially retained 
in the ER (Zhou et at, 1991 ), is consistent with this hypothesis and would indicate 
that dimerization is a prerequisite for quick exit out of this compartment. 
Multimerisation of protective protein precursors is a minor event under the 
conditions used here. Surprisingly, however, Zhou et a1 (1991) have found over 50 
% of secreted wildtype human precursor molecules in multimeric form. The latter 
result was obtained by applying a more concentrated protein preparation on the 
column. These results together indicate that at neutral pH a protein concentration 
dependent equilibrium exists between dimeric and multimeric protective protein 
precursors. Since multimerisation takes place in the absence of labeled j3-
galactosidase precursors,-it would seem that complex formation is a property of the 
protective protein precursor solely. Using purified recombinant human protective 
protein we are currently investigating in more detail the factors that influence its 
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multimerisation, whether it be in precursor state or in a mature two-chain 
conformation. 
Footnotes 
1) Abbreviations used are: DFP, diisopropylfluorophosphate; PCR, polymerase chain reaction; 
SOS, sodium dodecyl sulfate; M6P, mannose-6-phosphate; ER, endoplasmic reticulum, 
PAGE, polyacrylamide gel electrophoresis; Z. benzyloxycarbonyl. 
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A MUTATION IN A MILD FORM OF GALACTOSIAUDOSIS IMPAIRS 
DIMERIZATION OF THE PROTECTIVE PROTEIN AND RENDERS IT 
UNSTABLE 
Xiao Yan Zhou, Niels J. Galjart, Rob Willemsen, Nynke Gillemans, Hans Galjaard 
and Alessandra d'Azzo 
Dept. of Cell Biology and Genetics, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands 
Summary 
The lysosomal disorder galactoslalldosis Is caused by deficiency ol the prctectlve protein 
In the absence of which the activities ol the enzymes ~-galactosidase and neuraminidase 
are reduced. Aside from Its protective function towards the two glycosldases this protein 
has cathepsin AwUke activity. A point mutation In the protective protein gene, resulting In the 
substitution of Phe412 with Valin the gene product, was Identified In two unrelated patients 
with the late infantile form olthe disease. Expression In COS-1 cells of a protective protein 
eDNA with the base substitution resulted In the synthesis of a mutant protein that lacks 
cathepsin Awllke activity. The newly made mutant precursor was shown to be partially re· 
talned In the endoplasmic reticulum. Only a fraction Is transported to the lysosomes where 
It Is degraded soon after proteolytic processing Into the mature twoechaln form. Since the 
mutant precursor, contrary to the wild type protein, does not form homodlmers, the 
dlmerlzatlon process might be a condition for the proper targeting and stable confonnatlon 
of the protective protein. These results clarify the mechanism underlying the combined dee 
flctency In these patients, and give new Insight Into the structure/function relationship of the 
wild type protein. 
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Galactosialidosis is an inherited metabolic storage disorder transmitted as an auto-
somal recessive trait (O'Brien, 1989). It is caused by mutation of the gene encoding 
the lysosomal protective protein (d'Azzo eta!., 1982) which normally associates 
with the enzymes {3-D-galactosidase (E.C. 3.2.1.23) and N-acetyl-a-neu-
raminidase (sialidase, E.C. 3.2.1.18) and regulates their intralysosomal activity 
and stability (Verheijen et af., 1982; Hoogeveen eta/., 1983; van der Horst eta/., 
1989). Deficient or non functional protective protein causes impaired activities of 
the two glycosidases and consequent storage of predominantly sialylated 
oligosaccharides in tissues and urine (Wenger eta!., 1978; Okada et af., 1977; van 
Pelt et af., 1988a; 1988b;1989). 
Although the disorder is rare, several dozens of patients of different ethnic 
origin have been described (Pinsky eta!. 1974; Andria et af., 1981; Suzuki eta!. 
1984; Loonen eta/., 1984; Sewell eta/., 1987; Chitayat eta!., 1988). They are clini-
cally heterogeneous having either a very severe early onset form of the disease, 
mostly fatal at birth, or mild and slowly progressive late onset types. Patients with 
an early infantile phenotype have severe CNS involvement, macular cherry red 
spots, visceromegaly, skeletal abnormalities, renal dysfunction and coarse facies. 
Juvenile/adult forms, mainly of Japanese origin, are characterized by features like 
skeletal dysplasia, dysmorphism, macular cherry red spots, slowly progressive 
mental and motor deterioration and angiokeratoma. So far a defined, small group 
of patients represents the late infantile phenotype. These patients are all alive and 
have developed symptoms at 12-24 months oi age with the main features being 
visceromegaly, dysostosis multiplex, heart involvement, but no mental retardation 
(Pinksy eta!., 1974; Andria eta!., 1978; 1981; Chitayat eta/., 1988; Strisciuglio et 
a/., 1990}. This broad spectrum of clinical manifestations in distinct galactosialido-
sis phenotypes can only in part be correlated with differences in the level oi ex-
pression of protective protein mRNA (Galjart eta/., 1988) and the amount and/or 
property of immunoprecipitated polypeptide (d'Azzo et af., 1982; Palmeri et af., 
1986). 
The human protective protein is synthesized as a 54 kDa precursor that is 
cleaved and modified in lysosomes into a mature 32/20 kDa two-chain product 
(d'Azzo eta/., 1982; Galjart eta/., 1988). Traces of 32 kDa polypeptide could be 
immunoprecipitated from fibroblasts of two late infantile galactosialidosis patients, 
but only when these cells were treated with the protease inhibitor leupeptin 
(Palmeri et af., 1986; Strisciuglio eta!., 1988). These findings led to the supposition 
that the presence of a minimal amount of mature protective protein in these patients 
could account for their milder clinical course (Strisciuglio et af., 1988). 
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The primary structures of human, mouse and chicken protective proteins 
have been found to be homologous to yeast and plant serine carboxypeptidases 
(Galjart eta/., 1988, 1990, 1991 ). This observation led to the discovery that the 
protective protein has cathepsin A-like activity (Galjart et at., 1991 ). Clinically dis-
tinct galactosialidosis patients, reported to have reduced activity of a lysosomal 
carboxypeptidase called carb L (Tranchemontagne et at., 1990; Kase eta/., 1990), 
are thus deficient in the cathepsin A-like enzyme (Galjart et at., 1991 ). Although the 
physiological implications of these findings are as yet unclear, this lysosomal dis-
order should be viewed as the first one that is also associated with a protease de-
ficiency. Jackman eta/. (1990) have reported on a deamidase/carboxypeptidase 
enzyme purified from human platelets that enzymatically resembles cathepsin A 
and has sequence identity to the N-termini of the protective protein chains. Using 
protective protein mutants with targeted amino acid substitutions we have es-
tablished that the protective and catalytic activities of the protein are distinct (Galjart 
eta/., 1991 ), and the latter can only be exerted after conversion of the inactive pre-
cursor (zymogen) into the mature and stable two-chain form (Galjart eta/., 1990). 
We have identified different mutant alleles associated with the three clinical 
galactosialidosis phenotypes of mainly European patients. In the present study we 
focus on the mutation underlying two unrelated patients with the late infantile form 
of the disease. They both carry the same point mutation in the protective protein 
gene resulting in the substitution of Phe412 with Val in the gene product. The mu-
tation was shown to impair the formation of protective protein precursor homo-
dimers which in turn might be responsible for the observed partial retention of the 
mutant precursor polypeptide in the endoplasmic reticulum (ER). The fraction that 
does reach the lysosomes is catalytically inactive and undergoes rapid intralyso-
somal degradation. 
Results 
Point mutation identified in the protective protein/cathepsin A eDNA of two galac-
tosialidosis patients. 
The first patient analyzed is the child of healthy unrelated Italian parents. His disor-
der was diagnosed at the age of two and his clinical and biochemical characteris-
tics have been described earlier (Andria eta/., 1978; 1981; Palmeri et at., 1986). In 
total RNA preparations from the patient's fibroblasts a normal amount of 2 kb pro-
tective protein transcript was detected (Galjart et at., 1988). In cultured fibroblasts 
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this mRNA was translated into a 54 kDa mutated precursor that was only poorly, if 
at all, processed to the mature form (Palmeri et a!., 1986). Consequently, no 
cathepsin A-like activity was measured in cell lysates from the patient (Galjart eta!., 
1991 ). 
To identify the genetic lesion underlying this phenotype, we first analyzed 
the eDNA derived from the patient's mRNA. Four overlapping fragments, encom-
passing the entire coding region, were reverse transcribed, amplified by the poly-
merase chain reaction (PCR), cloned and sequenced on both strands. The only 
difference between normal and mutant nucleotide sequences was a single base 
substitution, T toG, at position 1324 of the normal eDNA (Galjart et af., 1988), 
changing Phe412 ([TC) to Val (Q.TC). Ten subclones of the eDNA portion including 
the base substitution showed the same mutation. The results were somewhat sur-
prising since the parents of this patient were reported to be non consanguineous. 
However, direct sequencing of a 239 bp genomic region surrounding the mutation, 
amplified by PCR from total DNA of the patient and his parents, confirmed the 
eDNA data (Figure 1, upper panel). The patient is clearly homozygous for the T to 
G transversion, whereas both carriers are heterozygous for this mutation. 
Since the T to G substitution generates a new Acyl restriction site in the mu-
tant DNA, this point mutation can be easily detected by digesting the amplified 239 
bp genomic fragment with Acyl. As shown in Figure 1 (lower panel), the patient's 
DNA releases upon digestion two fragments of 159 bp and 80 bp (lane 4), instead 
of the uncut fragment present in normal DNA (lane 1 ). Amplified samples from both 
parents display heterozygous patterns (lanes 2 and 3). We used this assay to 
screen for the T to G transversion DNA samples of seven clinically different galac-
tosialidosis patients. In only one other unrelated Canadian late infantile patient 
(Pinsky et af., 1974) the same mutation was found (not shown). It was reported ear-
lier that in cultured fibroblasts from this patient a small amount of protective protein 
precursor was synthesized that again failed to mature (Palmeri eta/., 1986). As de-
duced from the Acyl digestion pattern, this patient carries the T to G substitution on 
one allele, whereas the other has a normal sequence in that region. Direct se-
quencing of the corresponding genomic DNA fragment validated the compound 
heterozygosity. Only the product of the T to G mutant allele was seen in direct se-
quences of the patient's eDNA (not shown), suggesting that a second mutation in 
the other allele either impairs its transcription or gives rise to an unstable mRNA. 
Our findings indicating compound heterozygosity explain why a reduced amount of 




































Figure 1. Upper. 
Partial nucleotide sequence of the protective protein/cathepsin A gene 
from the Italian galactosialidosis patient and his parents. Genomic DNA was 
isolated from fibroblasts of a normal individual, the patient and his parents and 
subjected to asymmetric PCR in the region containing the mutation. The products 
were directly sequenced. A portion of the autoradiograph from the sequencing gels 
is shown. The T to G transversion is indicated in bold. Arrows point to the double 
band at one position that is present in the nucleotide sequences of both parents. 5' 
and 3' refer to the orientation of the protective protein eDNA (Gafjart et al, 1988). 
Lower. 
Acyl restriction enzyme assay for the T to G mutation. Genomic fragments, 
amplified from total DNA of the patient and his parents, were incubated with Acyl at 
3-r'C for 2 hr. Restriction fragments were analyzed by electrophoresis on a 4% 
NuSieve agarose gel and stained with ethidium bromide. Molecular sizes are 
indicated at left. 
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Vaf412 mutation impairs the catheptic activity of the mutant protein and causes 
partial retention of its precursor in the ER. 
To assess the effect of the Phe412 to Val amino acid substitution on the biochemi-
cal behaviour of the protective protein/cathepsin A, the mutation was introduced 
into the normal eDNA (Hu54) by oligonucleotide mediated site-directed mutage-
nesis. Normal and mutant cDNAs were expressed in COS-1 cells under the control 
of the SV40 early promoter. As shOwn in Table 1, the Phe412 to Val change ren-
ders the enzyme inactive since no increase in cathepsin A-like activity can be mea-
sured above endogenous COS-1 levels; in contrast a 1 0-fold higher activity is de-
tected in cells expressing the wild type protein. In transfected cells labeled with ei-
ther [3H]leucine (Figure 2, left panel) or with [32p]phosphate (Figure 2, right panel) 
the mutant protective protein is immunoprecipitated as a 54 kDa phosphorylated 
precursor that does not appear to be processed and is secreted to a lesser extent 
than the wild type form. These results demonstrate that the site directed Va1412 
mutation reproduces the patient's phenotype in that it gives rise to a catalytically 
inactive protective protein/cathepsin A with impaired post-translational processing. 
Table1. Cathepsin A-like activity in COS-1 cells transfected with wild type and 
mutant protective protein cDNAs. 
Transfected DNA 
Hu54 (sense) 







COS-1 cells were transfected with pCDHu54 sense (se), pCDHu54 Phe412 to Val or pCDHu54 
antisense (a). After 72 hr cells were harvested by trypsinization and cathepsin A-like activity was 
measured in cell extracts using N-carbobenzoxy-L-pheny!alanyl-L-alanine (Z-Phe-Afa} as a 
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lmmunoprecipitation of normal and mutant protective proteins in 
transfected COS-1 cells. COS-1 cells were transtected with pCDHu54 sense 
(wt, se}, pCDHu54 antisense (wt, a) and pCDHu54 Phe412 to Val (FV, se). Two 
days after transtection newly synthesized proteins were labeled for an additional 
12 hr with FHJieucine (left panel) or for 7 hr with r32p}phosphate (right panel). 
Labeled proteins from cells and media were immunoprecipitated, resolved on 
12.5% SDS-polyacrylamide gels under reducing conditions, and visualized by 
fluorography (left) or by autoradiography (right). Molecular sizes of precusor and 
mature polypeptides are indicated. Exposure times were 5 days for left panel, 1 
day for right panel. 
Ultrathin cryo-sections of COS-t cells, transfected with pCDHu54 (A, 
B and C) or pCDHu54 Phe412 to Val (D and E) and labeled with 
anti-32 kDa antibodies and goat anti-rabbit lgG-gold. In A, 8, and c 
extensive labeling of rough endoplasmic reticulum structures (R), Gofgi complex 
(G) and a lysosome (L) is shown, but not of a mitochondrion (M). In contrast, a 
weakly labeled Golgi complex (G) is seen in D. E shows strong labeling of rough 
endoplasmic reticulum (R) and a few gold particles in a lysosome (L). 
Magniffcations were 46.000 x for A, 58.000 x for 8, 93.000 x for C, 64.000 x forD 
and 65.000 x for E. 
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Using immunoelectronmicroscopy, we have studied the intracellular distri-
bution of Val412 protein overexpressed in COS-1 cells. As shown in Figure 3, the 
amount of gold particles present in the ER of cells expressing wild type and mutant 
protective proteins is similar (Figure 3, A and E). However, a drastically reduced la-
beling of the Golgi complex is found in cells expressing the Val412 mutant com-
pared with those expressing the normal protein (Figure 3, C and D). Labeling of 
lysosomes is detected in cells transfected with either of the two eDNA constructs, 
but again the overal number of grains is distinctly diminished (less than 1 0%) in 
lysosomes of cells transfected with the mutant eDNA (Figure 3, B and E and Table 
2). It therefore appears that the Phe412 to Val substitution causes retention of the 
precursor polypeptide in an early biosynthetic compartment. However, this reten-
tion can only be partial since some molecules of the total mutant precursor pool are 
routed to the Golgi complex, undergo phosphorylation as well as secretion and are 
correctly compartmentalized in lysosomes. 
Table 2. Quantitative data on the immunolabeling of lysosomes in different 
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1 ( .3) 
The values represent the average number of gold particles per lysosome. The standard error 
of the mean (SEM) is indicated between brackets. 
Mutant precursor does not dimerize at neutral pH. 
It was previously reported that mature lysosomal cathepsin A, purified from different 
species, elutes on gel filtration as a dimer of about 95-100 kDa (Simmons and 
Walter, 1980; Jackman eta!., 1990). We have recently shown that the protective 
protein can also form homodimers at the precursor level and neutral pH (N.J. Gal-
jart and A. d'Azzo, submitted), suggesting this to be an endoplasmic reticulum/early 
Golgi event. We have now tested the effect of the Phe412 to Val change on the elu-
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tion pattern of the mutant precursor after gel filtration. COS-1 cells were transfected 
with either wild type or mutant protective protein eDNA constructs, and labeled with 
3H-Ieucine. Medium samples containing the secreted precursor forms, were con-
centrated, desalted, and applied on a Sephacryl S-200 column. Protective protein 
precursor was immunoprecipitated from each fraction using anti-54 kDa antibodies. 
As shown in Figure 4, about 50% of wild type precursor is resolved as a dimer of 
-85 kDa, whereas the remaining -50% forms aggregates of high molecular weight 
(upper panel). Multimerization seems to be concentration dependent (N.J. Galjart 
and A. d'Azzo, submitted). In contrast the majority of the mutant polypeptide is im-
munoprecipitated as a monomer of -37 kDa ·and only a small fraction elutes as a 
multi mer (Figure 4, lower panel). Both normal and mutant native precursors appear 
to be non globular proteins since they elute later than expected for polypeptides of 
54 kDa. These findings suggest a correlation between the absence of dimerization 













Figure 4. Gel filtration analysis of normal and mutant protective protein precursors 
secreted by transfected COS-1 cells. Secreted radiolabeled proteins from COS· 
1 cells transfected with wild type or mutant (Phe412_vaJ) cDNAs were concentrated, 
desalted and applied on a Sephacry/ $-200 column. Precursors were 
immunoprecipitated, resolved and visualiZed as in Fig.2. The elution position of the 
separately applied globular protein markers is indicated above the fluorographs: 
ferritin (F), aldolase{ A), BSA(B), and ovalbumin(O). 
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Mutant 32120 kDa two-chain product is rapidly degraded. 
To test whether the amino acid substitution would affect or mask the recognition 
site of the endoprotease that normally converts the precursor to the two-chain form, 
the following experiment was performed. COS-1 cells, overexpressing either the 
normal or the mutant eDNA, secrete sufficient amounts of the corresponding 54 
kDa precursors. These secreted forms were subjected to partial in vitro proteolysis 
using a fixed concentration of trypsin at increasing time points of incubation (Figure 
5). After 2 minutes the normal precursor is already fully trimmed into 32 and 20 kDa 
subunits that remain rather stable during longer incubation times, though some 
degradation seems to occur after 30 minutes (Figure 5, left panel). The mutant pre-
cursor instead does undergo proteolytic cleavage but this is followed by rapid 
degradation of the 20 kDa subunit which is only barely visible after 2 minutes incu-
bation. It is likely that this event renders the 32 kDa chain also unstable (Figure 5, 
right panel). 
+Trypsin +Trypsin 
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Figure 5. Trypsin digest of normal and mutant protective protein precursors 
secreted by transfected COS-1 cells. Transfections were carried out with the 
pCD-constructs described in Table 1. Cells were labeled with (3H]Ieucine 48 hr after 
transtection. Aliquots of medium concentrates containing the secreted precursor 
polypeptides were incubated with 1 mg of trypsin at s?Jc tor 0,2,5, 10,30 minutes, 
respectiVely. Trypsin was inactivated by addition of 3 mg trypsin inhibitor. 
Radiotabeled proteins were immunoprecipitated, resolved and visualized as in Ag. 2. 
Lane 1, immunoprecipitation of intracellular protective protein from pCDHu54 
transfected C0$-1 celfs. Lanes 2-6, trypsin digest of normal protective protein 
precursor. Lane 7-12, trypsin digest of mutant precursor. Molecular sizes of precusor 
and mature polypeptides are indicated at left. Exposure time for lanes 1-6 was 48 hr, 
and for lanes 7-12 was 5 days. 
We next investigated whether the mutant protective protein retains the ca-
pacity to associate with 13-galactosidase. For this purpose COS-1 cells were double 
transfected with constructs encoding either wild type protective protein and 13-
galactosidase, or Val412 protein and 13-galactosidase. The physical association 
between either of the two protective proteins with 13-galactosidase was determined 
by measuring co-precipitation of the latter enzyme with monospecific anti protective 
protein antibodies (anti-54). In both COS-1 cell lysates about 70% of 13-galactosi-
dase activity was co-precipitated, under conditions that brought down virtually all 
cathepsin A-like activity. The association was specific since in cells co-expressing 
the mutant protective protein and human lysosomal f3-hexosaminidase the latter 
enzyme was not co-precipitated with the anti-54 antibodies. In addition, biosyn-
thetic labeling studies have provided evidence that the interaction between the 
mutant protective protein and 13-galactosidase can occur at precursor level (H. Mor-
reau and A. d'Azzo, submitted for publication). 
Taken together these results suggest that the Phe412 to Val substitution 
does not disturb the tertiary structure of the precursor polypeptide to the extent that 
it would completely inhibit its transport to lysosomes, endoproteolytic processing, 
and even association with the other two lysosomal enzymes. Once in lysosomes, 
however, the fast degradation of the mutant protein, initiated by endoproteolytic 
cleavage of the 54 kDa precursor, would explain the loss of protective function to-
wards f3-galactosidase and neuraminidase. 
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Discussion 
Galactosialidosis patients with the late infantile form of the disease make up a de-
fined subtype for the following reasons: they exhibit symptoms within the first two 
years of life, they have a slow and relatively mild progression of the disease, and, 
most important, the patients for whom a clinical update has been made (Chitayat et 
af., 1988; Strisciuglio et af., 1990, G. Andria and P. Strisciuglio, personal communi-
cation) do not show signs of mental retardation. The latter characteristic seems to 
be unique for this group and is in contrast with the severe neurological involvement 
observed in early infantile and even juvenile/adult cases. We were interested in 
identifying the genetic lesion(s) underlying this phenotype starting with the under-
standing of how a natural mutation in the gene impairs the gene product and at 
what subcellular leveL 
In this report we have described a point mutation in the protective protein 
gene present in two unrelated late infantile galactosialidosis patients of Italian and 
Canadian origin. The mutation consists of aT to G transversion at position 1324 of 
the human eDNA which results in the replacement of phenylalanine with valine at 
residue 412. The Italian patient is homozygous for this mutation whereas the 
Canadian patient is a compound heterozygote carrying the Val412 substitution to-
gether with an, as yet, unidentified lesion in the other allele. The unknown mutation 
apparently causes a significant decrease in the amount of protective protein mRNA 
suggesting a defect in transcription or mRNA stability. The T to G substitution in-
stead does not interfere with the synthesis of an mRNA of correct size and quantity. 
In both patients' fibroblasts this transcript is translated into an abnormal precursor 
that is not or hardly processed to the mature two-chain product and consequently 
lacks cathepsin A-like activity (Palmeri et af., 1986; Galjart et af., 1991 ). 
Using site directed mutants with the Phe412 to Val change we have 
demonstrated that this mutation is the one responsible for the in vivo phenotype 
affecting posttranslational modifications, intracellular transport and catalytic activity 
of the protective protein/cathepsin A Overexpression of the mutant protein in COS-
1 cells made it possible to follow its intracellular distribution for the first time. It be-
came apparent that only a fraction of the newly synthesized precursor pool leaves 
the endoplasmic reticulum and gets compartmentalized. These molecules fold 
properly inasmuch as they acquire the mannose-6-phosphate marker, are routed to 
lysosomes and are also secreted. In addition, there is evidence that the amino acid 
change does not prevent the recognition of the mutant precursor by one of the 
other components of the complex, ~-galactosidase. It is conceivable that in vivo a 
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fraction of Val412 precursor that exits the ER is associated with i)-galactosidase 
and reaches the lysosomes, where it gets rapidly degraded in its processed two-
chain form. This event would in turn provoke the loss of protective function towards 
J3-galactosidase and neuraminidase, although the mode and site of interaction of 
the latter with the other two components is until now unknown. Our results raise the 
possibility that the protective function of the protein, contrary to its catalytic activity, 
could be exerted already at precursor level. They are also conformable with the 
presence of residual mature protective protein in lysosomes of patients' fibroblasts 
(Palmeri eta/., 1986; Strisciuglio et at., 1988). 
The fate of the intralysosomal Val412 precursor and its retention in the ER 
could be attributed to a common faulty event, the lack of oligomerization. During the 
last few years it has become increasingly clear from a variety of systems that not 
only a protein's tertiary structure but also oligomeric state determines its intracellu-
lar transport, final targeting and stability. These early steps in protein biosynthesis 
often take place and are regulated in the ER (for review see Hurtley and Helenius, 
1989). The protective protein precursor by itself appears to exist as an oligomer, 
probably a dimer. In this form proteins thought to be identical or very homologous 
to the protective protein are also found in their mature and active state (Simmons 
and Walter, 1980; Jackman et at., 1990). The dimerization process could play a 
very important role in the correct targeting and stable conformation of the protective 
protein, since we find that the monomeric VaJ412 mutant is retarded in the ER. It is 
unclear at this time whether the rapid degradation of the mutant protein upon pro-
teolytic cleavage is solely due to its monomeric state or also to its inability to stably 
assemble into a two-chain polypeptide. The effects of the impaired dimerization of 
mutant protective protein resemble to some extend those caused by a number of 
natural mutations identified in the a-subunit of lysosomal J3-hexosaminidase 
(Neufeld, 1989; Navon and Proia, 1991; Paw et at., 1991 ). 
It is noteworthy that phenylalanine at position 412 is highly conserved 
among protective proteins of different species (Galjart et at., 1991 ). The mutation 
falls in a region of the 20 kDa subunit that is part of an internal repeat occurring 
once in each of the two chains and is characterized by recurring tryptophane 
residues that could be engaged in inter/intramolecular bonds. It has been postu-
lated that initial folding of at least one domain of a subunit is required for correct 
oligomeric assembly (Hurtley and Helenius, 1989). The "repeated" motif in the 
protective protein chains might expose surface features essential for the recogni-
tion and binding of monomeric molecules with each other. In this context the 
Phe412 to Val change could have dramatic structural consequences. 
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Finally it is important to keep in mind that the protective protein exerts, at 
least in vitro, a cathepsin A-like activity towards a variety of bioactive peptides 
(Jackman eta/., 1990). This activity is distinct from its protective function toward ~­
galactosidase and neuraminidase and is deficient in different galactosialidosis pa-
tients. The consequences of the deficiency of the enzymatic activity on other 
metabolic pathways, could be clarified by the identification of the natural sub-
strate(s) that are the target of this multifunctional protein in vivo. 
Materials and methods 
Cell culture 
Human skin fibroblasts from normal individuals and the Canadian late infantile galactosialidosis 
patient (Pinsky eta!., 1974) were obtained from the European Cell Bank, Rotterdam (Dr. W.J. 
Kleijer). Cells from the Italian late infantile galactosialidosis patient (Andria eta/., 1978) and both 
parents were provided by Dr. G. Andria, Dept. of Pediatrics, University of Napets, Italy. Fibroblasts 
were maintained in Dulbecco's modified Eagle's medium-Ham's F10 medium (1:1 vol/vol) 
supplemented with antibiotics and 10% fetal bovine serum. COS-1 cells (Giuzman, 1981) were 
grown in the same medium, supplemented with 5% fetal bovine serum. 
eDNA synthesis and cloning 
For the synthesis and amplification of mutant cDNAs four sets of oligonucleotide primers were 
synthesized on an Applied Biosystems 381 A oligonucleotide synthesizer according to the 
sequence of the human eDNA, Hu54 (Galjart eta/., 1988). The four sense primers correspond to 
nucleotide positions 5-24, 367-383, 701-720, and 1051-1070, respectively; the four antisense to 
positions 388-407, 750-731, 1080-1099, and 1450-1469, respectively. Eight bases were added 
to the 5' end of each primer to generate EcoRI sites and facilitate ligation of amplified DNA into a 
plasmid. Total RNA was isolated by the method of Auffray and Rougeon (1980). Four 
overlapping eDNA fragments, encompassing the entire coding region, were synthesized by 
reverse PCR (Hermans et at., 1988) and amplified on a Perkin-Elmer Cetus thermocycler 
programmed for 25 cycles. The fragments were digested with EcoRI and subcloned into plZ18 
or pTZ19. Nucleotide sequence analysis on both strands was performed using the dideoxy chain 
termination method adapted for double-stranded DNA (Murphy and Kavanagh, 1988). 
Analysis of amplified genomic DNA 
The 239 bp region of genomic DNA surrounding the mutation was PCR amplified according to 
Saiki eta!. (1988). The two oligonucleotide primers used in the reaction are derived from intronic. 
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sequences surrounding exon XIV (N.J. Galjart and A. d'Azzo, in preparation) in the protective 
protein gene that contains the mutation. The sense oligonucleotide primer sequence is 
S'TCTTTCCTGGTGGGGCAGAT 3' (primer 1) and includes 2 bp of the exon; the antisense primer 
sequence is: S'CCATACAGGGGCCAGATGGT 3' (primer 2) and is about 100 bp downstream of 
the exon. For direct DNA sequence analysis an aliquot of the amplified DNA sample was 
subjected to asymmetric PCR (Kadowaki et al., 1990), using only primer 1 for another 35 cycles. 
The amplified DNAs were sequenced with primer 2. Acyl digestion of PCR amplified genomic 
fragments was carried out using standard conditions (Sambrook et at., 1989). The resulting 
fragments were analyzed on a 4% NuSieve agarose gel. 
Site-Directed Mutagenesis 
In vitro mutagenesis of human protective protein eDNA was done as described by Higuchi et a/. 
(1988). using the whole 1.8 kb protective protein eDNA as a template. After synthesis by PCR of 
a full length eDNA containing the T to G transversion, the entire fragment was verified by 
sequencing on both strands. The two oligonucleotides used for site directed mutagenesis are 
S'ATTGCCGGCTTCGTGAAGGAG3' (sense) and 5'CTCCTTCACGAAGCCGGCAAT3' (antisense). 
Transfection of eDNA into COS-1 cells 
Normal and mutant protective protein cDNAs were subcloned into a derivative of the mammalian 
expression vector pCD-X (Okayama and Berg, 1983) as described earlier (Galjart et at., 1988). 
Transfection of COS-1 cells, metabolic labeling and preparation of cell extracts and media were 
carried out as reported earlier (Proia et at., 1984; Galjart eta!., 1988). Cells were labeled with 
[3H]leucine (143 Ci/mmol; Amersham Corp.) or with [32p]phosphate (carrier free, Amersham 
Corp.), for 12 hr or 7 hr, respectively. labeled proteins were immunoprecipitated with anti-54 kDa 
antibodies that recognize precursor and mature protective protein (Galjart et at., 1991). They 
were resolved on 12.5% SDS-polyacrylamide gels under reducing conditions and visualized by 
autoradiography ([32 P]Iabeled samples) or fluorography ([3H]Iabeled samples). Transfected 
COS-1 cells, lysed in double distilled water were assayed for cathepsin A activity using the N-
blocked dipeptide Z-Phe-Ala (Sachem Feinchemikalien AG, Bubendorf, Switzerland). using 
protocols adapted from the methods of Taylor and Tappel (1973) and Roth (1971). Total protein 
concentration was measured using the method of Smith eta!. (1985). 
lmmunoefectron microscopy 
Transfected COS-1 cells were fixed in 0.1 M phosphate buffer pH 7.3, containing 1% acrolein 
and 0.4% glutaraldehyde. Further embedding in gelatin, preparation for ultracryotomy and 
methods for immunoelectron microscopy were as reported earlier (Willemsen et at., 1986). The 
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antibodies against the 32 kDa denatured chain of human protective protein (anti-32 antibodies) 
have been descnbed (Galjan et at., 1988). 
Gel filtration 
Medium samples from transfected cells were collected, concentrated and desalted as described 
(Proia et al., 1984). 50% of this material was diluted in 50 mM 2-[N-morphotino] ethane sulfonic 
acid (MES) pH 6.95, containing 100 mM NaCI, and applied on a column (85x1.53 em) of 
Sephacryl S-200 HR (Pharmacia) equilibrated in the same buffer. The whole procedure was 
pertormed at 4oc. After gel filtration radiolabeled proteins were immunoprecipitated using anti-54 
antibodies and further processed as above. The column was separately run in the same buffer 
with the following set of globular protein markers (Pharmacia): ferritin {440 kDa), aldolase (158 
kDa), BSA (67 kDa) and ovalbumin (43 kDa). 
Limited proteolysis with trypsin 
Transfections and metabolic labeling of transfected cells with [3H]leucine was performed as 
above, with the exception that fetal bovine serum was omitted from the labeling medium. 
Secreted proteins were concentrated 20 fold with (NH4)2SO 4, in the presence of 1 mg/mt BSA, 
and desalted. Aliquots of 90 Ill medium concentrate were diluted to 200 J.Ll volume with 20 mM 
sodium phosphate pH 6.8. A modified protocol of Frisch and Neufeld (1981) was used for trypsin 
digestion. One sample was left on ice, the others were incubated with 1 !l9 of trypsin (Sigma) at 
37oc for 0, 2, 5, 10, 30 minutes, respectively. Reactions were stopped by addition of 3 J..l9 
bovine pancreas trypsin inhibitor (Sigma). At t = 0 the inhibitor was added before the trypsin. 
Radiolabed proteins were immunoprecipitated and further processed as described previously. 
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Normal lymphocyte prometaphase chromosome spreads 
were hybridized in situ using single· and double-color fluo--
rescence techniques. The results obtained with either the 
l.S·kb protective protein eDNA or a 12·kh genomic frag· 
ment of the human protective protein gene as probe demon~ 
strate that the PPGB gene is localized on the long arm of 
chromosome 20. This assignment was confirmed by hybrid· 
ization with whole chromosome DNA libraries. ,o Jlllll 
INTRODUCTION 
Human protective protein is the glycoprotein re· 
quired for stability and activity of the lysosomal en· 
zymes iJ·galactosidase (EC 3.2.1.23) and neuramini· 
dase (EC 3.2.1.18) (d'Azzo et aL, 1982; Hoogeveen et 
aL, 1983; Verheijen et aL, 1982, 1985). A primarydefi· 
ciency of the protective protein (d' Azzo et al., 1982) 
causes severely reduced !)·galactosidase and neur· 
aminidase activities and results in the metabolic star· 
age disorder galactosialidosis (Wenger et al., 1978; 
Okada et aL, 1978; Andria et al., 1981; Suzuki et aL, 
1984). In human cultured fibroblasts the protective 
protein is synthesized as a 54-kDaprecursor, which is 
post·translationally processed into a mature hetero· 
dimer of 32· and 20·kDa polypeptides, held together 
by disulfide bridges (d' Azzo et aL, 1982; Galjart et aL, 
1988). Cloning of human protective protein eDNA 
and analysis of its predicted amino acid sequence 
showed that the protective protein is homologous to 
yeast serine carboxypeptidases (Galjart et al., 1988)-
Domains essential for the proteolytic activity of these 
enzymes are completely conserved in the human pro· 
1 To whom correspondence should be addressed at Department 
of Ceil Biology and Genetics. Erasmus University. P.O. Box 1738. 
3000 DR Rotterdam. The Netberland.q. Fax: (O)lQ-4087212 
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tein, suggesting that the protective protein also func· 
tions as a serine carboxypeptidase. 
Two contradictory reports described the loca.liza· 
tion of the gene encoding human protective protein. 
Sips et al. (1985) localized it on chromosome 22, using 
an antibody preparation that recognized both human 
protective protein and !)·galactosidase to screen hu· 
man/mouse and human/Chinese hamster somatic 
cell hybrids. On the other hand, Mueller et aL (1986), 
by scoring for the increase in neuraminidase activity 
over the mouse background in human/mouse somatic 
cell hybrids. localized on chromosome 20 a gene that 
is defective in a galactosialidosis patient. They named 
it GSL (galactosialidosis). Here we show by double· 
fluorescence in situ hybridization that the gene en· 
coding the protective protein is located on the long 
ann of chromosome 20. Our results are substantiated 
by the fact that both the human eDNA and a genomic 
DNA fragment containing almost the entire gene en· 




Reagents and enzymes were obtained from the fol· 
lowing companies: RNase A, digoxigenin·ll·dUTP, 
mouse anti·digoxigenin, and blocking reagent from 
Boehringer (Mannhei.m, Germany); biotin-11·dUTP, 
rabbit anti·mouse TRITC, goat anti·rabbii. TRITC, 
propidium iodide, the antifading reagent 1,4·diazabi· 
cyclo·(2,2,2)-octane, and actinomycin D from Sigma 
(U.S.A.); avidin·D·FITC and biotinated goat anti· 
avidin from Vector Laboratories (U.S.A.); pepsin and 
4',6·diamidino·2-phenylindole (DAPI) from Serva 
(Germany). 
In Situ Hybridization 
Routine prometaphase spreads obtained from a 
primary peripheral blood lymphocyte culture of a 
346 WIEGANT ET AL. 
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healthy male were treated with RNase A (100 ,ug/ml 
2X SSC) for 1 hat 37"e, using 100 ,ul solution under a 
25 X 50-mm2 coverslip. The slides were then rinsed 
three times for 5 min with 2X SSe and further incu-
bated with pepsin (50 ,ug/ml 10 mM Hel) for 10 min 
at 37"C. After a rinse in PBS and a 5-min wash in 
PBS containing 50 mM MgClz_, postfi:xation was per-
formed with formaldehyde (1% (vjv)) in PBS con-
taining 50 rnJy[ Mgel~. This step was followed by a 
PBS rinse and gradual dehydration of the slides in 
ethanoL The eDNA (1.8 kb) and a fragment of geno-
mic DNA (12 kb) were labeled with biotin-11-dUTP 
essentially according to Langer et al. (1981). The 
Bluescript DNA libraries specific for chromosomes 
19, 20, 21, and 22 (generous :;ifts of Dr. J. W. Gray, 
Lawrence Livermore Laboratories, U.S.A.) were la-
beled with digoxigenin-11-dUTP using a similar 
nick-translation format. 
For single hybridizations with the biotinated 
eDNA, the hybridization mixture contained 2 ng of 
the probe, 100 ng of sonicated salmon sperm DNA, 
and 100 ng of yeast tRNA in 1 ,ul of 50% formamide, 
50 mM phosphate, 10% dextran sulfate, 2X SSC, pH 
7.0. The probe mixture (10 ,ul) was applied to the 
slides, covered with a coverslip of 18 X 18 mm?, and 
sealed with rubber cement. Probe and chromosomal 
DNA were denatured simultaneously by placing the 
slides on a 80"C metal plate in an incubator for 2.5 
min. Hybridization was allowed to take place over-
night in a moist chamber. 
For double-fluorescence in situ hybridization (e.g .. 
the biotinated genomic probe and a digoxiginated-
chromosome library) the labeled probes were mixed 
in the hybridization buffer, which contained in addi-
tion a 500-fold excess of sonicated unlabeled total hu-
man placental DNA. This probe-competitor mixture 
was denatured prior to hybridization for 5 min at 
75°C, quickly chilled, :1nd subsequently incubated for 
2-4 hat 37"e to compete out repetitive sequences in 
any of the probes. Chromosomal DNA was denatured 
separately on the slide by immersing it in 70% form-
amide, 10 mM phosphate, 2X SSe at SO"C for 2.5 min. 
The slides were then washed twice for 5 min with cold 
70% ethanol (-20"C), dehydrated, and dried at 37"C. 
The 3rC hybridization mixture was subsequently 
applied under a coverslip, and hybridization was al-
lowed to continue overnight. 
After hybridizations, coverslips were removed and 
slides were washed three times for 20 min in 50% 
formamide, 2X SSC, pH 7.0, at 45"C, followed by 
three 5-min washes in 0.1X SSe at 60"C, and finally 
rinsed in 4X SSC, 0.05% Tween 20 (vjv) at room tem-
perature (RT). 
Immunocytochemical Detection and Banding 
The detection of the biotinated eDNA hybridiza-
tion was performed essentially according to the am-
plification method of Finkel et aL (1986), using the 
high salt washes recommended by Lawrence et al. 
(1983). Briefly, slides were preincubated in 4X SSe, 
5% nonfat dry milk (NFD) for 20 min at RT. After 
incubation with avidin-D-FITe in 4X SSC/NFD for 
20 min at RT, the signals were amplified with biotin-
ated goat anti-avidin-D in 4X SSe, 20 min at RT, 
followed by another incubation with avidin-D-FITC. 
Three 3-min washes with 4X SSe, 0.05% Tween-20 
were performed at RT. Finally, the slides were rinsed 
once for 5 min with PBS, dehydrated through aneth-
anol series, and air-dried. The chromosomes were 
banded by an incubation with 100 ng DAPI/ml 0.2 M 
sodium phosphate/0.1 M citric acid, pH 7.0, for 25 
min at RT. After two 2-min washes in ~0. the_slides 
were incubated with 0.3 mg actinomycin D /mllO mM 
sodium phosphate, pH 7.0, 1 m.MEDTA for 18 min at 
RT. After two 2-min washes in H.O, the slides were 
mounted in an antifade medium ~ontaining 9 parts 
glycerol. 1 part 1M Tris · Hel. pH 7.5, 2% 1,4-diaza-
bicyclo(2,2,2)-octane, and 0.02% thiomersal. 
Detection of the signals from the simultaneous hy-
bridization with digoxigenated library DNA and bio-
tinated genomic DNA was performed as follows. 
Slides were preincubated in 4X SSC~'PD, washed 
with 4X SSC, 0.05% Tween-20, and incubated with 
avid.in-D-FITC in 4X SSC/NFD for 20 min at RT. 
They were subsequently washed twice for 5 min with 
4X SSC, 0.05% Tween-20 and once for 5 min with 0.1 
M Tris · Hel, 0.15 M NaCl. 0.05% Tween 20. pH 7.5 
(TNT). Afterward they were incubated with a mix· 
ture of biotinated goat anti-avidin-D and mouse 
monoclonal anti-digo:xigenin, diluted in 0.1 M 
Tris-Hel, pH 7.5, 0.15 M NaCl, 0.5% blocking re-
agent (TNB), for 30 min at 37"C. After three 5-:min 
washes with TNT, the slides were treated with a mi.'{-
FIG. l. Fluorescence in situ bybridizntion oftbe 1.8-kb biotinated protective proteincDNA. (A) Fluorescein image sbowingthe specific2 
X 2 hybridization si[:ru~ls (arrows). (B) DAPI/octinomycin image of the microscopic field. 
FIG. 2. Double-fluorescence in. situ hybridization with biotinated 12-kb genomic protective protein DNA and digo>:iginnted chromosome 
19 librazy DNA. (A) Fluorescein signals resulting from the protective protein-DNA in. situ. hybridization. (B) Rhodamine signnls obtained by 
in. situ hybridization with chromo$ome 19 DNA. (C) DAPI/octinomycin counterstaining. 
FIG. 3. Double-fluorescence in. situ hybridization with biotinated 12·kb genomic protective protein DNA and digoxigenatedchromosomc 
20 library DNA. (A) Fluorescein sip1als resultiD.g from the protective protein-DNA in.sicuhybridization. (B) Rhodamine sip1cls obtained by 
in.-situ hybridization with chromosome 20 DNA. (C) DAPI/aetinomycin counterstaining. 
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ture ofavidin-D-FITC and rabbit anti-mouse TRITC 
diluted in TNB. for 30 min at 37°C. Finally, after 
three 5-min washes with TNT, the slides were incu-
bated for 30 min at 37°C with goat anti-rabbit TRITC 
diluted in TNB. They were then washed three times 
for 5 min with TNT, dehydrated through an ethanol 
series, air-dried, and mounted in antifade medium 
containing 150 ng DAPI/ml, as a DNA counterstain. 
Photomicrographs were taken on a Dialux (Leitz) 
microscope equipped for epillumination on a 640 asa 
color slide film (3M). 
RESULTS AND DISCUSSION 
The eDNA encoding human protective protein bas 
been cloned and characterized (Galjart et aL, 1988). 
Using the eDNA as a probe we have analyzed on 
Southern blots restricted DNA from a number of hu-
man/mouse and human/Chinese hamster somatic 
cell hybrids. The locus for the protective protein, how-
ever. could not be unambiguously assigned, although 
in one hybrid cell line, pgMe25Nu (Geurts van Kessel 
et aL, 1981), that retained only human chromosome 
22, no human·speeific hybridization fragments could 
be detected (data not sho'W!l). Thus the gene encoding 
the protective protein could not be on chromosome 
22. For a conclusive localization and to confirm either 
of the previously published reports. we decided to per· 
form in situ hybridization. The entire 1.8·kb protec· 
tive protein eDNA and a 12-kb genomic DNA frag-
ment (containing all coding exons) were indepen-
dently used as probes. 
Figure 1A shows a single hybridization with the 
biotinated eDNA. Although chromosome banding 
with the counterstaining used is poorly resolved on 
the color micrograph (Fig. !B), under the microscope 
the region carrying the in situ hybridization signal 
was unambiguously identified as 20q13.L The fre-
quency of metaphase plates carrying the expected 2 
X 2 spots on the chromatids was about 0.1. The same 
chromosomal assignment was made with the single 
hybridization using the biotinated genomic DNA. 
The number of plates with four spots was higher (0.4) 
and, as a consequence of the larger target, the hybrid-
ization intensities were stronger (results not shown). 
To confirm the cytogenetic assignment, double-fluo-
rescence in situ hybridization (Hopman et al., 1986: 
Nederlof et aL, 1989, 1990) was performed with duo-
mosome-specific libraries for 19. 20, 21, and 22. Fig-
ures 2 and 3 show the results of such hybridizations 
with the protective protein genomic DNA (2A and 
3A) and the libraries of chromosome 19 (2B) and 20 
(38). The proteetive protein specific signals axe 
clearly on chromosome 20. 
Taken together, the results obtained with two dif-
ferent DNA probes and two independent ways of clas-
166 
sifying chromosomes demonstrate that the PPGB 
gene encoding humtln protective protein is on chro-
mosome 20q13.L Furthermore, they confirm and ex-
tend the observation of Mueller et aL (1986), indicat-
ing that the PPGB gene is almost certainly the same 
as the GSL gene. 
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2.3 1 Discussion 
The results presented in publications 1-7 demonstrate that human protective pro-
tein, encoded by a gene on chromosome 20, is synthesized as a precursor of 54 
kDa, that is phosphorylated on a single Asn-linked oligosaccharide chain which 
allows its transport to lysosomes via the MPR targeting system. Probably in an en-
dosomal!lysosomal compartment the precursor is proteolytically modified into a 
two-chain form consisting of disulfide-linked 32 and 20 kDa polypeptides. The 32 
kDa component is subsequently further trimmed at its C-terminus. A schematic 
representation of these events is given in Figure 3. 
Characterisation of the primary structure of the protective protein revealed 
that it maintains another function, namely as a serine carboxypeptidase, distinct 
from its protective role towards ~-galactosidase and neuraminidase. The catalytic 
activity is unleashed only after conversion of the 54 kDa zymogen to the two-chain 
form. It still needs to be determined whether the precursor already has protective 
function or not. 
Serine carboxypeptidases are a family of single and two-chain enzymes that 
are present in many different species, ranging from yeast to fungi, plants and man 
(for review see Breddam, 1986). Most of them are aspecific peptidases, involved in 
general protein turnover, but the KEX1 gene product of yeast has carboxypepti-
dase-6-like activity and participates in hormone processing (Dmochowska et at, 
1987). Comparison of the structure of the protective protein with that of other serine 
carboxypeptidases allows several speculations to be made. First, some of the plant 
peptidases have been purified in an active two-chain form from which the amino 
acid sequences of the subunits were chemically determined (for a compendium of 
these sequences see Sorensen et at, 1989). In the case of barley carboxypepti-
dase I, these sequences were compared with the one of the precursor polypeptide 
that was deduced from the isolated eDNA It was shown that the two subunits origi-
nate from a single chain precursor polypeptide that in addition contains a stretch of 
amino acids separating the two chains (Doan and Fincher, 1988). This highly re-
sembles the biosynthesis and processing of the protective protein and provides a 
verified example in a homologous carboxypeptidase of C- (or N-) terminal trimming 
after the initial endoproteolytic processing step. The analogy in maturation events 
might indicate a similar function for the intermediate stretches of amino acids in the 
plant carboxypeptidase and protective protein precursors, namely to keep these 
forms in an inactive state. In zn2+ carboxypeptidase B, such an "inactivation· func-
tion resides within its propeptide segment, which simply obstructs the access of a 
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Three proteolytic processing steps are thought to occur during the life 
cycle of the protective protein, 1) signal sequence cleavage, 2) the first 
endosomal/lysosomal endoprotease cleavage and 3) C-terminal trimming 
of the 32 kDa polypeptide. Oligosaccharide side chains on the two 
subunits can be distinguished because the one on the 32 kDa 
polypeptide carries the M6P-recognition marker. In keeping with the 
predictions made in the text, the intermediate stretch of amino acids 
between 32 and 20 kDa chains is placed in front of the serine active site 
residue in the precursor molecule. Disulfide bridges connect the two 
chains. Of the nine cysteines in human protective protein cys375 is 
shown. since it migh'l be in the catalytic site (see text). 
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substrate to the preformed active site (Coli eta/, 1991 ). limited proteolysis of pro-
carboxypeptidase B with trypsin removes this inactivating segment and exposes 
the active site. It will be of interest to determine whether a similar activation 
mechanism exists for the two-chain serine carboxypeptidases. 
Second, it is noteworthy that the two-chain plant serine carboxypeptidases, 
that bear such striking structural resemblance to the protective protein, also form 
dimers but not multimers (Breddam, 1986). Remarkably, and perhaps related to 
this is the fact that no neuraminidases exist in the plant kingdom. Maybe this 
implies that during evolution the protective protein acquired its catalytic activity first 
and its protective function later. 
A third speculation that can be made is that Cys at amino acid position 375 
in the active human protective protein is near the substrate binding site within the 
catalytic center, since this was shown to be the case for the homologous residue of 
yeast carboxypeptidase Y (Breddam and Svendsen, 1984; Winther and Breddam, 
1987). Catalytic activity should then be modulated by reagents that interact with 
sulfhydryl groups, a prediction that is indeed corroborated in several reports 
(Jackman eta/, 1990; Kawamura eta!, 1974; 1975; Tranche montagne eta/, 1990). 
What remains are an even number of cysteines (8) in the human protective protein, 
that, as is the case for Cys375, are conserved in the mouse and chicken homo-
logues and that potentially could form intramolecular disulfide bridges. In addition, 
mouse and chicken protective proteins contain 2 extra cysteines, one on each sub-
unit of their respective two-chain forms, but at different positions. 
The protective protein is most likely identical to a carboxypepti-
dase/deamidase, secreted by human platelets upon thrombin stimulation (Jackman 
eta/, 1990). In vitro this enzyme cleaves a number of important bioactive peptides 
among which are substance P, oxytocin and angiotensin I. Its deamidase activity is 
optimal at neutral pH, whereas its carboxypeptidase activity has an optimal pH of 
5.0, with the artificial substrate furylacryloyi-Phe-Phe. The resemblance between 
the protective protein and the carboxypeptidase/deamidase is strengthened by the 
fact that both proteins maintain cathepsin A-like activity. Cathepsin A has been pu-
rified from many tissues and species, it is a carboxypeptidase which cleaves N-
blocked dipeptides optimally at pH 5.5 and has a preference for hydrophobic 
residues in the (pen)ultimate position of the substrate protein. Other residues, but 
not lysine or arginine, may also be released (reviewed by McDonald and Barrett, 
1986). Cathepsin A was shown to have deamidase activity as well (Matsuda, 
1976). Because of its broad substrate specificity cathepsin A is thought to be in-
volved in lysosomal protein turnover. If the protective protein and cathepsin A turn 
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out to be identical this hypothesis can be directly tested, by comparing cellular 
protein degradation in galactosialidosis and normal fibroblasts. Some authors have 
postulated a physiological role for cathepsin A in the conversion of angiotensin I to 
angiotensin II (Miller eta/, 1988; 1991 ). Together, the data suggest that the role of 
the protective protein/cathepsin A might include protein turnover as well as the 
(in)activation of bioactive peptides and might be extended to an extralysosomal 
compartment. This could imply that some tissues have a differential need for the 
protective protein. Consistent with this is the observation that murine protective 
protein mRNA is differentially expressed in various mouse tissues (publication 2) 
and that its expression pattern differs from that of f3-galactosidase mRNA (Morreau 
eta/, 1991 ). A function of the protective protein outside the complex explains the 
previously unaddressed observation that in extracts of normal human fibroblasts 
the majority of the protective protein is not present in the high molecular weight 
complex together with f3-galactosidase, but is instead immunoprecipitated from a 
"monomeric" peak (Hoogeveen eta/, 1983). 
Our results in publications 5 and 6 demonstrate that dimerization of the pro-
tective protein/cathepsin A occurs at precursor level and neutral pH, suggesting 
that it takes place in an early biosynthetic compartment. Dimerization could be a 
requirement for timely exit of the precursor out of the ER. This hypothesis is sup-
ported by the observation that a natural mutant of the protective protein fails to form 
dimers and is largely retained in the ER (publication 6). We have evidence that 
protective protein and f3-galactosidase precursors associate at an early stage of 
biosynthesis, indicating that their assembly is not restricted to the lysosomal envi-
ronment (H. Morreau and A. d'Azzo, manuscript in preparation). The advantage of 
this event in normal cells could be to create pools of free and assembled molecules 
that are committed to different functions already at an early stage and could poten-
tially be targeted differentially according to the respective functions. It needs to be 
further investigated to what extent and in which stoichiometry association occurs in 
normal cells and tissues and whether this influences the dimerization of the protec-
tive protein precursor. It should be mentioned that in galactosialidosis fibroblasts, 
which are completely devoid of the protective protein, B-galactosidase can reach 
the lysosomes. Its proteolytic processing in these cells is, however, clearly delayed 
compared to normal fibroblasts (d'Azzo eta/, 1982). 
The finding that some in vitro mutagenized protective proteins, retained in 
the ER, prevent lysosomal targeting of B-galactosidase (H. Morreau and A. d'Azzo, 
manuscript in preparation) has important consequences for the interpretation of the 
molecular events in galactosialidosis and perhaps even GMt-gangliosidosis. 
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Natural mutants of the protective protein may exist that retain a large part of the a-
galactosidase precursor pool in the ER, thereby causing an additional negative ef-
fect on its lysosomal activity. One could consider this kind of mutant protective pro-
teins to have a "dominant" effect. The mutated form of the protective protein, pre-
sent in the late infantile galactosialidosis patient described in publication 6, would 
have a "recessive" character instead. In the latter case the mutant protective protein 
could actually be rescued from premature ER degradation because its association 
to B-galactosidase precursors would ensure its exit out of this compartment. An in-
verse situation, that could also be envisaged, is that there are "dominant" mutations 
in the B-galactosidase protein that influence the protective protein. Remarkably, the 
proteolytic processing of the latter indeed seems altered in two cell lines derived 
from pateints with the infantile and adult forms of GM1-gangliosidosis, respectively 
(Hoogeveen eta/, 1984). These fibroblasts need to be reexamined with the 
monospecific antibodies against the protective protein that are now available. 
Lysosomes have a pivotal function in the intracellular degradation of a multi-
tude of macromolecules. They are the "dead end" route in a largely interconnected 
vesicular system that has its beginning in the ER. In spite of their well established 
digestive role the supramolecular structure of proteins within lysosomes is still un-
known. Therefore, predictions of how intralysosomal degradation could be carried 
out in the most effective way are speculative. Several reasons given in the intro-
duction explain why a stepwise macromolecular degradation is speeded up if the 
enzymes that act sequentially on a given substrate were to form complexes. In 
addition, in lysosomes complex formation could prevent the rapid degradation of 
the true lysosomal constituents by other hydrolases. On the other hand, there are 
many different types of substrates. If each would demand complexed enzymes for 
its quick degradation this would require as many complexes as there are sub-
strates. Therefore, it may be that most lysosomal enzymes are only temporarily and 
loosely associated within complexes and that these vary constantly in enzymic 
composition, depending on incoming substrate. 
A hypothetical model incorporating these considerations as well as data on 
the structure of the protective protein/cathepsin A is presented in Figure 4. In lyse-
somes (and perhaps other organelles) an equilibrium could exist between multi-
meric (matrix) and dimeric (free) protective proteins. In the absence of B-galactosi-
dase and neuraminidase, this balance could be dependent on the protective pro-
tein concentration, its conformation (precursor or mature) and other physiological 
parameters, such as pH, ion concentration and incoming substrate. In COS-1 cells, 
transiently transfected with the protective protein eDNA, overexpression of the pro-
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tein could lead to premature multimerisation in an early biosynthetic compartment. 
Preexisting intralysosomal matrices of the protective protein specifically attract B-
galactosidase and/or neuraminidase molecules and when both enzymes are as-
sociated the complex is most stable. By maintaining, in most cells and tissues, a 
surplus amount of lysosomal protective protein with respect to B-galactosidase and 
neuraminidase the existence of "empty" matrices that can easily be converted into 
dimeric cathepsin A is ensured. The function of the free pool of protective pro-
tein/cathepsin A in lysosomes would be the degradation of proteins and/or bioac-
tive peptides (the extensively purified toad skin enzyme and the human deamidase 
are found solely as homodimers of 94-100 kDa (Jackman eta/, 1990; Simmons et 
a!, 1980)). It remains to be determined whether the complexed pool participates in 
the digestion of macromolecules. If so, the target substrates for the peptidase and 
the two glycosidases should be rather small because of the steric hindrance within 
the complex. 
The model implies that the signals for matrix formation are embedded within 
the structure of the protective protein only. Because of this, in GM1-gangliosidosis 
fibroblasts neither lysosomal neuraminidase nor cathepsin A activities are severely 
affected. Instead, in galactosialidosis the lack of a preexisting matrix would cause 
the impaired combined glycosidase deficiency. Since mouse and chicken protec-
tive proteins have maintained the capacity to form matrices in lysosomes, it is logi-
cal that they are able to complement a deficiency of human protective protein in 
galactosialidosis cells. Nevertheless, multimers formed by these heterologous 
proteins might have a reduced affinity for human neuraminidase. 
The model is in keeping with the idea that there may be more than one type 
of complex in lysosomes. This would explain why in glycoprotein preparations from 
human placenta B-galactosidase activity is detected in two multimeric peaks, one 
with and one without neuraminidase (Verheijen et at, 1985). It is not excluded that 
other lysosomal enzymes temporarily associate to the matrix, perhaps in varying 
amount, composition and in a loose conformation. Evidence in support of a multi-
component matrix is the recent finding that complexes purified through B-galactosi-
dase affinity chromatography also contain small amounts of lysosomal a-N-acetyl-
galactosaminidase (Tsuji et at, 1989). It should be mentioned, however, that this 
enzyme is not deficient in galactosialidosis (van Diggelen eta!, 1988). Another in-
dication for a multicomponent complex comes from the fact that cathepsin A has 
been copurified with prolylcarboxypeptidase, although rigorous further isolation 
methods separated the two enzyme activities (Odya et at, 1978). 
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All the steps depicted in Figure 4, some of which speculative, can and will be 
tested in the near future. However, a thorough understanding of the determinants 
on the protective protein that are responsible for its different conformations awaits 
the resolution of its three-dimensional structure by means of crystallographic 
analyses. Concomitantly with these studies, homologous recombination in embry-
onic stem cells (Thomas and Capecchi, 1987) in combination with the "hit and run" 
procedure (Hasty eta/, 1991) will create animals with targeted protective pro-
tein/cathepsin A mutations, that will allow a better understanding of the molecular 
mechanisms underlying galactosialidosis and might also be of help in the identifi-
cation of the natural substrates of the protective protein. Until these investigations 
have been concluded the name given to the protective protein/cathepsin 
A/deamidase can be chosen rather freely and will presumably be based on one's 
historic ties with this fascinating multifunctional protein. 
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Figure 4. Putative quaternary structures of the protective protein. 
It has been determined that the protective protein can form homodimers at precusor 
level, presumably within the ER. The model indicates that these homodimers may 
form matrices of lysosomal protective protein, to which subsequently other lysosomal 
enzymes could bind. No proteolytic processing steps are indicated in this figure. The 
quaternary structures of lysosomal ~-galactosidase and neuraminidase and of the 
multimeric/complex forms depicted here are hypothetical. 
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Lysosomes are a class of heterogeneous acidic vesicles, surrounded by a single 
membrane, that play a key role in the degradation of a variety of macromolecules. 
lntralysosomal breakdown of substrates is carried out by a large number of hydro-
lases that work best at acid pH. Some of these enzymes require additional cofac-
tors for full catalytic activity. Many of the hydrolases act in concert on a substrate, 
indicating the need for their organization into a higher order structure in order to 
speed up degradation. If, due to a mutation, a lysosomal protein is deficient a halt 
in the chain of catalytic events on a substrate occurs, resulting in its accumulation 
in the lysosome with consequent dysfunction of this organelle. In turn, this leads to 
the appearance of a lysosomal storage disorder. 
Due to the vesicular structure of the lysosome both the macromolecular 
substrates as well as the lysosomal enzymes have to be transported to this com-
partment before degradation can occur. Several pathways that deliver lysosomal 
proteins to their destination have been described, the best characterized of which 
is the M6P targeting system that makes use of two related receptors recognizing 
soluble lysosomal proteins. In turn, the latter must contain determinants within their 
tertiary structure that allows their segregation from other non-lysosomal proteins. 
Lysosomes, their biogenesis and role in intracellular degradation, their constituents 
and the targeting of these proteins, are the subject of chapter 1. 
In chapter 2 the experimental work is discussed, starting with an introduction 
(section 2.1) on the subject of this thesis: the protective protein. It is a lysosomal 
glycoprotein that was discovered through its deficiency in the metabolic storage 
disorder galactosialidosis. This rare autosomal disease is characterized by the 
severely reduced activities of the lysosomal enzymes f3-galactosidase and 
neuraminidase. Galactosialidosis patients are heterogeneous with respect to their 
clinical manifestations, ranging in phenotype from a very severe early infantile 
form, that is fatal within childhood, to milder late infantile and juvenile/adult types. A 
high molecular weight complex in which 13-galactosidase, neuraminidase and the 
protective protein are present, can be isolated from various tissues and species, 
but is absent in fibroblasts of galactosialidosis patients. Since in the latter cell type 
13-galactosidase is normally synthesized but rapidly degraded upon arrival in lyse-
somes it was postulated that in normal cells a high molecular weight complex of 
these three glycoproteins exists, which renders the two glycosidases active and 
stable within the acidic environment of the lysosome. 
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Biosynthetic labeling and immunoprecipitation studies in normal fibroblasts 
revealed that the protective protein is synthesized as a precursor of 54 kDa, that is 
proteolytically modified to a 32 kDa mature form. The cloning of the eDNA encoding 
human protective protein, described in publication 1 (section 2.2), !ought us that the 
54 kDa precursor polypeptide is actually processed into a two-chain form of 32 and 
20 kDa subunits that are held together by disulfide bridges. Most strikingly, how-
ever, was the obseNation that the primary structure of the protective protein is ho-
mologous to those of yeast and plant serine carboxypeptidases. The catalytic triad 
Ser-His-Asp, responsible for the activation of the serine residue in these exopepti-
dases, is conseNed in the protective protein and each amino acid is embedded in 
domains of high similarity to the other carboxypeptidases. Human and mouse pro-
tective proteins bind the serine protease inhibitor DFP, but only in their mature two-
chain state, demonstrating that the 54 kDa precursor is a tnue zymogen (publication 
3). Further studies, described in publication 4, provide direct evidence that the 
protective protein has carboxypeptidase activity and indicate that it might be identi-
cal to a previously partially characterized protease, cathepsin A. Using in vitro ma-
nipulated active site mutants of human protective protein we could demonstrate 
that in spite of their loss of catalytic activity these mutants retain their protective 
function towards i)-galactosidase and neuraminidase. Thus, protective function and 
catalytic activity are distinct. 
Analysis of the structure of the protective protein and of residues and do-
mains that govern its correct folding as well as intracellular transport and 
processing is included in publication 5. It is demonstrated that human protective 
protein spontaneously forms homodimers already at precursor level and neutral 
pH. Furthermore, of the two oligosaccharide chains present on the human protein 
the one on the 32 kDa subunit acquires the M6P recognition marker, whereas the 
one on the 20 kDa subunit appears to be essential for the stability of the mature 
two-chain protein. 
The gene encoding human protective protein is localized on chromosome 
20 (publication 7). A natural mutation in this gene is found in two unrelated patients 
with the late infantile form of galactosialidosis (publication 6). Gelfiltration studies 
demonstrate that the mutant protective protein precursor, containing a Phe to Val 
amino acid substitution at position 412, cannot form homodimers. Moreover, the 
latter precursor is partially retained in the endoplasmic reticulum and those 
molecules that do reach the lysosomes are quickly degraded once they are 
cleaved into the 32/20 kDa mature form. We speculate therefore that dimerization 
of the protective protein might be an important event for its proper targeting and 
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stable conformation. Also, the presence of a residual lysosomal amount of protec-
tive protein in tissues of the two patients might account for their relatively mild clini-
cal manifestations. 
Our current model, which is described in section 2.3, is that the protective 
protein/cathepsin A, a pleiotropic member of the serine carboxypeptidase family, 
can either be assembled in complexes with {)-galactosidase and/or neuraminidase, 
yet it might also function on its own. This equilibrium is dependent on as yet unde-
fined factors but complex formation would be initiated by the protective protein. 
Once in complex its carboxypeptidase activity might be modulated by the other two 
enzymes. A recent report by the group of Dr. Erdos at the University of Chicago, 
extends the role of the protective protein even further. In an effort to purify a deami-
dase/carboxypeptidase released by human platelets this group came to the unex-
pected finding that their enzyme is identical at its N-termini to the protective protein 
32/20 kDa chains. The deamidase/carboxypeptidase activity could be responsible 
for the local (in)activation of bioactive peptides. 
The experiments described in this thesis have delineated a novel function 
for the protective protein, namely as a serine carboxypeptidase. They have also 
enlarged our knowledge on the biosynthesis, transport and proteolytic processing 
and on the structure of this protein, both in normal as well as in mutated state. In 
order to assess properly the different roles of this multifunctional lysosomal enzyme 
it is of importance to gain better insight into the mechanisms that control complex 
formation and the site(s) and mode(s)of association of the various components of 
the complex(es). In this respect the cloning of the eDNA encoding human {)-galac-
tosidase (publication 2) has allowed a more detailed study on its association with 
the protective protein, which apparently can already occur in an early biosynthetic 
compartment. Also, transgenic animals having targeted mutations in the protective 
protein gene will provide very useful model systems in which to study the contribu-




Lysosomen, een heterogene verzameling van zure vesikels omgeven door een 
enkel membraan, spelen een sleutelrol in de afbraak van een verscheidenheid 
aan macromoleculen. lntralysosomale degradatie wordt uitgevoerd door groot 
aantal hydrolasen met een zuur pH optimum. Sommige hebben niet enzymatische 
cofactoren nodig voor hun katalytische activiteit. Vaak breken lysosomale enzymen 
een substraat in een strikte volgorde af. Een versnelde afbraak van substraten 
wordt mogelijk gemaakt door een verzameling, bijvoorbeeld in een complex, van 
enzymen die na elkaar werken . Als door een mutatie een lysosomaal eiwit defect 
is stokt de afbraak van bepaalde substraten, hetgeen stapeling van deels gede-
gradeerde macromoleculen in lysosomen tot gevolg heeft. Uiteindelijk kunnen 
deze hierdoor niet meer naar behoren functioneren en ontwikkelt zich een lysosc-
male stapelingsziekte. 
Vanwege de lysosomale structuur moeten zowel substraten als lysosomale 
enzymen via specifieke transport routes naar het lysosoom geleid worden. Een 
aantal van deze routes zijn recentelijk beschreven, de bekendste maakt gebruik 
van twee onderling verwante receptor eiwitten, die oplosbare lysosomale eiwitten 
herkennen en vervoeren. Op hun beurt bevatten lysosomale eiwitten specifieke 
signalen waardoor ze onderscheiden worden van de talloze andere eiwitten die 
niet bestemd zijn voor het lysosoom. Hoofdstuk 1 beschrijft lysosomen, hun 
ontstaan en hun rol in intracellulaire afbraak. Bovendien geeft het een overzicht 
van lysosomale eiwitten alsmede de manier waarop deze naar lysosomen 
vervoerd worden. 
In hoofdstuk 2 word! het experimentele werk besproken, beginnend met een 
in Ieiding over het 'protective protein', het onderwerp van dit proefschrift. Dit is een 
lysosomaal glycoprote'ine dat is ontdekt doordat het defect is in de lysosomale 
stapelingsziekte galactosialidosis. Deze zeldzame aangeboren afwijking wordt 
gekenmerkt door een gereduceerde activiteit van de lysosomale enzymen ~­
galactosidase en neuraminidase. Galactosialidosis patienten worden klinisch 
ingedeeld in drie typen, al naar gelang de leeftijd waarop de ziekte zich openbaart 
en de hevigheid van de symptomen. De ernstigste of 'vroeg-infantiele' vorm van de 
ziekte leidt tot de dood kart na de geboorte, de andere twee vormen (de 'laat-in-
fantiele' en 'juveniele/adulte' typen) zijn wat milder van aard. 
Uit normale cellen en weefsels van verschillende organismen kan een 
complex geTsoleerd worden waarin zich ~-galactosidase, neuraminidase en het 
'protective protein' bevinden. Dit complex is afwezig in gekweekte fibroblasten van 
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galactosialidosis patienten. Bovendien wordt 13-galactosidase in deze cellen wei 
normaal aangemaakt, maar eenmaal in het lysosoom wordt dit enzym versneld 
afgebroken. Deze waarnemingen leidden tot de hypothese dat normaliter in lyso-
somen een hoog moleculair complex van de drie voornoemde glycoprote"inen 
aanwezig is dat ervoor zorgdraagt dat 13-galactosidase en neuraminidase actief en 
stabiel zijn in hun zure omgeving temidden van de andere hydrolasen. 
Proeven waarbij radioactief aangemaakt 'protective protein' in normale fi-
broblasten werd geTmmunoprecipiteerd toonden aan dat het eiwit gesynthetiseerd 
wordt als een 54 kDa precursor vorm, die proteolytisch geklieft word! tot een 32 
kDa matuur eiwit. Klonering van het eDNA dat codeert voor het humane 'protective 
protein' (zie publicatie 1 in sectie 2.2) leerde ens dat de 54 kDa precursor feitelijk 
in twee ketens gesplitst wordt, van 32 en 20 kDa, die verbonden zijn door zwavel 
bruggen. Het meest verrassend was echter de ontdekking dat de aminozuur 
volgorde van het 'protective protein', voorspeld op basis van het gekloneerde 
eDNA, homoloog is aan die van gist en plante serine carboxypeptidasen. Drie 
specifieke aminozuren, Ser-His-Asp, die in al deze exopeptidasen verant-
woordelijk zijn voor de activering van het serine residue in het katalytische cen-
trum, zijn bewaard gebleven in het 'protective protein'. Bovendien liggen ze ver-
ankerd in van elkaar gescheiden domeinen in het eiwit, die qua aminozuur volgor-
de sterk lijken op overeenkomstige domeinen in de andere carboxypeptidasen. 
Het humane 'protective protein' is nauw verwant aan het overeenkomstige muize 
eiwit (publicatie3). Seide glycoprote"inen binden DFP, een specifieke rem mer van 
serine proteasen, maar doen dit slechts in hun mature 32120 kDa vorm. Dit wijst 
erop dat het 54 kDa polypeptide de zymogeen vorm van het 'protective protein' is 
(publicatie 3). Verdere experimenten, beschreven in publicatie 4, bewijzen direct 
dat het 'protective protein' serine carboxypeptidase activiteit heeft en duiden erop 
dat dit eiwit weleens identiek zou kunnen zijn aan lysosomaal cathepsine A, een 
enzym dat vroeger gedeeltelijk gekarakteriseerd is. In vitro gemaakte mutante 
'protective proteins', die geen katalytische activiteit hebben, zijn neg steeds in staat 
tot bescherming van 13-galactosidase en neuraminidase. Dit toont aan dat katalyti-
sche activiteit en de beschermende rei twee aparte functies zijn, verenigd in een 
eiwit (publicatie 4). 
In publicatie 5 wordt de structuur van het 'protective protein' verder ontleed 
en worden signalen/domeinen op het eiwit gelokaliseerd die mede verant-
woordelijk zijn voor goede eiwit vouwing, transport naar het lysosoom en prote-
olytische modificatie. We tonen aan dat het 'protective protein' reeds als precursor 
en bij neutrale pH spontaan homodimeren vormt. Van de twee suikerketens aan-
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wezig op het precursor eiwit wordt de groep op het 32 kDa polypeptide gefos-
foryleerd, een modificatie die dient voor transport van het eiwit naar het lysosoom. 
De aanwezigheid van de suikerketen op de 20 kDa subeenheid is hoogstwaar-
schijnlijk belangrijk voor de stabiliteit van het mature 'protective protein'. 
Het gen coderend voor het humane 'protective protein' is gelokaliseerd op 
chromosoom 20 (publicatie 7). Een mutatie in dit gen is gevonden in twee niet ver-
wante galactosialidosis patienten, die beida lijden aan de milde, 'laat-infantiele' 
vorm van de ziekte (publicatie 6). De experimenten Iaten zien dat het gemuteerde 
'protective protein' een aminozuur substitutie heeft ondergaan, waarbij op positie 
412 in het eiwit de normale phenylalanine vervangen is door valine. Hierdoor kan 
het gemuteerde eiwit, in tegenstelling tot de normale precursor, geen homo-
dimeren meer vormen. Bovendien word! de gemuteerde precursor gedeeltelijk 
vastgehouden in het endoplasmatisch reticulum. Die precursor moleculen die dit 
compartiment verlaten kunnen het lysosoom bereiken, maar eenmaal daar 
aangekomen en gesplitst in de 32/20 kDa mature vorm wordt het gemuteerde eiwit 
versneld afgebroken. Dit doet ens veronderstellen dat de vorming van dimeren 
door het 'protective protein' belangrijk is voor een stabiele conformatie, alsmede 
voor een correct en efficient transport van dit eiwit naar het lysosoom. De aan-
wezigheid van een sterk verlaagde hoeveelheid 'protective protein' in lysosomen 
van de twee hier beschreven patienten zou een verklaring kunnen geven voor de 
relatief milde vorm van galactosialidosis die bij hen gevonden wordt. 
In sectie 2.3 word! een nieuw model gepresenteerd, gebaseerd op de 
recentelijk verworven kennis van het 'protective protein', of cathepsine A. Het stelt 
voor dat dit eiwit aileen kan functioneren, als dimeer, maar dat het ook in eiwitcom-
plexen met de enzymen ~-galactosidase en/of neuraminidase kan voorkomen. Dit 
evenwicht is afhankelijk van tot nu toe onbekende factoren, maar de vorming van 
complexen wordt door het 'protective protein' geTnitieerd. De carboxypeptidase ac-
tiviteit van het eiwit zou, eenmaal in een complex, gereguleerd kunnen worden 
door de andere twee enzymen. Kort geleden he eft de groep van Dr. Erdos van de 
universiteit van Chicago een artikel gepubliceerd, dat een extra rol van het 
'protective protein' suggereert. Deze auteurs vonden dat een deami-
dase/carboxypeptidase, dat zij gezuiverd hadden uit bloedplaatjes, dezelfde 
aminoterminale aminozuur volgorde had als de 32 en 20 kDa ketens van het 
'protective protein'. De deamidase/carboxypeptidase activiteit zou verantwoordelijk 
kunnen zijn voor de plaatselijke (in)activering van bioactieve peptiden. 
De experimenten beschreven in dit proefschrift hebben een nieuwe functie 
toegevoegd aan het 'protective protein', namelijk die van serine carboxypeptidase. 
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Ook hebben zij bijgedragen tot een beter inzicht in de biosynthese, transport en 
proteolytische modificatie en structuur van dit eiwit, zowel in normale als in gemu-
teerde vorm. Om de verschillende rollen van het 'protective protein' goed te kun-
nen beoordelen is het nodig dat precies uitgezocht wordt welke mechanismen en 
factoren van invloed zijn op complex vorming en hoe en op welke intracellulaire 
plaats(en) de verschillende componenten van de complexen met elkaar kunnen 
associeren. De klonering van het eDNA coderend voor humaan 13-galactosidase 
(publicatie 2) heeft er toe geleid dat we konden vaststellen dat dit enzym al in een 
vroeg stadium en op precursor niveau kan associeren met het 'protective protein'. 
Transgene dieren met gerichte mutaties in het gen coderend voor het 'protective 
protein' zullen ook zeer waardevol blijken te zijn in het definieren van de verschil-
lende activiteiten van dit multifunctionele lysosomale enzym. 
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NAWOORD 
Door de jaren heen ben ik, hier in Rotterdam, door een aantal mensen in meer of 
mindere mate geholpen met mijn onderzoek. Mijn inmiddels in kleine kring be-
faamde zeef-geheugen zal ertoe bijdragen dat ik sommigen van hen vergeet te 
noemen, dus bij deze een dankwoord aan een ieder die heeft bijgedragen aan het 
tot stand komen van dit proefschrift. 
Mijn promotor, professor Galjaard, ben ik zeer erkentelijk voor zijn in mij 
gestelde vertrouwen en de door hem geboden mogelijkheden dit onderzoek te 
kunnen voltooien. Oak de andere Ieden van de promotiecommissie, de profes-
soren Bootsma, Borst en Hasilik dank ik voor het kritisch Iezen van dit manuscript 
en hun goede suggesties cq. kanttekeningen. 
Mijn co-promotor, Dr. Alessandra d'Azzo, kan ik nauwelijks genoeg be-
danken. Sandra, ik weet dat je niet zoveel om voetbal geeft, maar tach vind ik je de 
Johan Cruijff van de wetenschappelijke begeleiders ! Bedankt voor je neeit afla-
tende inzet, je inzicht en je vriendschap. Ik heb ondanks mijn koppigheid op aile 
vlakken van je geleerd en daardoor extra van deze jaren genoten. Nynke Gille-
mans, met jou en Sandra heb ik het Iangst samengewerkt. Velgens mij ben je enig 
in je soort, geed in wat je doet, fanatiek en onzelfzuchtig, wat een contrast met mij 
zou je bijna zeggen. Bedankt dat je mijn paranimf wilt zijn. Hans Morreau, die Iaat-
ste epmerking geld! oak veer jeu. Nu weet ik bevendien waar heeven zich bevin-
den, wat knorrecte sokken zijn en hoe in units te meten. Oat is tach de essentie van 
het Ieven. Erik Senten, bedankt voor de les, behalve in propjes geoien en Xiao Yan 
Zhou, you too, sje sje very much. Aarnoud van der Spoel, Robbert Rattier, Amelia 
Morrone en Arne van 't Haag, helaas was er slechts een korte tijd om met jullie 
sam en te werken, maar het was er niet minder prettig om. 
En de anderen ? Gerard Grosveld, mochten de goden huur betalen om in 
het linkerbeen van Brian Roy te kunnen wonen, dan hebben ze het optrekje in 
jouw hoofd (en handen) neg niet bezichtigd ! Mijnheer "de Generaal", bedankt voor 
je advies, steun en goede gesprekken. Van Gerard's groep ben ik Dies Meijer en 
Marieke von Undern erkentelijk voor hun hulp, met name 'in the early days', en 
natuurlijk Sjozef van Baal waar het de EHBO (eerste hulp bij onbegrip) met de 
computer betreft. Harold Gunther. jou bedank ik voor het gouden advies om een 
Macintosh aan te schaffen om daarmee het proefschrift te schrijven en voor je hulp 
bij de afwerking van dit manuscript. Rob Willemsen, jij hebt al het goede LM/EM 
werk gedaan, mijn dank voor deze bijzonder waardevolle bijdrage; Pim Visser. jij 
hebt een groat deel van de figuren getekend en Mirko Kuit, jij hebt bij mijn weten 
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vrijwel aile fotografie (behalve LM!EM) die hier gepubliceerd wordt verzorgd. Dank 
jullie wei. Jeanette Lokker, hartelijk bedankt voor al het type werk aan de artikel-
units en, samen met Rita Boucke, voor de 'reisverslagen' en andere gesprekken. 
Van de 24ste verdieping ben ik Henk Janse erkentelijk voor advies bij en, soms, 
oplossingen voor het meten van enzymactiviteiten. De rest van de medewerkers 
van de vakgroep Celbiologie en Genetica, wetenschappelijk en niet-wetenschap-
pelijk, van lab naar lab, van werkplaats naar keuken, van kweekhok naar bestel-
lingen: bij deze een ieder bedankt voor zijn/haar bijdrage. 
Tot slot is er Martine, maar jij staat voorop ... 
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geboren te Blaricum 
eindexamen VWO, 'Het Wageningsch Lyceum' 
aanvang studie Moleculaire Wetenschappen 
kandidaatsexamen Moleculaire Wetenschappen 
doctoraal examen Landouwwetenschappen, 
studierichting Moleculaire Wetenschappen, 
Landbouw Universiteit Wageningen 
hoofdvakken: 
Moleculaire Biologie, LUW, 
Biochemie, Universiteit van Amsterdam 
bijvak: 
Virologie, LUW 
aanvang promotie-onderzoek als AIO op de 
afdeling Celbiologie en Genetica, bij Prof. Dr. H. 
Galjaard en Dr. A. d'Azzo 
aanvang EMBO 'long term fellowship', in het 
'Laboratory of Gene Structure and Expression', 
NIMR, Mill Hill, London, England, bij Dr. F. Grosveld 
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